NewzIntel.com

    • Checkout Page
    • Contact Us
    • Default Redirect Page
    • Frontpage
    • Home-2
    • Home-3
    • Lost Password
    • Member Login
    • Member LogOut
    • Member TOS Page
    • My Account
    • NewzIntel Alert Control-Panel
    • NewzIntel Latest Reports
    • Post Views Counter
    • Privacy Policy
    • Public Individual Page
    • Register
    • Subscription Plan
    • Thank You Page

Category: Economy

  • MIL-OSI: Xunlei Limited Schedules 2025 Unaudited First Quarter Earnings Release on May 15, 2025

    Source: GlobeNewswire (MIL-OSI)

    SHENZHEN, China, May 08, 2025 (GLOBE NEWSWIRE) — Xunlei Limited (“Xunlei” or the “Company”) (NASDAQ: XNET), a leading technology company providing distributed cloud services in China, today announced that it plans to release its unaudited financial results for the first quarter ended March 31, 2025 on May 15, 2025 before market open.

    The earnings press release will be available on the Company’s investor relations page at http://ir.xunlei.com.

    Conference Call

    Xunlei’s management will host a conference call at 8:00 a.m. U.S. Eastern Time on May 15, 2025 (8:00 p.m. Beijing/Hong Kong Time), to discuss the Company’s quarterly results and recent business developments.

    Conference Call Preregistration

    Participant Online Registration:
    https://register-conf.media-server.com/register/BIe31316b11951413ca6026dd0a7227b38

    Please register to join the conference using the link provided above and dial in 10 minutes before the call is scheduled to begin. Once registered, the participants will receive an email with personal PIN and dial-in information, and participants can choose to access either via Dial-In or Call Me. A kindly reminder that “Call Me” does not work for China number.

    The Company will also broadcast a live audio webcast of the conference call. The webcast will be available at http://ir.xunlei.com. Following the earnings conference call, an archive of the call will be available at https://edge.media-server.com/mmc/p/vrett8r2

    About Xunlei

    Founded in 2003, Xunlei Limited (NASDAQ: XNET) is a leading technology company providing distributed cloud services in China. Xunlei provides a wide range of products and services across cloud acceleration, shared cloud computing and digital entertainment to deliver an efficient, smart and safe internet experience.

    Contact:
    Xunlei Limited Investor Relations

    Email: ir@xunlei.com
    Tel: +86 755 6111 1571
    Website: http://ir.xunlei.com

    The MIL Network –

    May 9, 2025
  • MIL-OSI: Live Oak Bancshares Announces Appointment of Patrick T. McHenry to Board of Directors

    Source: GlobeNewswire (MIL-OSI)

    WILMINGTON, N.C., May 08, 2025 (GLOBE NEWSWIRE) — Live Oak Bancshares announced the appointment of Patrick T. McHenry to its board of directors effective May 21, 2025. McHenry has also been appointed to the board of directors of Live Oak Bank.

    “It is a privilege for Live Oak to have the astute financial and policy expertise of Patrick’s caliber join our board of directors,” said Live Oak Bancshares Chairman and CEO James S. (Chip) Mahan III. “His service to the U.S. government, and experience as former chairman of the House Financial Services Committee, will be a valuable addition to our leadership as Live Oak continues its mission to be America’s small business bank.”

    McHenry currently lives in Washington, D.C. and serves as an advisor on public policy, financial services, fintech, and artificial intelligence matters, in addition to serving as a distinguished fellow at Georgetown University’s Psaros Center for Financial Markets and Policy. He spent 20 years in Congress and is the former Chairman of the House Financial Services Committee and U.S. Representative for North Carolina’s 10th Congressional District. During his time leading the committee, McHenry drove a robust legislative agenda focused on cryptocurrency, capital formation, AI, fintech, data privacy, and corporate governance issues, among other topics.

    “Small business is a critical component of the U.S. economy, and I have long respected Live Oak Bank’s approach to supporting the capital needs of American entrepreneurs,” said McHenry. “There is a unique culture at Live Oak–one driven by an embrace of innovation and technology, two things that inspired much of my public policy work over the last 20 years. I am delighted to be part of the journey Chip and the team are on to serve small businesses in my home state of North Carolina and around the country.”

    In addition to his role as Chairman of the Financial Services Committee, McHenry previously served in House Republican leadership as the Chief Deputy Whip and also served as Speaker Pro Tempore of the House in October of 2023. He is a native of Gastonia, NC and a graduate of Belmont Abbey College.

    About Live Oak Bancshares
    Live Oak Bancshares, Inc. (NYSE: LOB) is a financial holding company and parent company of Live Oak Bank. Live Oak Bancshares and its subsidiaries partner with businesses who share a groundbreaking focus on service and technology to redefine banking. To learn more, visit www.liveoak.bank.

    Contact:
    Claire Parker
    Live Oak Bank, Corporate Communications
    910.597.1592
    claire.parker@liveoak.bank

    The MIL Network –

    May 9, 2025
  • MIL-OSI: Obra Capital Announces Promotion of Peter Polanskyj to Chief Investment Officer

    Source: GlobeNewswire (MIL-OSI)

    NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) — Obra Capital, Inc. (along with its affiliated registered investment advisors, collectively “Obra”), an asset management firm with a specialized approach to alternative investing, today announced that Peter Polanskyj, Senior Managing Director and Head of Structured Credit, has been promoted to Chief Investment Officer.

    Since joining Obra in 2022, Mr. Polanskyj has been a key member of the leadership team, supporting the guidance and execution of the firm’s growth strategy and the development of both its platform and enhanced product set. In April 2024, he supported the launch of Obra’s first ETFs, creating investment options with access to a wide variety of securitized products. In December 2024, Mr. Polanskyj helped lead a $400 million close of Obra’s inaugural Collateralized Loan Obligation offering (“CLO”), further diversifying the firm’s strategies in alternative assets and structured credit to provide a range of solutions aimed at delivering long-term value for investors.

    In addition to new product launches, Mr. Polanskyj has demonstrated a proven track record of prudent capital stewardship, leveraging over 28 years of experience investing in a variety of structured investments to achieve a net growth rate for Obra’s insurance special situations strategy that has outpaced the firm’s initial expectations. In his new role, he will chair Obra’s Investment Committee, with oversight of the firm’s operations across its portfolio.

    “I’m thrilled to welcome Peter to fill this role on Obra’s leadership team,” said Blair Wallace, President and Chief Executive Officer. “He has contributed to the rapid growth of our platform by adeptly navigating a nuanced area of the market, launching unique products and providing strong performance for our investors. His specialized experience and skillset will be critical as we look to build on our momentum across credit and insurance investment opportunities.”

    Mr. Polanskyj added, “I am proud of the work we have done developing the capabilities that our investors are looking to access across insurance and credit. As I step into this new role as CIO, I look forward to continuing to work with Blair and the team to develop our platform and deliver for investors.”

    In addition, Matt Roesler has been promoted to Senior Managing Director and Head of Multi-Sector Credit. He continues to lead the management of Obra’s multi-sector credit, liability-driven and other insurance portfolios. Greg Nicolls has been promoted to Senior Managing Director and Head of Business Development and Investor Relations.

    Prior to joining Obra, Mr. Polanskyj was a Managing Director and Head of U.S. CLO Management at Sculptor Capital (formerly known as Och-Ziff), where he oversaw the creation, securitization and management of CLOs and similarly structured products. In his time with the firm, he grew this business from inception in 2012 to approximately $15 billion in assets in 2022. Prior to that role, he worked at Morgan Stanley in a variety of capacities, including as a strategist focused on credit, structured credit, equity derivatives and capital structure arbitrage. Previously, Mr. Polanskyj was a reinsurance actuary with a focus on property and casualty. Mr. Polanskyj holds a Bachelor of Arts in Economics and Mathematics from Rutgers University, where he was named a Henry Rutgers scholar, and a Master of Business Administration from Columbia Business School.

    About Obra Capital

    Obra is a specialized alternative asset management firm with approximately $5.6 billion in capital under management as of March 31, 2025. Obra provides investment products and solutions across insurance, multi-sector credit, asset-based finance and longevity investment strategies. Obra aims to generate long-term value and attractive returns for investors through a variety of funds and separate accounts. With capabilities in investing, originating, structuring and servicing, Obra strives to provide differentiated investment opportunities and capital solutions for investors worldwide. Obra owns and operates a CLO management business, a commercial real estate lending platform and an auto finance company. For more information about Obra and its registered investment advisors, please visit www.obra.com.

    Media Contact:
    Dan Gagnier
    Gagnier Communications
    Obra@gagnierfc.com
    646-569-5897

    The MIL Network –

    May 9, 2025
  • MIL-OSI: BermudAir Partners with Zero Hash to Launch First-of-Its-Kind Stablecoin Payments in Air Travel

    Source: GlobeNewswire (MIL-OSI)

    HAMILTON, Bermuda, May 08, 2025 (GLOBE NEWSWIRE) — BermudAir, Bermuda’s first homegrown airline, today announced a groundbreaking partnership with Zero Hash to let customers purchase flights with stablecoins as part of the standard booking flow by the end of 2025. The new feature, which makes BermudAir the world’s first airline to offer native stablecoin payments for tickets during online booking on its website and mobile app, will go live by the end of 2025. The collaboration is being showcased today at the inaugural Bermuda Digital Finance Forum, underscoring the event’s focus on empowering local Bermudian businesses through cutting-edge digital finance innovation.

    This partnership will allow BermudAir passengers to natively pay with stablecoins – digital currencies pegged to fiat value – directly on the airline’s website, just as easily as using a credit card. Once live, travelers can select from over a dozen stablecoin options at checkout, enabling seamless payments that settle nearly instantly across borders.

    “By accepting stablecoins, we’re eliminating the friction of currency exchange and foreign transaction fees for our international passengers,” said Adam Scott, Founder and CEO of BermudAir. “As Bermuda’s home airline, we are proud to lead the charge in crypto and stablecoin adoption within aviation. Allowing customers to pay for flights with stablecoins isn’t just about embracing the future of travel – it’s about making the experience faster, cheaper, and more inclusive for travelers worldwide.”

    International visitors represent the majority of Bermuda’s 200,000+ annual air arrivals, many of whom currently face 1–3% foreign transaction fees on credit card bookings.12 By offering a direct stablecoin payment option, BermudAir will offer the opportunity to eliminate those costs and deliver a smoother booking experience for its globally diverse clientele. Stablecoin payments also process 24/7, ensuring ticket purchases can be confirmed in minutes without banking delays, a clear win for travelers and tourism operators.

    Zero Hash, the leading crypto, stablecoin and tokenization infrastructure provider, will power the conversion and settlement of these transactions. Zero Hash Worldwide Ltd., which holds a Class F license issued by the Bermuda Monetary Authority (BMA) under the Digital Asset Business Act, will enable BermudAir to accept digital dollar payments in a compliant, secure manner.

    Zero Hash views stablecoins as a core Alternative Payment Method (APM) poised for mass adoption in everyday transactions. The numbers support this shift: over the past 24 months, nearly 750 million people have gained access to stablecoins and crypto via a primary account on platforms like Revolut, NuBank, Robinhood, PayPal, Stripe, and Venmo. In just the last 30 days, 29.2 million unique wallets processed 705 million stablecoin transactions – totaling $3.3 trillion in volume.3

    The travel industry is uniquely positioned to lead this adoption – an early mover in loyalty programs, digital wallets, and cross-border innovation, it has a proven track record of embracing financial infrastructure before the mainstream.

    “Zero Hash is thrilled to power this first-of-its-kind stablecoin payment offering in the airline industry,” said Edward Woodford, Founder and CEO of Zero Hash. “This partnership with BermudAir exemplifies the convergence of digital finance innovation. By leveraging our stablecoin payments infrastructure, BermudAir can deliver the seamless payments and global accessibility that customers expect in the future of travel. It’s a shining example of stablecoins making a real-world impact, and we’re excited to help empower Bermudian businesses through compliant, cutting-edge technology.”

    The announcement comes amid a broader movement to onboard Bermudian businesses into digital finance. Bermuda’s government has cultivated a robust regulatory framework for fintech, making the island a hub for crypto adoption and innovation.

    The Bermuda Digital Finance Forum, hosted by Penrose Partners, SALT and The Decentralized AI Society (DAIS), is bringing community leaders together to empower local businesses and residents to leverage digital finance.

    This effort builds on BermudAir’s track record of innovation in digital finance, including a prior issuance of stablecoin bond tokens in partnership with crypto custodian XBTO.

    BermudAir’s stablecoin payment feature will be accessed by booking on flybermudair.com and the airline’s mobile app. Travelers will simply choose the stablecoin payment option during checkout, and Zero Hash will seamlessly handle the crypto-to-fiat settlement in real time. Both companies anticipate that this convenience will appeal to overseas travelers and business flyers, who can avoid exchanging currencies or incurring bank fees by paying directly in digital dollars.


    About Zero Hash
    Zero Hash is the leading infrastructure provider for crypto, stablecoin, and tokenized assets. Its API and embeddable dev-kit enables innovators to easily launch solutions across cross-border payments, commerce, trading, remittance, payroll, tokenization and on/off-ramps.

    Zero Hash powers solutions for some of the largest and innovative companies including Interactive Brokers, Stripe, Shift4, Franklin Templeton, Felix Pago, Kalshi and LightSpark. Zero Hash Holdings is backed by investors, including Point72 Ventures, Bain Capital Ventures, and NYCA.

    Zero Hash Worldwide Ltd. holds a Class F license issued by the Bermuda Monetary Authority (BMA) under the Digital Asset Business Act 2018 of Bermuda.

    Zero Hash Trust Company LLC has been approved by the North Carolina Commissioner of Banks as a non-depository trust company.

    Zero Hash LLC is a FinCen-registered Money Service Business and a regulated Money Transmitter that can operate in 51 U.S. jurisdictions. Zero Hash LLC and Zero Hash Liquidity Services LLC are licensed to engage in virtual currency business activity by the New York State Department of Financial Services. In Canada, Zero Hash LLC is registered as a Money Service Business with FINTRAC.

    Zero Hash Australia Pty Ltd. is registered with AUSTRAC as a Digital Currency Exchange Provider, with DCE registered provider number DCE100804170-001. Zero Hash Australia Pty Ltd. is registered on the New Zealand register of financial service providers, with Financial Service Provider (FSP) number FSP1004503. Zero Hash Europe B.V. is registered as a Virtual Asset Services Provider (VASP) by the Dutch Central Bank (Relation number: R193684). Zero Hash Europe Sp. Zoo is registered as a VASP by the Tax Administration Chamber of Poland in Katowice (Registration number RDWW – 1212).

    Learn more by visiting zerohash.com or following us on X @ZeroHashX

    About BermudAir
    BermudAir is Bermuda’s airline, committed to redefining the travel experience. With a fleet of Embraer E175 and E190 aircraft renowned for exceptional performance and passenger comfort, BermudAir exemplifies its commitment to excellence. Operating convenient flights to and from Westchester Country Airport, Boston Logan International Airport, Fort Lauderdale-Hollywood International Airport, Orlando International Airport, Charleston International Airport, Raleigh-Durham International Airport, Bradley International Airport and Baltimore/Washington International Thurgood Marshall Airport, Rhode Island T. F. Green International Airport, and Richmond International Airport. BermudAir enhances connectivity to the U.S. East Coast, contributing to the growth and prosperity of Bermuda. BermudAir also operates flights to Toronto Pearson International Airport, Halifax Stanfield International Airport, and Montréal-Pierre Elliott Trudeau International Airport in Canada. With a dedication to exceptional service and curated onboard offerings that showcase the island’s renowned hospitality and varied food and beverages available locally, BermudAir provides an unparalleled travel experience. For more information, and to book flights, please visit www.flybermudair.com.


    1gotobermuda 2024 Visitor Arrivals Report
    2bankrate.com
    3Artemis Terminal

    The MIL Network –

    May 9, 2025
  • MIL-OSI: xSuite Group Partners with Trenex Consulting to Expand Global Reach

    Source: GlobeNewswire (MIL-OSI)

    Press Release xSuite

    xSuite Group Partners with Trenex Consulting to Expand Global Reach

    The Finance Automation consulting firm from the USA will now offer SAP user companies the software solutions of the German specialist for automated P2P processes

    Ahrensburg, Germany / Metairie, LA/USA – May 8, 2025 – xSuite Group and Trenex Consulting LLC entered into a partnership agreement in March 2025. As a new xSuite Solution Partner, Trenex will distribute, implement, and support xSuite’s solutions for automated invoice and procurement processes as well as archiving across the USA, Europe and the APAC region. Through this partnership with xSuite Group, Trenex is strategically repositioning itself within the SAP ecosystem and expanding its service portfolio for international customers.

    Headquartered in Louisiana, USA, Trenex Consulting is a globally operating IT advisory firm with deep expertise in financial process automation and SAP-driven business optimization. As companies worldwide face the challenges of digital transformation and transition to SAP S/4HANA, many are searching for modern, future-ready alternatives to legacy systems.

    Expanding SAP-Centric Capabilities

    The partnership allows Trenex to offer certified SAP solutions from xSuite that are compatible with all SAP deployment models—whether on-premises, in the cloud, or hybrid. xSuite’s modular and scalable P2P and archiving solutions stand out for their flexibility, global applicability, and futuristic product roadmap, making them ideal for companies to modernize their core financial processes ahead of their S/4 HANA migration.

    Shared Vision for Innovation and Client Value

    “We are excited to welcome Trenex as a solution partner that combines deep market knowledge with a strong track record in business process automation,” said Andreas Nowottka, Managing Director at xSuite Group. “Their commitment to delivering innovative and future-proof solutions to SAP clients around the globe aligns perfectly with xSuite’s mission.

    “Our clients demand state-of-the-art solutions—both technologically and functionally—regardless of whether they run SAP on-premises, in the cloud, or in a hybrid setup,” added Frank (Cheng) Fan, General Manager of Trenex Consulting LLC. “xSuite checks all the boxes: modular architecture, SAP certification, and international compatibility. We also greatly value their collaborative approach and future-driven roadmap, which will empower us to support our clients over the long term.”

    About Trenex Consulting LLC
    Trenex Consulting is a global IT solutions provider specializing in ERP, EPM, Financial Process Automation (FPA), and Robotic Process Automation (RPA). With deep SAP expertise, a multilingual team, and around-the-clock support, Trenex delivers tailored services to help businesses drive digital transformation and optimize core operations worldwide. https://www.trenexconsulting.com/

    About xSuite Group
    With offices in Asia, Europe, and the U.S., xSuite is a leading innovator in optimizing SAP-based P2P workflows. The company provides software solutions and implementation services to over 1,600 clients worldwide, making it a trusted partner in modernizing AP systems and automating manual, paper-based processes.

    Press Contact:
    xSuite Group / Headquarters

    Barbara Wirtz
    Marketing & PR
    Tel. +49 (0)4102/88 38 36
    barbara.wirtz@xsuite.com
    www.xsuite.com

    Partner Contact:
    xSuite Group / International

    Tony Cheung
    Global Vice President
    Enterprise Accounts & Strategic Alliances
    Tel. +44 7561 893170
    tony.cheung@xsuite.com
    www.xsuite.com

    Attachment

    • Frank (Cheng) Fan, General Manager Trenex Consulting LLC (l) and Thomas Radestock, CSO xSuite Group.

    The MIL Network –

    May 9, 2025
  • MIL-OSI: Parex Resources Announces First Quarter Results, Declaration of Q2 2025 Dividend, and Operational Update

    Source: GlobeNewswire (MIL-OSI)

    CALGARY, Alberta, May 08, 2025 (GLOBE NEWSWIRE) — Parex Resources Inc. (“Parex” or the “Company”) (TSX: PXT) is pleased to announce its financial and operating results for the three-month period ended March 31, 2025, the declaration of its Q2 2025 regular dividend of C$0.385 per share, as well as an operational update. All amounts herein are in United States Dollars (“USD”) unless otherwise stated.

    “We entered the year with a disciplined and diversified plan aimed at delivering steady performance, and given current market volatility, are focused on sustaining base production and maintaining flexibility,” commented Imad Mohsen, President & Chief Executive Officer.

    “After a measured first quarter, drilling activity is increasing consistent with our budget. The recent tuck-in acquisition of LLA-32, an asset integral to our development plans, along with encouraging exploration results, represent key milestones that will drive near-term production. While we are well-positioned to deliver a strong second half, we will closely monitor commodity prices and our capital allocation throughout the year to maximize shareholder value.”

    Key Highlights

    • Generated Q1 2025 funds flow provided by operations (“FFO”)(1) of $122 million and FFO per share(2)(3) of $1.24.
    • Tracking to deliver FY 2025 average production guidance of 43,000 to 47,000 boe/d; YTD 2025 average production is approximately 43,100 boe/d(5)(7), with plans intact for a growing H2 2025 production profile.
    • Positive initial results at two prospects in the Southern Llanos, which are driving near-field exploration momentum.
    • Capital expenditure(6) guidance for FY 2025 remains at $285 to $315 million, though the Company continues to monitor commodity prices and could revise lower if warranted by market conditions.
    • Executed a tuck-in acquisition of the remaining working interest at LLA-32 for total consideration of $16 million.

    Q1 2025 Results

    • Average oil & natural gas production was 43,658 boe/d(7).
    • Realized net income of $81 million or $0.82 per share basic(3).
    • Generated FFO(1) of $122 million and FFO per share(2)(3) of $1.24.
    • Current taxes were $12 million; at current Brent crude oil strip pricing, the Company expects its FY 2025 effective current tax rate to be 0-3%.
    • Produced an operating netback(2) of $39.40/boe and an FFO netback(2) of $30.90/boe from an average Brent price of $74.98/bbl.
    • Incurred $57 million of capital expenditures(6), primarily from activities at Cabrestero, Capachos, and LLA-34.
    • Generated $65 million of free funds flow(6) that was used for return of capital initiatives, $10 million of bank debt repayment and increasing working capital surplus(1); working capital surplus(1) was $69 million and cash $81 million at quarter end.
    • Paid a C$0.385 per share(4) regular quarterly dividend and repurchased 524,900 shares.

    (1) Capital management measure. See “Non-GAAP and Other Financial Measures Advisory.”
    (2) Non-GAAP ratio. See “Non-GAAP and Other Financial Measures Advisory.”
    (3) Based on weighted average basic shares for the period.
    (4) Supplementary financial measure. See “Non-GAAP and Other Financial Measures Advisory.”
    (5) Based on Q1 2025 actuals and estimated April 2025 average production; rounded for presentation purposes.
    (6) Non-GAAP financial measure. See “Non-GAAP and Other Financial Measures Advisory.”
    (7) See “Operational and Financial Highlights” for a breakdown of production by product type.

    Operational and Financial Highlights Three Months Ended
    (unaudited) Mar. 31, Mar. 31, Dec. 31,
      2025 2024 2024
    Operational      
    Average daily production      
    Light Crude Oil and Medium Crude Oil (bbl/d) 10,650   7,237   9,550  
    Heavy Crude Oil (bbl/d) 32,207   45,543   34,882  
    Crude Oil (bbl/d) 42,857   52,780   44,432  
    Conventional Natural Gas (mcf/d) 4,806   3,348   5,190  
    Oil & Gas (boe/d)(1) 43,658   53,338   45,297  
           
    Operating netback ($/boe)      
    Reference price – Brent ($/bbl) 74.98   81.87   74.01  
    Oil & gas sales(4) 67.29   70.80   63.73  
    Royalties(4) (9.22 ) (11.21 ) (9.43 )
    Net revenue(4) 58.07   59.59   54.30  
    Production expense(4) (14.41 ) (12.64 ) (15.53 )
    Transportation expense(4) (4.26 ) (3.40 ) (3.87 )
    Operating netback ($/boe)(2) 39.40   43.55   34.90  
           
    Funds flow provided by operations netback ($/boe)(2) 30.90   31.32   32.39  
           
    Financial ($000s except per share amounts)      
           
    Net income 80,629   60,093   (69,051 )
    Per share – basic(6) 0.82   0.58   (0.70 )
           
    Funds flow provided by operations(5) 121,944   148,307   141,201  
    Per share – basic(2)(6) 1.24   1.43   1.43  
           
    Capital expenditures(3) 57,054   85,421   82,110  
           
    Free funds flow(3) 64,890   62,886   59,091  
           
    EBITDA(3) 139,032   192,078   (10,419 )
    Adjusted EBITDA(3) 135,407   188,228   137,312  
           
    Long-term inventory expenditures (4,648 ) 3,843   (2,569 )
           
    Dividends paid 26,365   28,531   26,658  
    Per share – Cdn$(4)(6) 0.385   0.375   0.385  
           
    Shares repurchased 5,239   15,291   16,408  
    Number of shares repurchased (000s) 525   920   1,692  
           
    Outstanding shares (end of period) (000s)      
    Basic 97,814   102,914   98,339  
    Weighted average basic 98,115   103,474   99,063  
    Diluted(8) 99,105   103,829   99,238  
           
    Working capital surplus (deficit)(5) 69,040   55,901   59,397  
    Bank debt(7) 50,000   60,000   60,000  
    Cash 81,025   61,052   98,022  

    (1) Reference to crude oil or natural gas in the above table and elsewhere in this press release refer to the light and medium crude oil and heavy crude oil and conventional natural gas, respectively, product types as defined in National Instrument 51-101 – Standards of Disclosure for Oil and Gas Activities.
    (2) Non-GAAP ratio. See “Non-GAAP and Other Financial Measures Advisory”.
    (3) Non-GAAP financial measure. See “Non-GAAP and Other Financial Measures Advisory”.
    (4) Supplementary financial measure. See “Non-GAAP and Other Financial Measures Advisory”.
    (5) Capital management measure. See “Non-GAAP and Other Financial Measures Advisory”.
    (6) Per share amounts (with the exception of dividends) are based on weighted average common shares.
    (7) Borrowing limit of $240.0 million as of March 31, 2025.
    (8) Diluted shares as stated include common shares and stock options outstanding at period-end. The March 31, 2025 closing stock price was C$13.42 per share.

    LLA-32 Tuck-In Acquisition

    On March 14, 2025, Parex executed a tuck-in acquisition for the remaining working interest at LLA-32 for total consideration of $16 million. LLA-32 is located to the north and adjacent to the Company’s core LLA-34 and Cabrestero blocks.

    The strategic rationale for the acquisition was to gain full control of the asset, grow production, expand inventory, and add low-cost recompletion opportunities.

    Following the close of the acquisition, Parex started a workover program with positive results thus far, and in Q2 2025, initiated a five-well development campaign. Current production from LLA-32 is roughly 4,000 boe/d(1).

    Operational Update

    2025 Corporate Guidance & Outlook

    While Parex’s 2025 corporate guidance of average production of 43,000 to 47,000 boe/d and capital expenditures of $285 to $315 million remains unchanged as previously disclosed, the Company is closely monitoring oil price volatility to ensure that project economics remain robust.

    Given the conventional nature of Parex’s business and the structure of its drilling and service contracts, optionality exists to adjust activity levels in response to prevailing market conditions in order to ensure efficient capital allocation and maximization of shareholder value.

    For Q2 2025, average production is expected to be similar to Q1 2025, supported by increased development activity and preliminary near-field exploration success.

    Operational Update

    Average production for Q1 2025 of 43,658 boe/d(2) was in line with Management expectations. The quarter progressed steadily, which is aligned with the Company’s activity plan to support a growing H2 2025 production profile, as previously disclosed.

    April 2025 average production was 41,400 boe/d(3), with production generally consistent with lower activity levels and modest capital outlay in Q1 2025, as well as higher than budgeted downtime due to weather factors. Downtime levels have normalized and initial average production rates in May are roughly 43,200 boe/d(4).

    With budgeted activity underway, operational momentum is expected to build through the remainder of the year. Parex currently has three drilling rigs operating (two operated and one non-operated). In addition to enhanced oil recovery initiatives at Cabrestero and LLA-34, activity for Q2 2025 is primarily focused on development wells that are planned to be sequential in nature and located on existing pads that enable efficient production across parallel operations.

    Near-Term Development Activity

    • Drilling at LLA-34 that is expected to continue through Q2 2025, resulting in the expected completion of six in-fill wells;
    • Commencing operations at LLA-32, with the first well of the campaign to be completed in late Q2 2025; and
    • Achieving initial access in the Putumayo, with activity starting with a workover rig in Q2 2025.

    Near-Field Exploration Program plus Follow-Up Drilling

    As part of this program, two separate prospects have yielded positive initial results in the Southern Llanos, where operations are ongoing:

    • On LLA-74, a prospect was drilled successfully.
      • Initial production began in early May, with current output of approximately 1,200 bbl/d of heavy crude oil(5).
    • Also on LLA-74, a prospect was drilled via a vertical well.
      • Based on management’s positive initial assessment, the program has progressed with the design of two horizontal wells to optimize production and recovery.
      • The first follow-up horizontal well is currently being drilled, with expected production in late May.

    (1) Estimated average production for April 1, 2025 to April 30, 2025; light & medium crude oil: ~3,409 bbl/d, conventional natural gas: ~3,544 mcf/d; rounded for presentation purposes.
    (2) See “Operational and Financial Highlights” for a breakdown of production by product type.
    (3) Estimated average production for April 1, 2025 to April 30, 2025; light & medium crude oil: ~10,099 bbl/d, heavy crude oil: ~30,541 bbl/d, conventional natural gas: ~4,557 mcf/d; rounded for presentation purposes.
    (4) Estimated average production for May 1, 2025 to May 6, 2025; light & medium crude oil: ~10,538 bbl/d, heavy crude oil: ~31,869 bbl/d, conventional natural gas: ~4,756 mcf/d; rounded for presentation purposes.
    (5) Short-term production rate. See “Oil & Gas Matters Advisory.”

    Risk Management

    For Q1 2025, Parex entered into a Brent crude oil hedge to manage price risk on approximately 25% of planned net crude oil production, utilizing a Brent put spread at $60/bbl and $70/bbl. For Q2 2025, Parex entered into similar hedges for the months of April 2025 and May 2025.

    Parex plans to regularly evaluate market conditions, operational requirements, and other pertinent factors, to assess the need for any additional hedging actions as it progresses through 2025.

    Return of Capital Update

    Q2 2025 Dividend

    Parex’s Board of Directors have approved a Q2 2025 regular dividend of C$0.385 per share to shareholders of record on June 9, 2025, to be paid on June 16, 2025. This regular dividend payment to shareholders is designated as an “eligible dividend” for purposes of the Income Tax Act (Canada).

    Normal Course Issuer Bids

    In 2025, Parex has repurchased approximately 0.7 million shares under its NCIBs, for total consideration of roughly C$10 million.

    Q1 2025 Results – Conference Call & Webcast

    Parex will host a conference call and webcast to discuss its Q1 2025 results on Thursday, May 8, 2025, beginning at 9:30 am MT (11:30 am ET). To participate in the conference call or webcast, please see the access information below:

    Conference ID: 5403995
    Participant Toll-Free Dial-In Number: 1-646-307-1963
    Participant Dial-In Number: 1-647-932-3411
    Webcast: https://events.q4inc.com/attendee/867962059

    Annual General Meeting

    On Thursday, May 8, 2025, Parex will hold its Annual General Meeting at 11:00 am MT (1:00 pm ET) both in-person and virtually. Participants may attend at the 4th Floor Conference Center, Eight Avenue Place, East Tower, 525, 8th Ave SW, Calgary, Alberta – and virtual participants can join through the following link: https:meetnow.global/M4SULLK.

    Additional information regarding the Annual General Meeting, including meeting materials, can be found at www.parexresources.com under Investors.

    About Parex Resources Inc.

    Parex is one of the largest independent oil and gas companies in Colombia, focusing on sustainable conventional production. The Company’s corporate headquarters are in Calgary, Canada, with an operating office in Bogotá, Colombia. Parex shares trade on the Toronto Stock Exchange under the symbol PXT.

    For more information, please contact:

    Mike Kruchten
    Senior Vice President, Capital Markets & Corporate Planning
    Parex Resources Inc.
    403-517-1733
    investor.relations@parexresources.com

    Steven Eirich
    Senior Investor Relations & Communications Advisor
    Parex Resources Inc.
    587-293-3286
    investor.relations@parexresources.com

    NOT FOR DISTRIBUTION OR FOR DISSEMINATION IN THE UNITED STATES

    Non-GAAP and Other Financial Measures Advisory

    This press release uses various “non-GAAP financial measures”, “non-GAAP ratios”, “supplementary financial measures” and “capital management measures” (as such terms are defined in NI 52-112), which are described in further detail below. Such measures are not standardized financial measures under IFRS and might not be comparable to similar financial measures disclosed by other issuers. Investors are cautioned that non-GAAP financial measures should not be construed as alternatives to or more meaningful than the most directly comparable GAAP measures as indicators of Parex’s performance.

    These measures facilitate management’s comparisons to the Company’s historical operating results in assessing its results and strategic and operational decision-making and may be used by financial analysts and others in the oil and natural gas industry to evaluate the Company’s performance. Further, management believes that such financial measures are useful supplemental information to analyze operating performance and provide an indication of the results generated by the Company’s principal business activities.

    Set forth below is a description of the non-GAAP financial measures, non-GAAP ratios, supplementary financial measures and capital management measures used in this press release.

    Non-GAAP Financial Measures

    Capital expenditures, is a non-GAAP financial measure which the Company uses to describe its capital costs associated with oil and gas expenditures. The measure considers both property, plant and equipment expenditures and exploration and evaluation asset expenditures which are items in the Company’s statement of cash flows for the period and is calculated as follows:

      For the three months ended
      Mar. 31,   Mar. 31,   Dec. 31,
    ($000s)   2025     2024     2024
    Property, plant and equipment expenditures $ 44,951   $ 40,831   $ 62,799
    Exploration and evaluation expenditures   12,103     44,590     19,311
    Capital expenditures $ 57,054   $ 85,421   $ 82,110


    Free funds flow,
    is a non-GAAP financial measure that is determined by funds flow provided by operations less capital expenditures. The Company considers free funds flow to be a key measure as it demonstrates Parex’s ability to fund return of capital, such as the normal course issuer bid and dividends, without accessing outside funds and is calculated as follows:

      For the three months ended
      Mar. 31,   Mar. 31,   Dec. 31,
    ($000s)   2025     2024     2024
    Cash provided by operating activities $ 87,621   $ 97,412   $ 67,847
    Net change in non-cash assets and liabilities   34,323     50,895     73,354
    Funds flow provided by operations   121,944     148,307     141,201
    Capital expenditures   57,054     85,421     82,110
    Free funds flow $ 64,890   $ 62,886   $ 59,091


    EBITDA
    , is a non-GAAP financial measure that is defined as net income (loss) adjusted for finance income and expenses, other expenses, income tax expense (recovery) and depletion, depreciation and amortization.

    Adjusted EBITDA, is a non-GAAP financial measure defined as EBITDA adjusted for non-cash impairment charges, share-based compensation expense (recovery), unrealized foreign exchange gains (losses) and unrealized gains (losses) on risk management contracts.

    The Company considers EBITDA and Adjusted EBITDA to be key measures as they demonstrate Parex’s profitability before finance income and expenses, taxes, depletion, depreciation and amortization and other non-cash items. A reconciliation from net income to EBITDA and Adjusted EBITDA is as follows:

      For the three months ended
      Mar. 31,   Mar. 31,   Dec. 31,
    ($000s)   2025     2024     2024
    Net income (loss) $ 80,629     $ 60,093     $ (69,051 )
    Adjustments to reconcile net income (loss) to EBITDA:          
    Finance income   (1,297 )     (1,257 )     (998 )
    Finance expense   5,056       4,455       4,318  
    Other expenses   1,147       739       2,208  
    Income tax expense (recovery)   3,078       75,817       (880 )
    Depletion, depreciation and amortization   50,419       52,231       53,984  
    EBITDA $ 139,032     $ 192,078     $ (10,419 )
    Non-cash impairment charges   —       —       137,841  
    Share-based compensation expense (recovery)   2,092       (2,463 )     6,149  
    Unrealized foreign exchange (gain) loss   (4,919 )     (1,387 )     2,581  
    Unrealized (gain) loss on risk management contracts   (798 )     —       1,160  
    Adjusted EBITDA $ 135,407     $ 188,228     $ 137,312  


    Non-GAAP Ratios

    Operating netback per boe, is a non-GAAP ratio that the Company considers to be a key measure as it demonstrates Parex’ profitability relative to current commodity prices. Parex calculates operating netback per boe as operating netback (calculated as oil and natural gas sales from production, less royalties, operating, and transportation expense) divided by the total equivalent sales volume including purchased oil volumes for oil and natural gas sales price and transportation expense per boe and by the total equivalent sales volume excluding purchased oil volumes for royalties and operating expense per boe.

    Funds flow provided by operations netback per boe or FFO netback per boe, is a non-GAAP ratio that includes all cash generated from operating activities and is calculated before changes in non-cash assets and liabilities, divided by produced oil and natural gas sales volumes. The Company considers funds flow provided by operations netback per boe to be a key measure as it demonstrates Parex’s profitability after all cash costs relative to current commodity prices.

    Basic funds flow provided by operations per share or FFO per share, is a non-GAAP ratio that is calculated by dividing funds flow provided by operations by the weighted average number of basic shares outstanding. Parex presents basic funds flow provided by operations per share whereby per share amounts are calculated using weighted-average shares outstanding, consistent with the calculation of earnings per share. The Company considers basic funds flow provided by operations per share or FFO per share to be a key measure as it demonstrates Parex’s profitability after all cash costs relative to the weighted average number of basic shares outstanding.

    Capital Management Measures

    Funds flow provided by operations, is a capital management measure that includes all cash generated from operating activities and is calculated before changes in non-cash assets and liabilities. The Company considers funds flow provided by operations to be a key measure as it demonstrates Parex’s profitability after all cash costs. A reconciliation from cash provided by operating activities to funds flow provided by operations is as follows:

      For the three months ended
      Mar. 31,   Mar. 31,   Dec. 31,
    ($000s)   2025     2024     2024
    Cash provided by operating activities $ 87,621   $ 97,412   $ 67,847
    Net change in non-cash assets and liabilities   34,323     50,895     73,354
    Funds flow provided by operations $ 121,944   $ 148,307   $ 141,201

    Working capital surplus, is a capital management measure which the Company uses to describe its liquidity position and ability to meet its short-term liabilities. Working capital surplus is defined as current assets less current liabilities.

      For the three months ended
      Mar. 31,   Mar. 31,   Dec. 31,
    ($000s)   2025     2024     2024
    Current assets $ 259,256   $ 276,113   $ 245,943
    Current liabilities   190,216     220,212     186,546
    Working capital surplus $ 69,040   $ 55,901   $ 59,397


    Supplementary Financial Measures

    “Oil and natural gas sales price per boe” is comprised of total commodity sales from oil and natural gas production, as determined in accordance with IFRS, divided by the total oil and natural gas sales volumes including purchased oil volumes.

    “Royalties per boe” is comprised of royalties, as determined in accordance with IFRS, divided by the total equivalent sales volume and excludes purchased oil volumes.

    “Net revenue per boe” is comprised of net revenue, as determined in accordance with IFRS, divided by the total equivalent sales volume and includes purchased oil volumes.

    “Production expense per boe” is comprised of production expense, as determined in accordance with IFRS, divided by the total equivalent sales volume and excludes purchased oil volumes.

    “Transportation expense per boe” is comprised of transportation expense, as determined in accordance with IFRS, divided by the total equivalent sales volumes including purchased oil volumes.

    “Dividends paid per share” is comprised of dividends declared, as determined in accordance with IFRS, divided by the number of shares outstanding at the dividend record date.

    Oil & Gas Matters Advisory

    The term “Boe” means a barrel of oil equivalent on the basis of 6 Mcf of natural gas to 1 barrel of oil (“bbl”). Boe’s may be misleading, particularly if used in isolation. A boe conversation ratio of 6 Mcf: 1 Bbl is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. Given the value ratio based on the current price of crude oil as compared to natural gas is significantly different from the energy equivalency of 6 Mcf: 1Bbl, utilizing a conversion ratio at 6 Mcf: 1 Bbl may be misleading as an indication of value.

    This press release contains a number of oil and gas metrics, including, operating netbacks and FFO netbacks. These oil and gas metrics have been prepared by management and do not have standardized meanings or standard methods of calculation and therefore such measures may not be comparable to similar measures used by other companies and should not be used to make comparisons. Such metrics have been included herein to provide readers with additional measures to evaluate the Company’s performance; however, such measures are not reliable indicators of the future performance of the Company and future performance may not compare to the performance in previous periods and therefore such metrics should not be unduly relied upon. Management uses these oil and gas metrics for its own performance measurements and to provide security holders with measures to compare the Company’s operations over time. Readers are cautioned that the information provided by these metrics, or that can be derived from the metrics presented in this news release, should not be relied upon for investment or other purposes.

    Any reference in this press release to short-term production rates are useful in confirming the presence of hydrocarbons, however such rates are not determination of the rates at which such wells will continue production and decline thereafter and readers are cautioned not to place reliance on such rates in calculating the aggregate production of Parex.

    Distribution Advisory

    The Company’s future shareholder distributions, including but not limited to the payment of dividends and the acquisition by the Company of its shares pursuant to an NCIB, if any, and the level thereof is uncertain. Any decision to pay further dividends on the common shares (including the actual amount, the declaration date, the record date and the payment date in connection therewith and any special dividends) or acquire shares of the Company will be subject to the discretion of the Board of Directors of Parex and may depend on a variety of factors, including, without limitation the Company’s business performance, financial condition, financial requirements, growth plans, expected capital requirements and other conditions existing at such future time including, without limitation, contractual restrictions and satisfaction of the solvency tests imposed on the Company under applicable corporate law. Further, the actual amount, the declaration date, the record date and the payment date of any dividend are subject to the discretion of the Board. There can be no assurance that the Company will pay dividends or repurchase any shares of the Company in the future.

    Advisory on Forward Looking Statements

    Certain information regarding Parex set forth in this document contains forward-looking statements that involve substantial known and unknown risks and uncertainties. The use of any of the words “plan”, “expect”, “prospective”, “project”, “intend”, “believe”, “should”, “anticipate”, “estimate”, “forecast”, “guidance”, “budget” or other similar words, or statements that certain events or conditions “may” or “will” occur are intended to identify forward-looking statements. Such statements represent Parex’s internal projections, estimates or beliefs concerning, among other things, future growth, results of operations, production, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, plans for and results of drilling activity, environmental matters, business prospects and opportunities. These statements are only predictions and actual events or results may differ materially. Although the Company’s management believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievement since such expectations are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause Parex’s actual results to differ materially from those expressed or implied in any forward-looking statements made by, or on behalf of, Parex.

    In particular, forward-looking statements contained in this document include, but are not limited to, statements with respect to: the Company’s focus, plans, priorities and strategies; average production guidance and capital expenditure guidance; expectations and plans regarding the Company’s drilling activity, the Company’s production profile, prospects in the Southern Llanos, the LLA-32 tuck-in acquisition, drilling and programs at LLA-34, LLA-32, Putumayo, and LLA-74; expectations about the Company’s FY 2025 tax rate; plans with respect to assessing the need for additional hedging in 2025; the anticipated terms of the Company’s Q2 2025 regular quarterly dividend, including its expectation that it will be designated as an “eligible dividend”; and the anticipated date and time of Parex’s conference call to discuss Q1 2025 results.

    These forward-looking statements are subject to numerous risks and uncertainties, including but not limited to, the impact of general economic conditions in Canada and Colombia; an unpredictable tariff and trade environment; prolonged volatility in commodity prices; industry conditions including changes in laws and regulations including adoption of new environmental laws and regulations, and changes in how they are interpreted and enforced in Canada and Colombia; determinations by OPEC and other countries as to production levels; competition; lack of availability of qualified personnel; the results of exploration and development drilling and related activities; obtaining required approvals of regulatory authorities in Canada and Colombia; the risks associated with negotiating with foreign governments as well as country risk associated with conducting international activities; volatility in market prices for oil; fluctuations in foreign exchange or interest rates; environmental risks; changes in income tax laws or changes in tax laws and incentive programs relating to the oil industry; changes to pipeline capacity; ability to access sufficient capital from internal and external sources; failure of counterparties to perform under contracts; the risk that Brent oil prices may be lower than anticipated; the risk that Parex’s evaluation of its existing portfolio of development and exploration opportunities may not be consistent with its expectations; the risk that Parex may not have sufficient financial resources in the future to provide distributions to its shareholders; the risk that the Board may not declare dividends in the future or that Parex’s dividend policy changes; the risk that Parex may not be responsive to changes in commodity prices; the risk that Parex may not meet its production guidance for the year ended December 31, 2025; the risk that Parex’s 2025 capital expenditures may be greater or less than anticipated; the risk that plans and expectations related to Parex’s drilling program as disclosed herein do not materialize as expected and/or at all; and other factors, many of which are beyond the control of the Company.

    Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on these and other factors that could affect Parex’s operations and financial results are included in reports on file with Canadian securities regulatory authorities and may be accessed through the SEDAR+ website (www.sedarplus.ca).

    Although the forward-looking statements contained in this document are based upon assumptions which Management believes to be reasonable, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. With respect to forward-looking statements contained in this document, Parex has made assumptions regarding, among other things: current and anticipated commodity prices and royalty regimes; availability of skilled labour; timing and amount of capital expenditures; future exchange rates; the price of oil, including the anticipated Brent oil price; the impact of increasing competition; conditions in general economic and financial markets; availability of drilling and related equipment; effects of regulation by governmental agencies; receipt of partner, regulatory and community approvals; royalty rates; future operating costs; uninterrupted access to areas of Parex’s operations and infrastructure; recoverability of reserves and future production rates; the status of litigation; timing of drilling and completion of wells; on-stream timing of production from successful exploration wells; operational performance of non-operated producing fields; pipeline capacity; that Parex will have sufficient cash flow, debt or equity sources or other financial resources required to fund its capital and operating expenditures and requirements as needed; that Parex’s conduct and results of operations will be consistent with its expectations; that Parex will have the ability to develop its oil and gas properties in the manner currently contemplated; that Parex’s evaluation of its existing portfolio of development and exploration opportunities is consistent with its expectations; current or, where applicable, proposed industry conditions, laws and regulations will continue in effect or as anticipated as described herein; that the estimates of Parex’s production and reserves volumes and the assumptions related thereto (including commodity prices and development costs) are accurate in all material respects; that Parex will be able to obtain contract extensions or fulfill the contractual obligations required to retain its rights to explore, develop and exploit any of its undeveloped properties; that Parex will have sufficient financial resources to pay dividends and acquire shares pursuant to its NCIB in the future; that Parex is able to execute its plans with respect to the Company’s drilling program as disclosed herein; and other matters.

    Management has included the above summary of assumptions and risks related to forward-looking information provided in this document in order to provide shareholders with a more complete perspective on Parex’s current and future operations and such information may not be appropriate for other purposes. Parex’s actual results, performance or achievement could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what benefits Parex will derive. These forward-looking statements are made as of the date of this document and Parex disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

    This press release contains information that may be considered a financial outlook under applicable securities laws about the Company’s potential financial position, including, but not limited to; Parex’s FY 2025 capital expenditure guidance; Parex 2025 guidance, including anticipated Brent crude oil average prices, funds flow provided by operations netback; funds flow provided by operations, capital expenditures, free funds flow; and the anticipated terms of the Company’s Q2 2025 regular quarterly dividend including its expectation that it will be designated as an “eligible dividend”, all of which are subject to numerous assumptions, risk factors, limitations and qualifications, including those set forth in the above paragraphs. The actual results of operations of the Company and the resulting financial results will vary from the amounts set forth in this press release and such variations may be material. This information has been provided for illustration only and with respect to future periods are based on budgets and forecasts that are speculative and are subject to a variety of contingencies and may not be appropriate for other purposes. Accordingly, these estimates are not to be relied upon as indicative of future results. Except as required by applicable securities laws, the Company undertakes no obligation to update such financial outlook. The financial outlook contained in this press release was made as of the date of this press release and was provided for the purpose of providing further information about the Company’s potential future business operations. Readers are cautioned that the financial outlook contained in this press release is not conclusive and is subject to change.

    The following abbreviations used in this press release have the meanings set forth below:

    bbl one barrel
    bbls barrels
    bbl/d barrels per day
    boe barrels of oil equivalent of natural gas; one barrel of oil or natural gas liquids for six thousand cubic feet of natural gas
    boe/d barrels of oil equivalent of natural gas per day
    mcf thousand cubic feet
    mcf/d thousand cubic feet per day
    W.I. working interest

    PDF available: http://ml.globenewswire.com/Resource/Download/974163af-5043-41d6-a129-53a272c53539

    The MIL Network –

    May 9, 2025
  • MIL-OSI Economics: RBI imposes monetary penalty on Shree Warana Sahakari Bank Limited, Warananagar, Maharashtra

    Source: Reserve Bank of India

    The Reserve Bank of India (RBI) has, by an order dated May 05, 2025, imposed a monetary penalty of ₹2.00 lakh (Rupees Two Lakh only) on Shree Warana Sahakari Bank Limited, Warananagar, Maharashtra (the bank) for contravention of the provisions of Section 26A read with Section 56 of the Banking Regulation Act, 1949 (BR Act). This penalty has been imposed in exercise of powers conferred on RBI under the provisions of Section 47A(1)(c) read with Sections 46(4)(i) and 56 of the BR Act.

    The statutory inspection of the bank was conducted by RBI with reference to its financial position as on March 31, 2024. Based on supervisory findings of contravention of statutory provisions and related correspondence in that regard, a notice was issued to the bank advising it to show cause as to why penalty should not be imposed on it for its failure to comply with the said statutory provisions. After considering the bank’s reply to the notice, RBI found, inter alia, that the following charge against the bank was sustained, warranting imposition of monetary penalty:

    The bank had failed to transfer eligible unclaimed amounts to the Depositor Education and Awareness Fund within the prescribed time.

    This action is based on deficiencies in statutory compliance and is not intended to pronounce upon the validity of any transaction or agreement entered into by the bank with its customers. Further, imposition of monetary penalty is without prejudice to any other action that may be initiated by RBI against the bank.

    (Puneet Pancholy)  
    Chief General Manager

    Press Release: 2025-2026/284

    MIL OSI Economics –

    May 9, 2025
  • MIL-OSI: Sky Quarry Signs LOI with R & R Solutions to Explore Expansion of Southwest Operations and Accelerate Market Deployment

    Source: GlobeNewswire (MIL-OSI)

    WOODS CROSS, Utah, May 08, 2025 (GLOBE NEWSWIRE) — Sky Quarry Inc. (NASDAQ: SKYQ) (“Sky Quarry” or “the Company”), an integrated energy solutions company committed to revolutionizing the waste asphalt shingle recycling industry, today announced that it has signed a non-binding Letter of Intent (LOI) with R & R Solutions Inc., the only permitted asphalt shingle recycler in New Mexico. The LOI represents a strategic step in Sky Quarry’s plan to expand its national network of modular waste-to-energy facilities and unlock new revenue opportunities in the Southwest.

    The proposed partnership will focus on planning the deployment of Sky Quarry’s proprietary equipment, mechanical processes, and intellectual property (IP) at R & R Solutions’ existing permitted site in Albuquerque, New Mexico. If implemented, the proposed project will support the production of high-value byproducts, including asphalt-coated limestone, sand, granules, bitumen, and structural-grade ground shingles for use in roofing, road repair, sealants, and other infrastructure applications.

    As part of Sky Quarry’s differentiated business model, the Company expects to generate revenue both from accepting asphalt shingle waste and from selling the recovered byproducts. At the proposed New Mexico site, Sky Quarry estimates that approximately 100,000 tons of asphalt shingle waste could be processed per year and believes that this could generate substantial annual revenue from collection fees and the sale of recycled materials such as granules and sand. The Company also believes that the feedstock could yield the equivalent of up to 150,000 barrels of oil when fully refined, representing additional potential revenue.

    “The opportunity to collaborate with R & R Solutions and build on an existing permitted site creates an attractive entry point for strengthening our national scale-up efforts and advancing commercialization,” said David Sealock, CEO and Chairman of Sky Quarry. “The Albuquerque region presents a particularly compelling opportunity due to its proximity to our PR Spring facility in Utah, which will serve as a regional hub for hydrocarbon extraction. Upon reaching an agreement with R&R Solutions based on the LOI, we believe that leveraging existing infrastructure and integrating operations across both sites will accelerate deployment, reduce capital intensity, and improve supply chain logistics for recovered oil products, efficiencies that we believe will drive stronger margins and long-term value.”

    Founded in 2013, R & R Solutions brings over a decade of experience as a leader in responsible recycling practices and is deeply integrated into the New Mexico construction ecosystem. “The proposed partnership with Sky Quarry will mark a strategic step forward for R & R Solutions,” said Jerry Daniele, Vice President of R & R Solutions. “We’ve built a strong foundation as the region’s only permitted shingle recycler, and we believe that this collaboration will give us the tools to expand our capabilities, accelerate growth, and deliver broader impact. It will allow us to scale the value we provide to customers and communities across New Mexico and move beyond traditional recycling into large-scale resource recovery, driving meaningful economic impact in the region.”

    About Sky Quarry Inc.

    Sky Quarry Inc. (NASDAQ:SKYQ) and its subsidiaries are, collectively, an oil production, refining, and a development-stage environmental remediation company formed to deploy technologies to facilitate the recycling of waste asphalt shingles and remediation of oil-saturated sands and soils. Our waste-to-energy mission is to repurpose and upcycle millions of tons of asphalt shingle waste, diverting them from landfills. By doing so, we can contribute to improved waste management, promote resource efficiency, conserve natural resources, and reduce environmental impact. For more information, please visit skyquarry.com.

    Forward-Looking Statements

    This press release may include ”forward-looking statements.” All statements pertaining to our future financial and/or operating results, future events, or future developments may constitute forward-looking statements. The statements may be identified by words such as “expect,” “look forward to,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project,” or words of similar meaning. Such statements are based on the current expectations and certain assumptions of our management, of which many are beyond our control. These are subject to a number of risks, uncertainties, and factors, including but not limited to those described in our disclosures. Should one or more of these risks or uncertainties materialize or should underlying expectations not occur or assumptions prove incorrect, actual results, performance, or our achievements may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. We neither intend, nor assume any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated. You are urged to carefully review and consider any cautionary statements and the Company’s other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Company’s Form 10-K as filed with the SEC on March 31, 2025. Forward-looking statements speak only as of the date of the document in which they are contained.

    Investor Relations
    Jennifer Standley
    Director of Investor Relations
    Ir@skyquarry.com

    Company Website
    www.skyquarry.com

    The MIL Network –

    May 9, 2025
  • MIL-OSI: Stack Capital Group Inc. Reports Q1-2025 Financial Results

    Source: GlobeNewswire (MIL-OSI)

    TORONTO, May 08, 2025 (GLOBE NEWSWIRE) — Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX:STCK; TSX:STCK.WT.A) today announced its financial results for the quarter ended March 31, 2025. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated.

    Company Commentary:

    • As at March 31, 2025, Book Value per Share (BVpS) of the Company was $12.06, compared with $12.29 as at December 31, 2024.
    • Stack Capital had its first portfolio investment, CoreWeave (an AI hyper-scaler) go public on March 28, 2025, an exciting milestone for both the Company and CoreWeave. During the quarter, and prior to the IPO, Stack invested an additional US$2.2 million into CoreWeave.
    • As of March 31, 2025, the Company wrote down its investment in CoreWeave by US$2.4 million to reflect its closing price of US$37.08. Since then, however, CoreWeave’s share price has increased to US$53.60 (as of close on May 7, 2025), representing a 45% gain from March 31, 2025, equating to an estimated $0.45 increase to Stack Capital’s BVpS since quarter end. The Company believes that CoreWeave’s share price has the potential to increase over the next several months as it reports its initial quarterly results, announces potential new business deals, and general market sentiment improves with anticipated resolutions to global trade/tariffs and other geo-political issues.
    • During Q1, Shield AI raised US$240 million at a US$5.3 billion valuation, resulting in an increase to the position value within the portfolio. Shield AI also recently announced significant strategic partnerships with both Boeing (March 2025) and Airbus U.S. Space & Defense (April 2025). Shield AI’s Hivemind solution will be used to improve and expand unmanned capabilities across the aerial programs at both companies, serving to further validate Shield AI’s leadership position in AI pilot technology.
    • Following quarter-end, SpaceX received approval from the Federal Aviation Administration (FAA) to increase the number of its Starship launches to 25 times per year, up from 5 times per annum under its previous license. This increase in launch cadence for future Starship test flights is significant and will eventually benefit Starlink (SpaceX’ satellite communications business) through the faster deployment of its next generation satellites, once Starship becomes fully operational.
    • In March, Locus Robotics unveiled its brand new ‘Array’ autonomous mobile robot at LogiMat in Stuttgart, Germany, and at ProMat in Chicago. As the industry’s most advanced AI-powered, zero-touch fulfillment system, Array eliminates 90% of manual labour for picking, putaway, and returns of merchandise within warehouse and third-party logistics facilities. Leveraging the latest advances in AI vision technology, Array delivers ultra-efficient order picking, unmatched cost per pick, along with the unique ability to pick and consolidate multiple orders simultaneously.
    • Following quarter-end, Omio, a leading multi-modal travel booking platform, announced its expansion into Southeast Asia, unlocking over 14,000 bus routes from over 1,800 transportation providers across Singapore, Vietnam, Thailand, Malaysia, Indonesia, and Cambodia, adding to its existing flight options in the region. Omio also plans to add ferry and rail services over the coming months and is aiming to be a comprehensive multi-modal travel provider by Q4-2025, in time for peak season of Southeast Asian travel. Following the announcement, the Omio app now unifies transportation across 3 continents and 45 countries.
    • As at March 31, 2025, the Book Value of the Company was $129.7 million, and the Book Value per Share was $12.06. A detailed summary of Book Value per Share is as follows:
    Breakdown of Book Value per Share as at March 31, 2025:  
    SpaceXi(space exploration & satellite communications) $ 2.18  
    Locus Robotics, Inc. (autonomous robots)   1.32  
    Canva, Inc. (graphic design)   1.29  
    Omio, Inc.ii(travel & leisure)   1.11  
    Hopper, Inc. (travel & leisure)   1.07  
    Newfront Insurance, Inc. (insurance & benefits)   1.07  
    Prove Identity, Inc.iii(cyber-security)   1.02  
    CoreWeave, Inc. (AI hyper-scaler)   1.01  
    Bolt Financial, Inc. (e-commerce)   0.50  
    Shield AI, Inc.iv(military defence)   0.39  
    Varo Money, Inc. (neo-banking)   0.13  
    Cash   1.00  
    Net other assets   (0.03 )
    Book Value per Share $ 12.06  

    i the Company is invested in Space Exploration Technologies Corp. (“SpaceX”) through a Special Purpose Vehicle, Space LP.
    ii the Company invested in shares of GoEuro Corp. which carries on business as Omio.
    iii the fair value of Prove Identity Inc. includes an unrealized deferred gain of $1,021,025
    iv the Company is invested in Shield AI through a Special Purpose Vehicle, Defence AI LP

    About Stack Capital

    Stack Capital is an investment holding company and its business objective is to invest in equity, debt and/or other securities of growth-to-late-stage private businesses. Through Stack Capital, shareholders have the opportunity to gain exposure to a diversified private investment portfolio; participate in the private market; and have liquidity due to the listing of the Common Shares & Warrants on the TSX. At the same time, the public structure also allows the Company to focus its efforts on maximizing long-term performance through a portfolio of high growth businesses, which are not widely available to most Canadian investors. SC Partners Ltd. acts as the Company’s administrator and is responsible to source and advise with respect to all investments for the Company.

    For more information, please visit our website at www.stackcapitalgroup.com or contact:
    Brian Viveiros
    VP, Corporate Development, and Investor Relations
    647.280.3307
    brian@stackcapitalgroup.com

    Non-IFRS Financial Measures

    This press release may make reference to the following financial measures which are not recognized under International Financial Reporting Standards (“IFRS”), and which do not have a standard meaning prescribed by IFRS:

    • Book Value – the aggregate fair value of the assets of the Company on the referenced date, less the aggregate carrying value of the liabilities, excluding any deferred taxes or unrealized deferred gains or losses if applicable, of the Company; and
    • Book Value per Share (BVpS) – the Book Value on the referenced day divided by the aggregate number of Common Shares that are outstanding on such day.

    The Company’s Book Value and Book Value per Share is a measure of the performance of the Company as a whole. The Company’s method of determining this financial measure may differ from other issuers’ methods and, accordingly, this amount may not be comparable to measures used by other issuers. This financial measure is not a performance measure as defined under IFRS and should not be considered either in isolation of, or as a substitute for, net earnings per share prepared in accordance with IFRS.

    Cautionary Note Regarding Forward-Looking Information

    This press release contains forward-looking information. Such forward-looking statements or information are provided for the purpose of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Any such forward-looking information may be identified by words such as “proposed”, “expects”, “intends”, “may”, “will”, and similar expressions. Forward-looking information contained or referred to in this press release includes but may not be limited to the business of Stack Capital and the risks associated therewith, including those identified in the Annual Information Filing under the heading “Risk Factors”.

    Forward-looking statements or information are based on a number of factors and assumptions which have been used to develop such statements and information, but which may prove to be incorrect. Although Stack Capital believes that the expectations reflected in such forward-looking statements or information are reasonable, undue reliance should not be placed on forward-looking statements because Stack Capital can give no assurance that such expectations will prove to be correct. Factors that could cause actual results to differ materially from those described in such forward-looking information include, but are not limited to, the ability to capitalize on investment opportunities. The forward-looking information in this press release reflects the current expectations, assumptions and/or beliefs of Stack Capital based on information currently available to Stack Capital.

    Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Stack Capital disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events, or results or otherwise. The forward-looking statements or information contained in this press release are expressly qualified by this cautionary statement.

    The MIL Network –

    May 9, 2025
  • MIL-OSI Economics: US anesthesia and respiratory devices market faces disruption as tariffs drive supply chain shift, says GlobalData

    Source: GlobalData

    US anesthesia and respiratory devices market faces disruption as tariffs drive supply chain shift, says GlobalData

    Posted in Medical Devices

    The US anesthesia and respiratory (A&R) devices market faces major disruption as new US tariffs hit foreign-made products, with majority of all 510(k) approved devices manufactured outside the country. This raises serious supply chain concerns and may shift market dynamics in favor of domestic manufacturers, even as the market grows from $4.4 billion in 2023 to a projected $7.5 billion in 2033, according to GlobalData, a leading data and analytics company.

    An analysis of GlobalData’s Medsource Database reveals that an estimated 67% of all 510(k) approved A&R devices are manufactured outside the US while 54% of those are manufactured solely outside the US.

    Aidan Robertson, Medical Analyst at GlobalData, comments: “A&R may be especially susceptible to changes in trade policies as a significant portion of the products are manufactured outside the US. This may cause issues in how effectively these devices can be provided to the relevant patient population.”

    GlobalData attributes the US anesthesia and respiratory devices market growth to an aging population which in turn is increasing the prevalence of respiratory related illnesses as well as advancements in technology relating to A&R.

    Robertson continues: “Some barriers to the growth include the higher costs of newer anesthesia and respiratory devices, which can limit accessibility. More recently, the ongoing trade war has emerged as a key challenge, discouraging product development, disrupting medical device supply chains, and increasing costs for consumers.”

    With US tariffs on China still at 145%, the impact is significant on the estimated 17% of 510(k) approved anesthesia and respiratory products made in China, especially the 10% manufactured exclusively there.

    Robertson concludes: “Companies facing greater financial risk, such as Respironics, may consider shifting more production to the US. However, this can lead to significant short-term revenue losses, benefiting competitors with stronger domestic manufacturing operations. As a result, the US anesthesia and respiratory market may see a shift in market share as healthcare providers turn to suppliers better positioned to navigate the tariffs.”

    MIL OSI Economics –

    May 9, 2025
  • MIL-OSI Economics: India and Japan drive revenue growth among top 20 APAC banks as Chinese giants slow down, reveals GlobalData

    Source: GlobalData

    India and Japan drive revenue growth among top 20 APAC banks as Chinese giants slow down, reveals GlobalData

    Posted in Business Fundamentals

    The top 20 Asia-Pacific (APAC) banks saw a modest 6.5% increase in combined revenue from $1.6 trillion in 2023 to $1.75 trillion in 2024, driven by exceptional growth from Indian and Japanese banks. On the other hand, several Chinese banks faced stagnation or declines amid tighter regulations and slowing credit demand. This shift highlights evolving regional dynamics and signals changing leadership in APAC’s banking landscape, reveals GlobalData, a leading data and analytics company.

    Murthy Grandhi, Company Profiles Analyst at GlobalData, comments: “APAC banking landscape witnessed a striking shift in momentum in 2024, as Indian and Japanese banks delivered powerful revenue growth, some of the China’s traditionally dominant institutions recorded either marginal gains or outright declines. It also reveals not just a reshuffling of leaders, but also deeper structural signals driven by macroeconomic realignments, domestic policy shifts, and evolving capital flows.”

    Only three banks achieved revenue growth exceeding 40% in 2024: India’s HDFC Bank led with an impressive 89.5% year-on-year (YoY) increase, while Japan’s Sumitomo Mitsui Financial and Mizuho Financial followed with growth rates of 42.8% and 41.6%, respectively

    Grandhi explains: “HDFC Bank’s rise can be attributed to its merger with HDFC Ltd., robust retail lending growth, and digital banking expansion. Likewise, State Bank of India recorded a 19.4% jump to $72 billion, fueled by rising credit demand in infrastructure, manufacturing, and rural segments.

    “Japanese banks staged a strong comeback after years of modest performance. This surge is underpinned by enhanced cross-border M&A advisory, corporate lending in Southeast Asia, and increased activity in the green finance space.”

    Japan-based Mitsubishi UFJ Financial posted an 11.7% increase to $81.7 billion, reflecting stronger domestic lending and strategic international acquisitions.

    Chinese banks continued to dominate the revenue leaderboard, securing 11 of the top 20 positions. ICBC led with $227.9 billion in revenue, though it posted a slight YoY contraction of -0.6%. Similarly, China Construction Bank ($198.1 billion, -2%), Postal Savings Bank of China ($81.7 billion, -0.7%), and Shanghai Pudong Development Bank ($49.2 billion, -4.4%) reflected a slowdown. The declines stem from reduced credit demand, property sector headwinds, and the cautious lending stance amid tighter regulatory controls.

    Nevertheless, Bank of China showed resilience with a 2.6% increase in revenue to $177.6 billion, supported by strong offshore financing operations and currency settlements, benefiting from the yuan’s expanding role in trade settlements.

    Grandhi concludes: “As the global financial system braces for a volatile 2025, APAC banks are navigating a complex matrix of geopolitical tensions, tariff escalations, and tightening liquidity. The US-China trade recalibration, semiconductor export restrictions, and ongoing regional disputes could dampen cross-border capital flows and increase regulatory compliance costs.

    “However, banks with strong domestic franchises, digital agility, and diversified international exposure, especially in India, Japan, and Australia, are better positioned to weather uncertainty and tap into structural growth trends, including fintech adoption, infrastructure financing, and ESG-related lending. The year ahead will test these institutions not just on balance sheet strength but on their ability to adapt strategically in an evolving global order.”

    MIL OSI Economics –

    May 9, 2025
  • MIL-OSI Asia-Pac: HKEX chairman reappointed

    Source: Hong Kong Information Services

    The Chief Executive has approved the reappointment of Carlson Tong as Chairman of the Hong Kong Exchanges & Clearing Limited (HKEX) with immediate effect.

    Mr Tong was re-elected HKEX Chairman by the directors at the board meeting on April 30. The Chief Executive granted approval under the Securities & Futures Ordinance.

    Financial Secretary Paul Chan said under the leadership of Mr Tong, HKEX took forward various reforms, including enhancing the listing vetting process, implementing the specialist technology listing channel, establishing the Technology Enterprises Channel, and launching the trading arrangement under severe weather.

    Mr Chan also expressed confidence that with Mr Tong’s leadership, HKEX will continuously strive to enhance the competitiveness of Hong Kong’s capital market and consolidate the city’s status as a global leading international financial centre.

    Mr Tong’s chairmanship will coincide with his term of appointment as an HKEX board member, due to conclude at the end of the 2027 HKEX annual general meeting.

    MIL OSI Asia Pacific News –

    May 9, 2025
  • MIL-OSI Asia-Pac: HK hosts 6G summit

    Source: Hong Kong Information Services

    The 6G Global Summit opened in Hong Kong today, marking the first time for the summit to be held in the Asia-Pacific region.

    The two-day summit is being hosted by the Communications Authority and has attracted hundreds of representatives of regulatory bodies, telecommunications operators and corporations from more than 80 countries to explore the potential of sixth-generation (6G) mobile communications technology in shaping the future.

    In his keynote speech, Secretary for Commerce & Economic Development Algernon Yau said that Hong Kong is uniquely positioned to play a leading role in 6G development, with the Government committed to fostering a conducive environment for technological advancement and preparing for the 6G era.

    He noted that major mobile network operators in the city have actively commenced testing and successfully validating the 5G-Advanced network in various applications such as large-scale drone shows, world class sports events and more.

    As regards the Government’s efforts in the relevant areas, Mr Yau said: “We are also proactively exploring further facilitation measures from a telecommunications perspective to support the development of a low-altitude economy.”

    He also pointed out that the Government is conducting a study to streamline relevant licensing procedures for Low Earth Orbit satellites.

    For his part, Director-General of Communications Chaucer Leung noted at the summit’s opening ceremony that Hong Kong is the first economy in the world to have auctioned a radio spectrum in the upper six gigahertz band.

    The spectrum is suitable for the provision of 5G services now and 6G services in the future, he said, adding that the first set of technical standards for 6G is expected to be finalised in 2029 so that a commercial service can be introduced in the following year.

    The summit features discussions on 6G developments, including standardisation, technological innovations, sustainability and potential applications as well as the strategic role of the Asia-Pacific region and the opportunities presented by a more connected and intelligent global network.

    First held in 2022, this is the summit’s fourth edition. The previous two editions were held in Bahrain in 2023 and the UK in 2024.

    MIL OSI Asia Pacific News –

    May 9, 2025
  • MIL-OSI United Kingdom: Help us improve Park and Ride sites across York

    Source: City of York

    Published Thursday, 8 May 2025

    City of York Council has today begun a month-long public consultation to help inform the design of future improvements at five of York’s Park and Ride sites.

    The planned works aim to attract new customers to use the Park & Ride, and will provide more accessible, easier to use facilities and greater transport options such as improved cycling parking.  Five of York’s six Park and Ride sites are included in the project; Poppleton Bar, Grimston Bar, Askham Bar, Rawcliffe Bar and Monks Cross. The Designer Outlet Park and Ride site is not owned by the council, so will not be affected by the planned upgrades.

    The changes proposed include:

    • The introduction of overnight car parking at Rawcliffe Bar and Askham Bar Park and Ride sites to support the city’s residents and visitors, plus our thriving overnight economy.
    • Better located dedicated parking for oversized vehicles at Askham Bar, Rawcliffe Bar and Grimston Bar (daytime only). A new building will also be delivered to replace outdated facilities at Grimston
    • Improvements to the accessibility of the sites and parking areas; new waiting facilities, lighting, pathways, refurbished toilets including Changing Places facilities
    • Improved facilities for multi-modal trips. The improvements included will vary by site (e.g. long-distance bus and coach routes, car club vehicles, improved cycle parking and lockers).

    Overnight parking will offer greater flexibility to both residents taking trips away from York (e.g. using Park and Ride to connect to train services for commuting or a weekend away) as well as visitors coming into the city for overnight stays. It will be offered at Askham Bar and Rawcliffe Bar – chosen because they are most easily reached from major towns and cities such as Leeds.

    Some of the main principles of offering overnight parking are:

    • Drivers will have access to their cars 24 hours a day, so you can drop off or collect your car at any time
    • Offering a viable option for longer stays that avoids the need to drive into and pay for parking in the city centre, helping reduce congestion
    • The sites will have improved CCTV, security and lighting
    • Bus services won’t be running through the night. Taxis or cycles can be used to get to either site and collect your car during hours when buses aren’t running
    • The service will not be offered to vehicles higher than a small van – so will not be available for campervans or caravans. No facilities will be offered and no one will be able to stay in their vehicle overnight.

    The project is fully funded by the UK Government’s Bus Service Improvement Plan (BSIP). York was allocated over £17m to improve the city’s bus network and £4m of this has been allocated to improving the Park and Ride sites. Alongside the Park and Ride project, BSIP funding is being used to deliver an on-going programme of works to install new real-time information screens across the city and surrounding villages; improved lighting and shelters, plus reducing fares for young people to just £1.

    Last year saw a considerable increase in Park and Ride usage, with over 4.5m passenger journeys – the highest number since the Covid pandemic.

    Cllr Kate Ravilious, Executive Member for Transport at City of York Council, said:

    “York’s Park and Ride is already a huge success story, offering excellent services for York’s residents, commuters and visitors. This project will increase transport options for everyone, making the sites themselves more accessible, encouraging even greater use. By introducing overnight parking at two sites we will offer a convenient alternative to driving and parking in the city centre, helping to reduce traffic congestion, improve bus reliability and free up the roads for those who need to drive.

    “I’d encourage everyone, whether you live in York or further afield, and whether you use the Park and Ride or not, to feedback on our proposals and help us maximise the benefits of the Park & Ride site upgrades”.

    The consultation is open between Thursday 8 May and Monday 9 June.

    To take part people can:

    • Read and complete the online survey at ourbigconversation.york.gov.uk
    • Email us at ourbigconversation@york.gov.uk, or write to us via freepost: Park and Ride Consultation, Freepost RTEG-TYYU-KLTZ, City of York Council, West Offices, Station Rise, York, YO1 6GA
    • Phone customer services on 01904 551550 and they will pass a message to the project team

    To find out more visit ourbigconversation.york.gov.uk

    MIL OSI United Kingdom –

    May 9, 2025
  • MIL-OSI United Kingdom: Court upholds CMA’s £99m fine on pharma over excessive NHS thyroid drug prices

    Source: United Kingdom – Government Statements

    Press release

    Court upholds CMA’s £99m fine on pharma over excessive NHS thyroid drug prices

    The Court of Appeal has unanimously upheld the CMA’s finding that Advanz broke the law by overcharging the NHS for essential thyroid drug liothyronine.

    • CMA secures important win in the Court of Appeal after Advanz and Cinven sought to appeal
    • Court of Appeal also reinstated the CMA’s original fine of £51.9 million on Cinven after the CAT reduced the figure to £37.1 million in 2023
    • Total amount in fines stands at £99 million, divided amongst Advanz’s owners across the infringement period: £6.2m for HgCapital; £51.9m for Cinven; and £40.9m for Advanz

    In a unanimous judgment, the Court of Appeal has confirmed the Competition and Markets Authority’s (CMA) finding of excessive and unfair pricing in the supply of liothyronine tablets in the UK; and has reinstated the full penalty of £51.9 million imposed by the CMA on private equity firm Cinven.

    Liothyronine is an essential medicine used to treat thyroid hormone deficiency. In 2006, the total NHS annual spend on the tablets was £600,000. Between 2009 and 2017, Advanz, the sole supplier of liothyronine tablets in the UK, increased the price it charged from £20 to £248 per box – an increase of over 1,110%. As a result, NHS annual spending on liothyronine jumped from over £2.3 million in 2009 to more than £30 million by 2016.

    After an extensive investigation, in July 2021, the CMA found that Advanz had broken the law by this level of pricing to the NHS, without justification: the cost of producing the tablets did not increase significantly; and there was no evidence of meaningful innovation or investment by the supplier. The CMA fined Advanz Pharma (the current owner of the Advanz business) together with two former owners (HgCapital and Cinven) for their part in the infringement over their ownership periods.  

    All three companies originally appealed the CMA’s decision before the Competition Appeal Tribunal (CAT). In August 2023, the CAT fully upheld the CMA’s findings, but reduced the penalties imposed on HgCapital and Cinven.

    HgCapital decided not to pursue its appeal further, instead agreeing with the CMA to pay its fine of £6.2 million. Advanz and Cinven both sought permission to appeal the CAT’s decision to the Court of Appeal and the CMA, in turn, sought to overturn the CAT’s reduction in Cinven’s penalty.

    Following a 3-day hearing in December 2024, the Court of Appeal unanimously refused Advanz Pharma and Cinven permission to appeal the CAT judgment, ruling that they had no arguable basis upon which to challenge the CAT’s decision to uphold the CMA’s findings.

    The Court of Appeal also agreed that the CMA’s original penalty for Cinven was appropriate and reinstated it in full to £51.9 million.

    Sarah Cardell, Chief Executive of the CMA, said:

    This is another resounding win for the CMA in this case – and a vote of confidence for the work we do to protect consumers and tackle illegal behaviour.

    Prices charged to the NHS, and ultimately taxpayers, must be fair. We will continue to stand up for patients and take action against companies that abuse their market power, thereby harming consumers and the wider economy.

    For more information on the CMA’s investigation, visit the Liothyronine tablets: suspected excessive and unfair pricing case page.

    Notes for editors:

    1. For media queries, please contact the press office on press@cma.gov.uk or on 020 3738 6460.
    2. Advanz Pharma and Cinven both appealed against the CAT’s judgment. The CMA cross-appealed against the CAT’s reduction of Cinven’s penalty from £51.9 million to £37.1 million.
    3. HgCapital did not appeal the CAT’s judgment.
    4. A three-day hearing took place in December 2024 to hear all parties’ appeals. The Court of Appeal had adjourned all applications for permission to appeal the CAT’s judgment into a ’rolled-up’ hearing of both those applications for permission and the substantive appeals.
    5. Previous action taken by the CMA in relation to the pharmaceutical sector and the fines imposed:
      •      Fludrocortisone (2019): £2.3 million in fines and £8 million redress to the NHS for market-sharing.
      •       Nortriptyline (2020): £3.4 million in fines and £1 million redress to the NHS for illegal arrangements including market-sharing and information exchange.
      •       Paroxetine (2021): £27.1 million in fines for anti-competitive agreements and abuse of dominance.
      •       Hydrocortisone (2021): £260 million in fines for excessive and unfair pricing and market sharing (currently under appeal).

    Share this page

    The following links open in a new tab

    • Share on Facebook (opens in new tab)
    • Share on Twitter (opens in new tab)

    Updates to this page

    Published 8 May 2025

    MIL OSI United Kingdom –

    May 9, 2025
  • MIL-OSI Russia: /Economic Review/ New Professions Fuel China’s Booming Cultural and Tourism Sector

    Translation. Region: Russian Federal

    Source: People’s Republic of China in Russian – People’s Republic of China in Russian –

    Source: People’s Republic of China – State Council News

    CHANGCHUN, May 8 (Xinhua) — As dawn broke over Mount Taishan in east China’s Shandong Province, 26-year-old Wang Yang packed his backpack with essentials such as a first aid kit, trekking poles and sugar candies to replenish his energy.

    He is preparing to lead a family of five on a six-hour climb to the summit, his seventh tour group over the five-day May Day weekend that ended Monday.

    Wang Yang is part of a growing trend of “climbing guides” – people who keep company as they explore China’s scenic beauty spots. The new profession, which attracts students, mountaineering enthusiasts and guesthouse owners, offers personalized services such as route planning, photography and even “encouraging verbal therapy” to hikers along the way.

    Charging service fees ranging from 400 to 1,500 yuan (US$55 to US$208) depending on the difficulty of the route, some such guides manage to earn up to 30,000 yuan a month.

    The emergence of the new profession reflects a broader boom in tourism. For example, in the first quarter of 2025, Taishan was visited 1.27 million times, up 12.6 percent year-on-year. In 2023 and 2024, the mountain was visited more than 8 million times annually.

    “The move towards personalized and specialized services also reflects a significant increase in consumer demand,” said Wang Yang, who, thanks to his newfound knowledge of emergency medical care, was able to help revive a tourist suffering from hypoglycemia.

    About 1,000 kilometers away in northeast China’s Jilin Province, 50-year-old Yu Wei sat in a ski resort cabin, studying a thick stack of work notes. A technician by training, he played a key role in developing China’s first national standards for “ski patrol rescuers,” a newly recognized national profession.

    When Yu Wei entered the industry in 1995, China’s ski resorts relied on equipment donated by foreign countries and had few active holidaymakers. But that all changed after Beijing won the 2022 Winter Olympics in 2015, and ski visits to the country’s ski slopes increased to 234 million in 2024-25.

    “Now that 70 percent of skiers are snowboarding and trying difficult tricks, rescue work requires new skills,” said Yu Wei, whose team has developed protocols such as the “18-minute golden patrol cycle” to meet the changing demands of the sport.

    The emergence of new roles in the tourism industry, from food reviewers to sports technicians, reflects broader changes in society. Song Zhiqiang, a popular content creator from Yanbian Korean Autonomous Region (Jilin Province, northeast China), has turned food vlogging into a powerful marketing tool, increasing local sales and consumption by more than 10 million yuan. Industry data shows that social media influencers like Song Zhiqiang will help the country’s entrepreneurs earn 133.3 billion yuan in 2024.

    Since 2019, China has officially recognized 93 new occupations, with the total number of “new economy” workers reaching 84 million people, accounting for 21 percent of the country’s total workforce.

    “These occupations are not just jobs; they are indicators of rising consumption levels,” said Zhou Guangxu, an associate professor at the Institute of Labor Affairs at Renmin University of China. -0-

    MIL OSI Russia News –

    May 9, 2025
  • MIL-OSI Europe: Press release – Parliament backs extension of trade liberalisation measure for Ukrainian imports

    Source: European Parliament 3

    MEPs voted on Thursday to renew the suspension of import duties and quotas for certain imports from Ukraine, such as iron and steel, due to expire on 5 June 2025.

    With the adoption of the Autonomous Trade Measures (ATM) Regulation, the EU liberalised trade with Ukraine by suspending trade defence measures on 4 June 2022. This exemption has since been renewed, with the most recent extension due to expire on 5 June.

    MEPs have now approved the proposed prolongation of these trade liberalisation measures, which focus steel, to provide Ukraine with vital export revenues.

    Quote

    Parliament’s rapporteur Karin Karlsbro (Renew, SE) said: ”Ukraine’s steel industry is the backbone of the Ukrainian economy. It continues to deliver, despite many workers having left the steel plants to fight on the front lines and factories being subjected to severe attacks by Russia. The deepening of trade relations between the EU and Ukraine is not a matter of charity, but a mutually beneficial exchange that strengthens both parties.”

    The proposal was adopted by 354 votes in favour and 147 against, with 53 abstentions. The new regulation will enter into force for three years, until June 2028, once an agreement has been reached with the Council.

    The Commission is currently working on a longer-term solution to offer economic certainty for EU-Ukraine trade.

    MIL OSI Europe News –

    May 9, 2025
  • MIL-OSI: Royalty Pharma Reports First Quarter 2025 Results

    Source: GlobeNewswire (MIL-OSI)

    • Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%
    • Net cash provided by operating activities of $596 million
    • Raised full year 2025 guidance: Portfolio Receipts expected to be $2,975 to $3,125 million

    NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts.

    “Our business momentum continued in the first quarter of 2025 as we delivered double-digit growth in Portfolio Receipts and raised our financial guidance,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Guided by our dynamic capital allocation framework, we repurchased over $700 million of our Class A ordinary shares given our attractive outlook, we expanded our development-stage portfolio with an R&D funding partnership with Biogen and we again increased our quarterly dividend. Looking ahead, we have strong fundamental tailwinds underpinning our business with a robust deal pipeline and we remain on track to acquire our external manager in the second quarter. We plan to share further details on our attractive long-term outlook at our upcoming Investor Day in September.”

    Double-digit growth in Royalty Receipts and Portfolio Receipts

    • Royalty Receipts grew 12% to $788 million, primarily driven by strong performance from the cystic fibrosis franchise, Trelegy and Xtandi.
    • Portfolio Receipts increased by 17% to $839 million.

    Significant repurchase activity under recently announced $3 billion authorization

    • Repurchased 23 million Class A ordinary shares for $723 million guided by dynamic capital allocation framework.
    • Capital Deployment of $101 million; entered into Phase 3 R&D funding collaboration for Biogen’s litifilimab.
    • Increased quarterly dividend by approximately 5%.

    Positive clinical and regulatory updates across royalty portfolio

    • Johnson & Johnson’s Tremfya received FDA and EC approval in Crohn’s disease, EC approval in ulcerative colitis.
    • Positive Phase 3 results for Emalex’s ecopipam in Tourette syndrome.
    • Roche to initiate a Phase 3 program for trontinemab in Alzheimer’s disease later this year.

    Raised financial guidance for full year 2025 (excludes contribution from future transactions)

    • Royalty Pharma expects 2025 Portfolio Receipts to be between $2,975 million and $3,125 million, representing expected growth of 6% to 12%.
    • The company expects to update 2025 guidance for payments and operating and professional costs and interest paid after the closing of the internalization transaction, which is expected in the second quarter of 2025.

    Financial & Liquidity Summary

      Three Months Ended March 31,
      (unaudited)
    ($ and shares in millions) 2025 2024 Change
    Portfolio Receipts 839 717 17%
    Net cash provided by operating activities 596 665 (10)%
    Adjusted EBITDA (non-GAAP)* 738 656 12%
    Portfolio Cash Flow (non-GAAP)* 611 584 5%
    Weighted average Class A ordinary shares outstanding – diluted 578 597 (3)%

    *See “Liquidity and Capital Resources” section. Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures calculated in accordance with the credit agreement.

    Portfolio Receipts Highlights

          Three Months Ended March 31,
          (unaudited)
    ($ in millions)     2025 2024 Change
    Products: Marketers: Therapeutic Area:      
    Cystic fibrosis franchise Vertex Rare disease 250 218 14%
    Trelegy GSK Respiratory 85 71 21%
    Tysabri Biogen Neuroscience 61 69 (12)%
    Evrysdi Roche Rare disease 53 45 17%
    Xtandi Pfizer, Astellas Cancer 52 41 28%
    Imbruvica AbbVie, J&J Cancer 46 50 (8)%
    Promacta Novartis Hematology 44 43 4%
    Tremfya Johnson & Johnson Immunology 36 36 (1)%
    Cabometyx/Cometriq Exelixis, Ipsen, Takeda Cancer 21 18 16%
    Spinraza Biogen Rare disease 13 7 95%
    Trodelvy Gilead Cancer 13 10 23%
    Erleada Johnson & Johnson Cancer 11 9 21%
    Other products(5) 105 88 19%
    Royalty Receipts 788 705 12%
    Milestones and other contractual receipts 51 12 309%
    Portfolio Receipts 839 717 17%

    Amounts shown in the table may not add due to rounding.

    Royalty Receipts was $788 million in the first quarter of 2025, an increase of 12% compared to $705 million in the first quarter of 2024. The increase was primarily driven by strong growth from the cystic fibrosis franchise, Trelegy and Xtandi, as well as royalties from the 2024 launch of Voranigo.

    Portfolio Receipts was $839 million in the first quarter of 2025, an increase of 17% compared to $717 million in the first quarter of 2024, primarily driven by the same Royalty Receipts increases noted above and a milestone payment of $27 million related to Airsupra.

    Liquidity and Capital Resources

    Royalty Pharma’s liquidity and capital resources are summarized below:

    As of March 31, 2025, Royalty Pharma had cash and cash equivalents of $1.1 billion and total debt with principal value of $7.8 billion.

    In January 2025, Royalty Pharma completed the sale of the MorphoSys Development Funding Bonds for $511 million in upfront cash. This payment, combined with quarterly repayments received prior to the sale, resulted in total cash proceeds of $530 million on the $300 million investment that was made in September 2022. The proceeds provide added flexibility to pursue the company’s dynamic capital allocation strategy.

    In January 2025, Royalty Pharma announced a new share repurchase program under which it may repurchase up to $3.0 billion of its Class A ordinary shares. During the first quarter of 2025, Royalty Pharma repurchased approximately 23 million Class A ordinary shares for $723 million. During the first quarter of 2024, Royalty Pharma did not repurchase any Class A ordinary shares. The weighted-average number of diluted Class A ordinary shares outstanding for the first quarter of 2025 was 578 million as compared to 597 million for the first quarter of 2024.

    Liquidity Summary

      Three Months Ended March 31,
      (unaudited)
    ($ in millions) 2025   2024  
    Portfolio Receipts 839   717  
    Payments for operating and professional costs (102)   (61)  
    Adjusted EBITDA (non-GAAP) 738   656  
    Interest paid, net (127)   (73)  
    Portfolio Cash Flow (non-GAAP) 611   584  

    Amounts may not add due to rounding.

    • Adjusted EBITDA (non-GAAP) was $738 million in the first quarter of 2025. Adjusted EBITDA is calculated as Portfolio Receipts minus payments for operating and professional costs. Payments for operating and professional costs for the first quarter of 2025 included a $33 million one-time payment related to the management fee on the sale of the MorphoSys Development Funding Bonds.
    • Portfolio Cash Flow (non-GAAP) was $611 million in the first quarter of 2025. Portfolio Cash Flow is calculated as Adjusted EBITDA minus interest paid or received, net. This measure reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases, or utilized for other discretionary investments.

    Refer to Table 4 for Royalty Pharma’s reconciliation of each non-GAAP measure to the most directly comparable GAAP financial measure, net cash provided by operating activities.

    Capital Deployment reflects cash payments during the period for new and previously announced transactions. Capital Deployment was $101 million in the first quarter of 2025, consisting primarily of the upfront research and development (“R&D”) funding for litifilimab (discussed further below) and a milestone payment related to Trelegy.

    In April 2025, Ferring Pharmaceuticals announced U.S. Food and Drug Administration (“FDA”) approval of a new manufacturing hub in Parsippany, NJ for Adstiladrin, its novel gene therapy for bladder cancer. The approval triggered a $200 million milestone payment that was paid in the second quarter of 2025 as part of the royalty agreement announced in 2023.

    The table below details Capital Deployment by category:

    Capital Deployment

      Three Months Ended March 31,
      (unaudited)
    ($ in millions) 2025   2024  
    Acquisitions of financial royalty assets (1)   (86)  
    Development-stage funding payments (51)   (1)  
    Milestone payments (50)   —  
    Investments in equity method investees —   (7)  
    Contributions from legacy non-controlling interests – R&D 0   0  
    Capital Deployment (101)   (93)  

    Amounts may not add due to rounding.

    Royalty Transactions

    In February 2025, Royalty Pharma entered into an R&D funding arrangement with Biogen to provide up to $250 million over six quarters, including $50 million upfront for the development of litifilimab. Litifilimab is in Phase 3 development for the treatment of lupus. The announced transaction amount reflects the entire amount of capital committed for new transactions during the year, including potential future milestones.

    The information in this section should be read together with Royalty Pharma’s reports and documents filed with the SEC at www.sec.gov and the reader is also encouraged to review all other press releases and information available in the Investors section of Royalty Pharma’s website at www.royaltypharma.com.

    Internalization Transaction

    In January 2025, Royalty Pharma agreed to acquire its external manager, RP Management, LLC (the “Manager”) (press release). This transaction to simplify Royalty Pharma’s corporate structure is expected to result in multiple benefits for shareholders. On a financial basis, the acquisition is expected to reduce costs and enhance economic returns on investments. Specifically, the acquisition will generate cash savings of greater than $100 million in 2026, rising to greater than $175 million in 2030 and driving cumulative savings of greater than $1.6 billion over ten years. The acquisition also increases shareholder alignment, enhances corporate governance, ensures management continuity and simplifies Royalty Pharma’s corporate structure.

    The total transaction value of approximately $1.1 billion(7) consists of approximately 24.5 million shares of Royalty Pharma equity that will vest over five to nine years, approximately $100 million in cash(8), and the assumption of $380 million of the Manager’s existing debt.

    The closing of the internalization transaction is subject to shareholders’ approval of the issuance of the share consideration and other customary closing conditions, including required regulatory approvals. The shareholder meeting will take place on May 12, 2025 and the transaction is estimated to close during the second quarter of 2025.

    Key Developments Relating to the Portfolio

    The key developments related to Royalty Pharma’s royalty interests are discussed below based on disclosures from the marketers of the products.

    Tremfya In May 2025, Johnson & Johnson announced that the European Commission (“EC”) approved Tremfya for the treatment of adult patients with moderately to severely active Crohn’s disease.

    In April 2025, Johnson & Johnson announced that the EC approved Tremfya for the treatment of adult patients with moderately to severely active ulcerative colitis.

    In March 2025, Johnson & Johnson announced that the FDA approved Tremfya, which is now the first and only IL-23 offering both subcutaneous and intravenous induction options for the treatment of adults with moderately to severely active Crohn’s disease.

    aficamten In May 2025, Cytokinetics announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application for aficamten to December 26, 2025. The FDA notified Cytokinetics that additional time is required to conduct a full review of the company’s proposed Risk Evaluation and Mitigation Strategy (REMS). No additional clinical data or studies have been requested of Cytokinetics by the FDA.
    Cobenfy In April 2025, Bristol Myers Squibb announced that topline results from the Phase 3 ARISE trial evaluating Cobenfy as an adjunctive treatment to atypical antipsychotics in adults with schizophrenia did not reach the threshold for a statistically significant difference compared to placebo with an atypical antipsychotic for the primary endpoint of the change from baseline to Week 6 in the Positive and Negative Syndrome Scale (PANSS) total score.
    Trodelvy In April 2025, Gilead announced positive topline results from the Phase 3 Ascent-04/Keynote-D19 study, demonstrating that Trodelvy plus Keytruda significantly improved progression-free survival (“PFS”) compared to Keytruda and chemotherapy in patients with previously untreated PD-L1+ metastatic triple-negative breast cancer. Overall survival (“OS”), a key secondary endpoint, was not mature at the time of the PFS primary analysis. However, there was an early trend in improvement for OS with Trodelvy plus Keytruda. Gilead will continue to monitor OS outcomes, with ongoing patient follow-up and further analyses.
    trontinemab In April 2025, Roche announced that new trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase 1b/2a Brainshuttle AD study. Roche expects to initiate a Phase 3 program for trontinemab later this year.
    ecopipam In February 2025, Emalex announced positive Phase 3 results for ecopipam in patients with Tourette syndrome. The study showed statistical significance between ecopipam and placebo for both the primary efficacy endpoint in pediatrics and the secondary efficacy endpoint in pediatrics and adults. Emalex will meet with the FDA and other global health authorities to discuss submission later this year of a New Drug Application (“NDA”).
    Spinraza In January 2025, Biogen announced that the FDA accepted the supplemental NDA and the European Medicines Agency validated the application for a higher dose regimen of Spinraza for spinal muscular atrophy.
    TEV-‘749 In January 2025, Teva announced that TEV-’749 (olanzapine LAI) achieved Phase 3 targeted injections without PDSS (post-injection delirium/sedation syndrome), and the full safety presentation is expected in the second quarter of 2025.


    2025 Financial Outlook

    Royalty Pharma has provided guidance for full year 2025, excluding new transactions and borrowings announced after the date of this release, as follows:

      Provided May 8th, 2025 Previous
    Portfolio Receipts $2,975 million to $3,125 million
    (Growth of ~+6% to 12% year/year)
    $2,900 million to $3,050 million
    (Growth of ~+4% to 9% year/year)
    Payments for operating and professional costs Approximately 10% of Portfolio Receipts Approximately 10% of Portfolio Receipts
    Interest paid $260 million $260 million

    The above Portfolio Receipts guidance represents expected growth of 6% to 12% in 2025. Royalty Pharma’s full year 2025 guidance reflects a negligible estimated foreign exchange impact to Portfolio Receipts, assuming current foreign exchange rates prevail for the rest of 2025.

    2025 guidance for payments for operating and professional costs and interest paid does not reflect the impact of the internalization transaction announced on January 10, 2025 and will be updated following the closing of the internalization transaction, which is expected in the second quarter of 2025.

    Total interest paid is based on the semi-annual interest payment schedule of Royalty Pharma’s existing notes and is anticipated to be approximately $260 million in 2025. Interest paid in the third quarter of 2025 is anticipated to be $119 million. De minimis amounts are anticipated in the second and fourth quarter of 2025. These projections assume no additional debt financing in 2025, including no drawdown on the revolving credit facility. In the first quarter of 2025, Royalty Pharma collected interest of $12 million on its cash and cash equivalents, which partially offset interest paid.

    Royalty Pharma today provides this guidance based on its most up-to-date view of its prospects. This guidance assumes no major unforeseen adverse events or changes in foreign exchange rates and excludes the contributions from transactions announced subsequent to the date of this press release.

    Financial Results Call

    Royalty Pharma will host a conference call and simultaneous webcast to discuss its first quarter 2025 results today at 8:30 a.m., Eastern Time. Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company’s website for at least 30 days.

    About Royalty Pharma plc

    Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 15 development-stage product candidates.

    Forward-Looking Statements

    The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

    This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities, market growth and plans for capital deployment, plus the benefits of the internalization transaction, including expected accretion, enhanced alignment with shareholders, increased investment returns, expectations regarding management continuity, transparency and governance, and the benefits of simplification to its structure. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.
    Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company’s own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source.

    For further information, please reference Royalty Pharma’s reports and documents filed with the U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR on the SEC’s website at www.sec.gov.

    Portfolio Receipts

    Portfolio Receipts is a key performance metric that represents Royalty Pharma’s ability to generate cash from Royalty Pharma’s portfolio investments, the primary source of capital that is deployed to make new portfolio investments. Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. Royalty Receipts includes variable payments based on sales of products, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma.

    Milestones and other contractual receipts include sales-based or regulatory milestone payments and other fixed contractual receipts, net of contractual payments to legacy non-controlling interests, that are attributed to Royalty Pharma. Portfolio Receipts does not include royalty receipts and milestones and other contractual receipts that were received on an accelerated basis under the terms of the agreement governing the receipt or payment. Portfolio Receipts also does not include proceeds from equity securities or proceeds from purchases and sales of marketable securities, both of which are not central to Royalty Pharma’s fundamental business strategy.

    Portfolio Receipts is calculated as the sum of the following line items from Royalty Pharma’s GAAP condensed consolidated statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities and Distributions from equity method investees less Distributions to legacy non-controlling interests – Portfolio Receipts, which represent contractual distributions of Royalty Receipts, milestones and other contractual receipts to the Legacy Investors Partnerships.

    Use of Non-GAAP Measures

    Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures that exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. Management believes that Adjusted EBITDA and Portfolio Cash Flow are important non-GAAP measures used to analyze liquidity because they are key components of certain material covenants contained within Royalty Pharma’s credit agreement. Royalty Pharma cautions readers that amounts presented in accordance with the definitions of Adjusted EBITDA and Portfolio Cash Flow may not be the same as similar measures used by other companies or analysts. These non-GAAP liquidity measures have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of Royalty Pharma’s results as reported under GAAP.

    The definitions of Adjusted EBITDA and Portfolio Cash Flow used by Royalty Pharma are the same as the definitions in the credit agreement. Noncompliance with the interest coverage ratio, leverage ratio and Portfolio Cash Flow ratio covenants under the credit agreement could result in lenders requiring the company to immediately repay all amounts borrowed. If Royalty Pharma cannot satisfy these covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA and Portfolio Cash Flow are critical to the assessment of Royalty Pharma’s liquidity.

    Adjusted EBITDA and Portfolio Cash Flow are used by management as key liquidity measures in the evaluation of the company’s ability to generate cash from operations. Management uses Adjusted EBITDA and Portfolio Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, debt repayments, dividends and other discretionary investments. Further, these non-GAAP liquidity measures help management, the audit committee and investors evaluate the company’s ability to generate liquidity from operating activities.

    The company has provided reconciliations of these non-GAAP liquidity measures to the most directly comparable GAAP financial measure, being net cash provided by operating activities in Table 4.

    Royalty Pharma Investor Relations and Communications

    +1 (212) 883-6772
    ir@royaltypharma.com

     
    Royalty Pharma plc
    Condensed Consolidated Statements of Operations (unaudited)
    Table 1
     
      Three Months Ended March 31,
    ($ in millions) 2025   2024  
    Income and other revenues    
    Income from financial royalty assets 539   542  
    Other royalty income and revenues 29   26  
    Total income and other revenues 568   568  
    Operating (income)/expense    
    Provision for changes in expected cash flows from financial royalty assets (127)   584  
    Research and development funding expense 51   1  
    General and administrative expenses 111   58  
    Total operating expense, net 34   642  
    Operating income/(loss) 534   (74)  
    Other (income)/expense    
    Equity in (earnings)/losses of equity method investees (6)   14  
    Interest expense 65   44  
    Other expense/(income), net 42   (128)  
    Total other expense/(income), net 101   (70)  
    Consolidated net income/(loss) before tax 433   (4)  
    Income tax expense —   —  
    Consolidated net income/(loss) 433   (4)  
    Net income/(loss) attributable to non-controlling interests 195   (9)  
    Net income attributable to Royalty Pharma plc 238   5  

    Amounts may not add due to rounding.

     
    Royalty Pharma plc
    Selected Balance Sheet Data (unaudited)
    Table 2
     
    ($ in millions) As of March 31, 2025 As of December 31, 2024
    Cash and cash equivalents 1,088 929
    Total current and non-current financial royalty assets, net 15,749 15,911
    Total assets 17,608 18,223
    Current portion of long-term debt 999 998
    Long-term debt, net of current portion 6,619 6,615
    Total liabilities 7,820 7,880
    Total shareholders’ equity 9,789 10,342

     

     
    Royalty Pharma plc
    Condensed Consolidated Statements of Cash Flows (unaudited)
    Table 3
     
       
      Three Months Ended March 31,
    ($ in millions) 2025   2024  
    Cash flows from operating activities:    
    Cash collections from financial royalty assets 830   745  
    Cash collections from intangible royalty assets 0   14  
    Other royalty cash collections 32   26  
    Distributions from equity method investees 13   13  
    Interest received 12   6  
    Development-stage funding payments (51)   (1)  
    Payments for operating and professional costs (102)   (61)  
    Interest paid (139)   (79)  
    Net cash provided by operating activities 596   665  
    Cash flows from investing activities:    
    Distributions from equity method investees 36   5  
    Investments in equity method investees —   (7)  
    Purchases of equity securities (4)   —  
    Proceeds from available for sale debt securities 13   1  
    Proceeds from sales of available for sale debt securities 511   —  
    Acquisitions of financial royalty assets (1)   (86)  
    Milestone payments (50)   —  
    Net cash provided by/(used in) investing activities 504   (87)  
    Cash flows from financing activities:    
    Distributions to legacy non-controlling interests – Portfolio Receipts (85)   (88)  
    Distributions to continuing non-controlling interests (54)   (32)  
    Dividends to shareholders (95)   (94)  
    Repurchases of Class A ordinary shares (709)   —  
    Contributions from legacy non-controlling interests – R&D 0   0  
    Contributions from non-controlling interests – other 1   1  
    Net cash used in financing activities (941)   (212)  
    Net change in cash and cash equivalents 159   366  
    Cash and cash equivalents, beginning of period 929   477  
    Cash and cash equivalents, end of period 1,088   843  

    Amounts may not add due to rounding.

     
    Royalty Pharma plc
    GAAP to Non-GAAP Reconciliation (unaudited)
    Table 4
     
      Three Months Ended March 31,
    ($ in millions) 2025   2024  
    Net cash provided by operating activities (GAAP) 596   665  
    Adjustments:    
    Proceeds from available for sale debt securities(6) 13   1  
    Distributions from equity method investees(6) 36   5  
    Interest paid, net(6) 127   73  
    Development-stage funding payments 51   1  
    Distributions to legacy non-controlling interests – Portfolio Receipts(6) (85)   (88)  
    Adjusted EBITDA (non-GAAP) 738   656  
    Interest paid, net(6) (127)   (73)  
    Portfolio Cash Flow (non-GAAP) 611   584  

    Amounts may not add due to rounding.

     
    Royalty Pharma plc
    Description of Approved Indications for Select Portfolio Therapies
    Table 5
     
    Cystic fibrosis franchise Cystic fibrosis
    Trelegy Chronic obstructive pulmonary disease and asthma
    Tysabri Relapsing forms of multiple sclerosis
    Evrysdi Spinal muscular atrophy
    Xtandi Prostate cancer
    Imbruvica Hematological malignancies and chronic graft versus host disease
    Promacta Chronic immune thrombocytopenia purpura and aplastic anemia
    Tremfya Plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease
    Cabometyx/Cometriq Kidney, liver and thyroid cancer
    Spinraza Spinal muscular atrophy
    Trodelvy Breast and bladder cancer
    Erleada Prostate cancer


    Notes

    (1)   Portfolio Receipts is a key performance metric that represents our ability to generate cash from Royalty Pharma’s portfolio investments, the primary source of capital that Royalty Pharma can deploy to make new portfolio investments. Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. Royalty Receipts includes variable payments based on sales of products, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma (“Royalty Receipts”). Milestones and other contractual receipts include sales-based or regulatory milestone payments and other fixed contractual receipts, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma. Portfolio Receipts does not include royalty receipts and milestones and other contractual receipts that were received on an accelerated basis under the terms of the agreement governing the receipt or payment. Portfolio Receipts also does not include proceeds from equity securities or marketable securities, both of which are not central to Royalty Pharma’s fundamental business strategy.

    Portfolio Receipts is calculated as the sum of the following line items from Royalty Pharma’s GAAP condensed consolidated statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities and Distributions from equity method investees less Distributions to legacy non-controlling interests – Portfolio Receipts, which represent contractual distributions of Royalty Receipts, milestones and other contractual receipts to the Legacy Investors Partnerships.

    (2)   Adjusted EBITDA is defined under the credit agreement as Portfolio Receipts minus payments for operating and professional costs. Operating and professional costs reflect Payments for operating and professional costs from the GAAP statements of cash flows. See GAAP to Non-GAAP reconciliation in Table 4.

    (3)   Portfolio Cash Flow is defined under the credit agreement as Adjusted EBITDA minus interest paid or received, net. See GAAP to Non-GAAP reconciliation in Table 4. Portfolio Cash Flow reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases or utilized for other discretionary investments.

    (4)   Capital Deployment is calculated as the summation of the following line items from Royalty Pharma’s GAAP condensed consolidated statements of cash flows: Investments in equity method investees, Purchases of available for sale debt securities, Acquisitions of financial royalty assets, Acquisitions of other financial assets, Milestone payments, Development-stage funding payments less Contributions from legacy non-controlling interests – R&D.

    (5)   Other products primarily include Royalty Receipts on the following products: Cimzia, Crysvita, Emgality, Entyvio, Farxiga/Onglyza, IDHIFA, Nesina, Nurtec ODT, Orladeyo, Rytelo, Soliqua, Voranigo and distributions from the Legacy SLP Interest, which is presented as Distributions from equity method investees on the GAAP condensed consolidated statements of cash flows.

    (6)   The table below shows the line item for each adjustment and the direct location for such line item on the GAAP condensed consolidated statements of cash flows.

    Reconciling Adjustment Statements of Cash Flows Classification
    Interest paid, net Operating activities (Interest paid less Interest received)
    Distributions from equity method investees Investing activities
    Proceeds from available for sale debt securities Investing activities
    Distributions to legacy non-controlling interests – Portfolio Receipts Financing activities
       

    (7)   The total transaction value of approximately $1.1 billion is based on the closing price of Royalty Pharma plc common stock of $26.20 on January 8, 2025.

    (8)   Consists of $200 million in cash less the amount of the management fees paid to the Manager from January 1, 2025 through the closing of the transaction.

    The MIL Network –

    May 8, 2025
  • MIL-OSI: Lucinity Featured in Chartis Research FinCrime and Compliance 50 Ranking for 2025

    Source: GlobeNewswire (MIL-OSI)

    REYKJAVIK, Iceland, May 08, 2025 (GLOBE NEWSWIRE) — Lucinity has been listed among the top 50 Financial Crime and Compliance (FCC) companies in the 2025 FCC50 ranking by Chartis Research. This recognition reflects Lucinity’s continued ability to deliver impactful, practical AI-driven solutions that help financial institutions address compliance challenges efficiently and consistently. Lucinity was selected from over 300 vendors evaluated for their innovation, client value, and measurable market impact. 

    The Chartis FCC50 report showcases leading companies shaping the $22 billion Regtech market at a time when demand for automation, scalable tools, and reliable AI is rising. The FCC50 ranking highlights vendors who demonstrate product maturity, successful GenAI integrations, and support for real-time, typology-specific workflows.  

    The 2025 report highlights how vendors like Lucinity, a leading company in AI and automation for financial crime, are shaping the compliance landscape. “Being included once again in the FCC50 validates our focus on improving the productivity and consistency of FinCrime investigations for compliance teams,” said Gudmundur Kristjansson, Founder and CEO of Lucinity. “We’ve always believed in delivering intelligent automation with a clear return on investment—tools that save time, cut costs, and improve compliance.” 

    Lucinity’s placement in this year’s FCC50 highlights its strong performance in innovation, case management functionality, and strategic execution. A key differentiator is the Luci AI Agent embedded within its Case Manager. Luci is an AI agent that autonomously executes complex tasks—like generating narratives, updating workflows, or escalating alerts—based on user intent or system events, driving real-time, proactive automation in financial crime operations. The platform allows institutions to reduce average case review times from 2.5 hours to just 25 minutes—a reduction validated by tier 1 financial institutions. 

    Another key differentiator is that Lucinity’s modular SaaS offering requires no system overhaul and integrates easily with third-party tools, enabling institutions to consolidate fragmented compliance efforts into a unified investigative workflow. The launch of Luci’s plugin further extended Lucinity’s reach, allowing financial institutions to deploy AI functionality across enterprise apps like Excel and CRM systems, delivering ROI from day one. 

    This achievement marks another milestone in a strong year for Lucinity, which follows previous recognition in Gartner’s Cool Vendors report, awards from Datos Insights, Microsoft Azure listing, and last year’s FCC50 ranking. Lucinity now continues to focus on expanding its AI software and scaling cost-efficient compliance solutions across North America and Europe.  

    About Lucinity 
    Lucinity is a SaaS company specializing in artificial intelligence for financial crime compliance with headquarters in Reykjavik, Iceland. Its platform accelerates investigations, reduces review times, and simplifies compliance through tools like the Luci AI Agent, Case Manager, Customer 360, Transaction Monitoring, and Regulatory Reporting. The company operates globally and serves major financial institutions across North America and Europe.

    Contact:
    celina@lucinity.com

    The MIL Network –

    May 8, 2025
  • MIL-OSI: Caliber Announces First Quarter 2025 Earnings Release & Conference Call

    Source: GlobeNewswire (MIL-OSI)

    SCOTTSDALE, Ariz., May 08, 2025 (GLOBE NEWSWIRE) — Caliber (NASDAQ: CWD), a real estate investor, developer, and manager, today announced that it will release its first quarter 2025 financial results after the close of the market on Thursday, May 15, 2025. Management invites all interested parties to its webcast/conference call the same day at 5:00 pm ET to discuss the results.

    Investors and interested parties can access the live earnings call by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) and ask to join the Caliber call or use conference ID 8746759.

    To listen to the call online, investors can visit the investor relations page of Caliber’s website at https://ir.caliberco.com/. The webcast replay of the conference call will be available on Caliber’s website shortly after the call concludes.

    Additional details:
    The news release and presentation materials will also be available on the Investor Relations site under “Financial Results”.

    About Caliber (CaliberCos Inc.)

    With over $2.9 billion in Managed Assets, Caliber’s 16-year track record of managing and developing real estate is built on a singular goal: to make money in all market conditions, specializing in hospitality, multi-family residential, and multi-tenant industrial. Our growth is fueled by performance and a key competitive advantage: we invest in projects, strategies, and geographies that global real estate institutions often overlook. Integral to this advantage is our in-house shared services group, which gives Caliber greater control over our real estate and enhanced visibility into future investment opportunities. There are multiple ways to participate in Caliber’s success: invest in Nasdaq-listed CaliberCos Inc. and/or invest directly in our Private Funds.

    Forward-Looking Statements
    This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the Company’s public offering filed with the SEC and other reports filed with the SEC thereafter. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

    CONTACTS:
    Caliber Investor Relations:
    Ilya Grozovsky
    +1 480-214-1915
    Ilya@CaliberCo.com

    The MIL Network –

    May 8, 2025
  • MIL-OSI: CoreCard Corporation Reports First Quarter 2025 Results

    Source: GlobeNewswire (MIL-OSI)

    NORCROSS, Ga., May 08, 2025 (GLOBE NEWSWIRE) — CoreCard Corporation (NYSE: CCRD) (“CoreCard” or the “Company”), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, announced today its financial results for the quarter ended March 31, 2025.

    “Overall revenue of $16.7 million in the first quarter exceeded our expectations, reflecting year-over-year total revenue growth of 28%, primarily driven by higher professional services rates from our largest customer and continued growth from our other customers,” said Leland Strange, CEO of CoreCard. “We continue to see encouraging results from the ongoing investment in our platform and processing capabilities, and we continue to onboard new customers that value the features and functionality offered by the CoreCard platform.”

    Financial Highlights for the three months ended March 31, 2025

    Total revenues in the three-month period ended March 31, 2025, was $16.7 million compared to $13.1 million in the comparable period in 2024.

    In the following table, revenue is disaggregated by type of revenue for the three months ended March 31, 2025, and 2024:

      Three Months Ended
      March 31,
    (in thousands) 2025     2024  
    License $ —     $ —  
    Professional services   8,702       5,826  
    Processing and maintenance   6,343       6,152  
    Third party   1,643       1,098  
    Total $ 16,688     $ 13,076  

    Income from operations was $2.8 million for the first quarter compared to income from operations of $0.5 million in the comparable prior year quarter.

    Net income was $1.9 million for the first quarter compared to net income of $0.4 million in the comparable prior year quarter.

    Earnings per diluted share was $0.24 for the first quarter compared to $0.05 in the comparable prior year quarter.

    Adjusted earnings per diluted share was $0.28 for the first quarter compared to $0.07 in the comparable prior year quarter.

    Adjusted EBITDA was $4.0 million for the first quarter compared to $1.7 million in the comparable prior year quarter.

    Use of Non-GAAP Financial Measures

    Reconciliations of non-GAAP financial measures to the most directly comparable financial results as determined in accordance with GAAP are included at the end of this press release following the accompanying financial data. For a description of these non-GAAP financial measures, including the reasons management uses each measure, please see the section of the tables titled “Information Regarding Non-GAAP Financial Measures”.

    Investor Conference Call
    The company is holding an investor conference call today, May 8, 2025, at 11 A.M. Eastern Time. Interested investors are invited to attend the conference call by accessing the webcast at https://www.webcast-eqs.com/register/corecardq12025/en or by dialing 1-877-407-0890. As part of the conference call CoreCard will be conducting a question-and-answer session where participants are invited to email their questions to questions@corecard.com prior to the call. A transcript of the call will be posted on the company’s website at investors.corecard.com as soon as available after the call.

    The company will file its Form 10-Q for the period ended March 31, 2025, with the Securities and Exchange Commission today. For additional information about reported results, investors will be able to access the Form 10-Q on the company’s website at investors.corecard.com or on the SEC website, www.sec.gov.

    About CoreCard

    CoreCard Corporation (NYSE: CCRD) provides the gold standard card issuing platform built for the future of global transactions in an embedded digital world. Dedicated to continual technological innovation in the ever-evolving payments industry backed by decades of deep expertise in credit card offerings, CoreCard helps customers conceptualize, implement, and manage all aspects of their issuing card programs. Keenly focused on steady, sustainable growth, CoreCard has earned the trust of some of the largest companies and financial institutions in the world, providing truly real-time transactions via their proven, reliable platform operating on private on-premise and leading cloud technology infrastructure.

    Forward-Looking Statements

    The forward-looking statements in this press release are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The Company’s actual results could differ materially from those indicated by the forward-looking statements because of various risks and uncertainties including those listed in Item 1A of the Company’s Annual Report on Form 10-K and in the Company’s other filings and reports with the Securities and Exchange Commission. All of the risks and uncertainties are beyond the ability of the Company to control, and in many cases, the Company cannot predict the risks and uncertainties that could cause its actual results to differ materially from those indicated by the forward-looking statements. When used in this press release, the words “believes,” “plans,” “expects,” “will,” “intends,” “continue,” “outlook,” “progressing,” and “anticipates” and similar expressions as they relate to the Company or its management are intended to identify forward-looking statements. Except as required by law, the Company is not obligated to publicly release any revisions to these forward-looking statements to reflect the events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

    CoreCard Corporation
    CONSOLIDATED STATEMENTS OF OPERATIONS
    (unaudited, in thousands, except share and per share amounts)
     
      Three Months Ended March 31,
        2025       2024  
    Revenue    
    Services $ 16,688     $ 13,076  
    Products   —       —  
    Total net revenue   16,688       13,076  
    Cost of revenue    
    Services   9,380       9,500  
    Products   —       —  
    Total cost of revenue   9,380       9,500  
    Expenses    
    Marketing   136       114  
    General and administrative   1,794       1,427  
    Development   2,571       1,508  
    Income from operations   2,807       527  
    Investment loss   (435 )     (204 )
    Other income, net   137       256  
    Income before income taxes   2,509       579  
    Income taxes   603       149  
    Net income $ 1,906     $ 430  
    Earnings per share:    
    Basic $ 0.24     $ 0.05  
    Diluted $ 0.24     $ 0.05  
    Basic weighted average common shares outstanding   7,786,679       8,236,135  
    Diluted weighted average common shares outstanding   8,086,423       8,247,788  
    CoreCard Corporation
    CONSOLIDATED BALANCE SHEETS
    (in thousands, except share and per share amounts)
     
    As of March 31, 2025   December 31, 2024
    ASSETS (unaudited)   (audited)
    Current assets:          
    Cash $ 22,068     $ 19,481  
    Marketable securities   5,575       5,410  
    Accounts receivable, net   8,527       10,235  
    Other current assets   5,145       5,048  
    Total current assets   41,315       40,174  
    Investments   3,344       3,776  
    Property and equipment, at cost less accumulated depreciation   13,605       12,282  
    Other long-term assets   6,130       6,106  
    Total assets $ 64,394     $ 62,338  
    LIABILITIES AND STOCKHOLDERS’ EQUITY    
    Current liabilities:    
    Accounts payable $ 1,514     $ 823  
    Deferred revenue, current portion   1,927       2,033  
    Accrued payroll   2,341       2,856  
    Accrued expenses   821       723  
    Other current liabilities   1,731       2,017  
    Total current liabilities   8,334       8,452  
    Noncurrent liabilities:    
    Deferred revenue, net of current portion   82       118  
    Long-term lease obligation   1,599       1,816  
    Other long-term liabilities   321       255  
    Total noncurrent liabilities   2,002       2,189  
    Stockholders’ equity:    
    Common stock, $0.01 par value: Authorized shares – 20,000,000;    
    Issued shares – 9,026,940 at March 31, 2025 and December 31, 2024    
    Outstanding shares – 7,786,679 at March 31, 2025 and December 31, 2024   92       91  
    Additional paid-in capital   18,400       17,928  
    Treasury stock, 1,240,261 shares at March 31, 2025 and December 31, 2024, at cost   (27,997 )     (27,997 )
    Accumulated other comprehensive loss   (111 )     (93 )
    Accumulated income   63,674       61,768  
    Total stockholders’ equity   54,058       51,697  
    Total liabilities and stockholders’ equity $ 64,394     $ 62,338  

    For further information, call
    Matt White, 770-564-5504 or
    email to matt@corecard.com

    Reconciliation of GAAP to NON-GAAP Measures

    Information Regarding Non-GAAP Measures

    In addition to the financial measures prepared in accordance with generally accepted accounting principles in the United States (“GAAP”), this press release contains certain non-GAAP financial measures. CoreCard considers Adjusted EBITDA and Adjusted earnings per diluted share (“Adjusted EPS”) as supplemental measures of the company’s performance that is not required by, nor presented in accordance with GAAP.

    We define Adjusted EBITDA as net income (loss) adjusted to exclude depreciation and amortization; share-based compensation expense; income tax expense (benefit); investment income (loss); and other income (expense), net. We believe that Adjusted EBITDA is an important measure of operating performance because it allows management and our board of directors to evaluate and compare our core operating results from period to period.

    We define Adjusted EPS as diluted earnings per share adjusted to exclude the impact of share-based compensation expense. We believe that Adjusted EPS is an important measure of operating performance because it allows management and our board of directors to evaluate and compare our core operating results from period to period.

    Adjusted EPS and Adjusted EBITDA should not be considered in isolation, or construed as an alternative to net income, or any other performance measures derived in accordance with GAAP, or as an alternative to cash flow from operating activities or as a measure of the company’s liquidity. In addition, other companies may calculate Adjusted EPS and Adjusted EBITDA differently than CoreCard, which limits its usefulness in comparing CoreCard’s financial results with those of other companies.

    The following table shows CoreCard’s GAAP results reconciled to non-GAAP results included in this release:

      Three Months Ended
      March 31,
    (in thousands)   2025     2024
    GAAP net income $ 1,906     $ 430  
    Share-based compensation   473       160  
    Income tax benefit   (118 )     (40 )
    Adjusted net income $ 2,261     $ 550  
    Adjusted EPS $ 0.28     $ 0.07  
    Weighted-average shares   8,086       8,248  
      Three Months Ended
      March 31,
    (in thousands)   2025     2024
    GAAP net income $ 1,906     $ 430  
    Depreciation and amortization   745       1,025  
    Share-based compensation   473       160  
    Investment loss   435       204  
    Other income, net   (137 )     (256 )
    Income tax expense   603       149  
    Adjusted EBITDA $ 4,025     $ 1,712  
    Total Revenue $ 16,688     $ 13,076  
    Adjusted EBITDA Margin   24.1 %     13.1 %

    The MIL Network –

    May 8, 2025
  • MIL-OSI Europe: Minutes – Wednesday, 7 May 2025 – Strasbourg – Final edition

    Source: European Parliament

    PV-10-2025-05-07

    EN

    EN

    iPlPv_Sit

    Minutes
    Wednesday, 7 May 2025 – Strasbourg

     Abbreviations and symbols

    + adopted
    – rejected
    ↓ lapsed
    W withdrawn
    RCV roll-call votes
    EV electronic vote
    SEC secret ballot
    split split vote
    sep separate vote
    am amendment
    CA compromise amendment
    CP corresponding part
    D deleting amendment
    = identical amendments
    § paragraph

    IN THE CHAIR: Martin HOJSÍK
    Vice-President

    1. Opening of the sitting

    The sitting opened at 09:00.


    2. Negotiations ahead of Parliament’s first reading (Rule 72) (action taken)

    The decisions of the LIBE and PECH committees and (jointly) the SEDE and ITRE committees to enter into interinstitutional negotiations had been announced on 5 May 2025 (minutes of 5.5.2025, item 12).

    Since no requests for vote had been made pursuant to Rule 72(2), the committees responsible had been able to begin negotiations after the expiry of the deadline set.


    3. EU support for a just, sustainable and comprehensive peace in Ukraine (debate)

    Council and Commission statements: EU support for a just, sustainable and comprehensive peace in Ukraine (2025/2685(RSP))

    Adam Szłapka (President-in-Office of the Council) and Ursula von der Leyen (President of the Commission) made the statements.

    The following spoke: Michael Gahler, on behalf of the PPE Group, Yannis Maniatis, on behalf of the S&D Group, Kinga Gál, on behalf of the PfE Group, Adam Bielan, on behalf of the ECR Group, Petras Auštrevičius, on behalf of the Renew Group, Terry Reintke, on behalf of the Verts/ALE Group, Özlem Demirel, on behalf of The Left Group, Hans Neuhoff, on behalf of the ESN Group, Sandra Kalniete, Thijs Reuten, Harald Vilimsky, who also declined to take a blue-card question from Moritz Körner, Alberico Gambino, Marie-Agnes Strack-Zimmermann, Virginijus Sinkevičius, Marc Botenga, who also answered a blue-card question from Sebastian Tynkkynen, Petar Volgin, Fidias Panayiotou, who also answered a blue-card question from Moritz Körner, Rasa Juknevičienė, Brando Benifei, Tom Vandendriessche, Mirosława Nykiel and Heléne Fritzon.

    IN THE CHAIR: Christel SCHALDEMOSE
    Vice-President

    The following spoke: Beata Szydło, Nathalie Loiseau, Mika Aaltola, Francisco Assis, Hannah Neumann, Paulius Saudargas, Marcos Ros Sempere, Roberto Vannacci, Victor Negrescu, Aurelijus Veryga, Hilde Vautmans, Matej Tonin, Danilo Della Valle, Francisco José Millán Mon, Tonino Picula, Pierre-Romain Thionnet, Salvatore De Meo, Raphaël Glucksmann, Merja Kyllönen, Ingeborg Ter Laak, Elena Yoncheva, Seán Kelly, who also answered a blue-card question from Petras Gražulis, Joanna Scheuring-Wielgus, Tamás Deutsch, Rihards Kols, Helmut Brandstätter, Adrián Vázquez Lázara, Vilija Blinkevičiūtė, Krzysztof Hetman, Jonas Sjöstedt, Danuše Nerudová, Tobias Cremer, Tomasz Buczek, Małgorzata Gosiewska, Dan Barna, Wouter Beke, Ignazio Roberto Marino, Irene Montero and Ana Miguel Pedro.

    The following spoke under the catch-the-eye procedure: Michał Szczerba, Juan Fernando López Aguilar, Viktória Ferenc, Arkadiusz Mularczyk, Dainius Žalimas, Jaume Asens Llodrà, Siegbert Frank Droese, Lukas Sieper, Maria Grapini, Damian Boeselager and Petras Gražulis.

    The following spoke: Valdis Dombrovskis (Member of the Commission) and Adam Szłapka.

    The debate closed.

    (The sitting was suspended at 11:19.)


    IN THE CHAIR: Roberta METSOLA
    President

    4. Resumption of the sitting

    The sitting resumed at 11:35.


    5. Commemoration of the 80th anniversary of the end of World War II in Europe

    The President made a statement to mark the 80th anniversary of the end of World War II in Europe.

    António Costa (President of the European Council), Robert Chot (Member of the Belgian Royal National Federation of War Volunteers), Janusz Komorowski (President of the Polish Association of Home Army Soldiers) and Janusz Maksymowicz (Vice-President of the Warsaw Uprising Insurgents Association), addressed the House.

    The House stood for the European anthem performed by soprano Francesca Sorteni, accompanied by Thomas Gautier and Claire Rigaux on violin, Marie Viard on cello and Emma Errara on viola.

    (The sitting was suspended for a few moments.)


    6. Resumption of the sitting

    The sitting resumed at 12:19.

    ⁂

    The following spoke: Valérie Hayer (the President noted her remarks. She pointed out that serving Europe in the House of democracy was an honourable commitment and called for everyone to respect what this represented).


    7. Welcome

    On behalf of Parliament, the President welcomed Dr Denis Mukwege, winner of the 2014 Sakharov Prize and 2018 Nobel Peace Prize, who had taken his seat in the distinguished visitors’ gallery.


    8. Voting time

    For detailed results of the votes, see also ‘Results of votes’ and ‘Results of roll-call votes’.


    8.1. Amending ERDF, Cohesion Fund and Just Transition Fund as regards specific measures to address strategic challenges in the context of the mid-term review ***I (vote)

    Amending ERDF, Cohesion Fund and Just Transition Fund as regards specific measures to address strategic challenges in the context of the mid-term review – (COM(2025)0123 – C10-0063/2025 – 2025/0084(COD))

    REQUEST FOR AN URGENT DECISION by the REGI Committee (Rule 170(5))

    Approved

    Vote: at a later part-session.

    Detailed voting results


    8.2. European Social Fund (ESF+): specific measures to address strategic challenges ***I (vote)

    European Social Fund (ESF+): specific measures to address strategic challenges – (COM(2025)0164 – C10-0064/2025 – 2025/0085(COD))

    REQUEST FOR AN URGENT DECISION by the EMPL Committee (Rule 170(5))

    Approved

    Vote: at a later part-session.

    Detailed voting results


    8.3. Discharge 2023: EU general budget – Commission, executive agencies and European Development Funds (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section III – Commission, executive agencies and the ninth, tenth and eleventh European Development Funds [COM(2024)0272 – C10-0067/2024 – 2024/2019(DEC)] – Committee on Budgetary Control. Rapporteur: Niclas Herbst (A10-0074/2025)

    (Majority of the votes cast)

    PROPOSALS FOR DECISIONS – Commission and executive agencies

    Adopted (P10_TA(2025)0077)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    PROPOSALS FOR DECISIONS – European Development Funds – EDF (9th, 10th and 11th)

    Adopted (P10_TA(2025)0077)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0077)

    Detailed voting results


    8.4. Discharge 2023: EU general budget – European Parliament (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section I – European Parliament [COM(2024)0272 – C10-0068/2024 – 2024/2020(DEC)] – Committee on Budgetary Control. Rapporteur: Monika Hohlmeier (A10-0062/2025)

    (Majority of the votes cast)

    PROPOSAL FOR A DECISION

    Adopted (P10_TA(2025)0078)

    Detailed voting results


    8.5. Discharge 2023: EU general budget – European Council and Council (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section II – European Council and Council [COM(2024)0272 – C10-0069/2024 – 2024/2021(DEC)] – Committee on Budgetary Control. Rapporteur: Joachim Stanisław Brudziński (A10-0052/2025)

    PROPOSAL FOR A DECISION

    Approved (P10_TA(2025)0079)

    Discharge postponed (see Annex V, Article 5(1)(b) to the Rules of Procedure)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0079)

    Detailed voting results


    8.6. Discharge 2023: EU general budget – Court of Justice of the European Union (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section IV – Court of Justice [COM(2024)0272 – C10-0070/2024 – 2024/2022(DEC)] – Committee on Budgetary Control. Rapporteur: Cristian Terheş (A10-0050/2025)

    (Majority of the votes cast)

    PROPOSAL FOR A DECISION

    Adopted (P10_TA(2025)0080)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0080)

    Detailed voting results


    8.7. Discharge 2023: EU general budget – Court of Auditors (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section V – Court of Auditors [COM(2024)0272 – C10-0071/2024 – 2024/2023(DEC)] – Committee on Budgetary Control. Rapporteur: Dick Erixon (A10-0047/2025)

    (Majority of the votes cast)

    PROPOSAL FOR A DECISION

    Adopted (P10_TA(2025)0081)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0081)

    Detailed voting results


    8.8. Discharge 2023: EU general budget – European Economic and Social Committee (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section VI – European Economic and Social Committee [COM(2024)0272 – C10-0073/2024 – 2024/2025(DEC)] – Committee on Budgetary Control. Rapporteur: Joachim Stanisław Brudziński (A10-0054/2025)

    (Majority of the votes cast)

    PROPOSAL FOR A DECISION

    Adopted (P10_TA(2025)0082)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0082)

    Detailed voting results


    8.9. Discharge 2023: EU general budget – Committee of the Regions (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section VII – Committee of the Regions [COM(2024)0272 – C10-0074/2024 – 2024/2026(DEC)] – Committee on Budgetary Control. Rapporteur: Joachim Stanisław Brudziński (A10-0046/2025)

    (Majority of the votes cast)

    PROPOSAL FOR A DECISION

    Adopted (P10_TA(2025)0083)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0083)

    Detailed voting results


    8.10. Discharge 2023: EU general budget – European Ombudsman (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section VIII – European Ombudsman [COM(2024)0272 – C10-0075/2024 – 2024/2027(DEC)] – Committee on Budgetary Control. Rapporteur: Joachim Stanisław Brudziński (A10-0055/2025)

    (Majority of the votes cast)

    PROPOSAL FOR A DECISION

    Adopted (P10_TA(2025)0084)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0084)

    Detailed voting results


    8.11. Discharge 2023: EU general budget – European Data Protection Supervisor (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section IX – European Data Protection Supervisor [COM(2024)0272 – C10-0076/2024 – 2024/2028(DEC)] – Committee on Budgetary Control. Rapporteur: Joachim Stanisław Brudziński (A10-0053/2025)

    (Majority of the votes cast)

    PROPOSAL FOR A DECISION

    Adopted (P10_TA(2025)0085)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0085)

    Detailed voting results


    8.12. Discharge 2023: EU general budget – European External Action Service (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section X – European External Action Service [COM(2024)0272 – C10-0072/2024 – 2024/2024(DEC)] – Committee on Budgetary Control. Rapporteur: Joachim Stanisław Brudziński (A10-0069/2025)

    (Majority of the votes cast)

    PROPOSAL FOR A DECISION

    Adopted (P10_TA(2025)0086)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0086)

    Detailed voting results


    8.13. Discharge 2023: European Public Prosecutor’s Office (vote)

    Report on discharge in respect of the implementation of the budget of the European Public Prosecutor’s Office for the financial year 2023 [COM(2024)0272 – C10-0077/2024 – 2024/2029(DEC)] – Committee on Budgetary Control. Rapporteur: Tomáš Zdechovský (A10-0051/2025)

    (Majority of the votes cast)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0087)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0087)

    Detailed voting results


    8.14. Discharge 2023: Agencies (vote)

    Report on discharge in respect of the implementation of the budget of the European Union Agencies for the financial year 2023 [COM(2024)0272 – C10-0078/2024 – 2024/2030(DEC)] – Committee on Budgetary Control. Rapporteur: Erik Marquardt (A10-0065/2025)

    (Majority of the votes cast)

    European Union Agency for the Cooperation of Energy Regulators (ACER)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Agency for Support for BEREC

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Translation Centre for the Bodies of the European Union (CdT)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Centre for the Development of Vocational Training (Cedefop)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Agency for Law Enforcement Training (CEPOL)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Aviation Safety Agency (EASA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Banking Authority (EBA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Centre for Disease Prevention and Control (ECDC)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Chemicals Agency (ECHA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Environment Agency (EEA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Fisheries Control Agency (EFCA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Food Safety Authority (EFSA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Institute for Gender Equality (EIGE)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Insurance and Occupational Pensions Authority (EIOPA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Institute of Innovation and Technology (EIT)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Labour Authority (ELA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Medicines Agency (EMA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Monitoring Centre for Drugs and Drug Addiction (now European Union Drugs Agency)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Maritime Safety Agency (EMSA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Agency for Cybersecurity (ENISA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Agency for Railways (ERA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Euratom Supply Agency (ESA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Securities and Markets Authority (ESMA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Training Foundation (ETF)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Agency for Asylum (EUAA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge and closure of the accounts was postponed (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Agency for the Operational Management of Large-Scale IT Systems in the Area of Freedom, Security and Justice (eu-LISA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Agency for Safety and Health at Work (EU-OSHA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Foundation for the Improvement of Living and Working Conditions (Eurofound)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Agency for Criminal Justice Cooperation (Eurojust)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Agency for Law Enforcement Cooperation (Europol)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Agency for the Space Programme (EUSPA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Agency for Fundamental Rights (FRA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Border and Coast Guard Agency (Frontex)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0088)

    Detailed voting results


    8.15. Discharge 2023: Joint Undertakings (vote)

    Report on discharge in respect of the implementation of the budget of the EU joint undertakings for the financial year 2023 [COM(2024)0272 – C10-0079/2024 – 2024/2031(DEC)] – Committee on Budgetary Control. Rapporteur: Michal Wiezik (A10-0056/2025)

    (Majority of the votes cast)

    Clean Aviation Joint Undertaking

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Circular Bio-based Europe Joint Undertaking

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Clean Hydrogen Joint Undertaking

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Europe’s Rail Joint Undertaking

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European High Performance Computing Joint Undertaking

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Joint Undertaking for ITER and the Development of Fusion Energy

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Global Health EDCTP3 Joint Undertaking

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Innovative Health Initiative Joint Undertaking

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Chips Joint Undertaking (before 21.9.2023: Key Digital Technologies Joint Undertaking)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Single European Sky ATM Research 3 Joint Undertaking

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Smart Networks and Services Joint Undertaking

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0089)

    Detailed voting results


    8.16. A revamped long-term budget for the Union in a changing world (vote)

    Report on a revamped long-term budget for the Union in a changing world [2024/2051(INI)] – Committee on Budgets. Rapporteurs: Siegfried Mureşan and Carla Tavares (A10-0076/2025)

    The debate had taken place on 6 May 2025 (minutes of 6.5.2025, item 9).

    (Majority of the votes cast)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0090)

    Detailed voting results


    8.17. The European Water Resilience Strategy (vote)

    Report on the European Water Resilience Strategy [2024/2104(INI)] – Committee on the Environment, Climate and Food Safety. Rapporteur: Thomas Bajada (A10-0073/2025)

    The debate had taken place on 6 May 2025 (minutes of 6.5.2025, item 13).

    (Majority of the votes cast)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0091)

    Detailed voting results


    8.18. 2023 and 2024 reports on Türkiye (vote)

    2023 and 2024 Commission reports on Türkiye [2025/2023(INI)] – Committee on Foreign Affairs. Rapporteur: Nacho Sánchez Amor (A10-0067/2025)

    The debate had taken place on 6 May 2025 (minutes of 6.5.2025, item 14).

    (Majority of the votes cast)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0092)

    The following had spoken:

    Nacho Sánchez Amor (rapporteur), to move an oral amendment to add a new paragraph after paragraph 31. Parliament had agreed to put the oral amendment to the vote.

    Jordan Bardella, to move an oral amendment to add a new paragraph after paragraph 36. Parliament had not agreed to put the oral amendment to the vote as more than 39 Members had opposed it.

    Detailed voting results


    8.19. 2023 and 2024 reports on Serbia (vote)

    Report on the 2023 and 2024 Commission reports on Serbia [2025/2022(INI)] – Committee on Foreign Affairs. Rapporteur: Tonino Picula (A10-0072/2025)

    The debate had taken place on 6 May 2025 (minutes of 6.5.2025, item 16).

    (Majority of the votes cast)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0093)

    The following had spoken:

    Tonino Picula (rapporteur), to move an oral amendment to paragraph 23. Parliament had agreed to put the oral amendment to the vote.

    Detailed voting results


    8.20. 2023 and 2024 reports on Kosovo (vote)

    Report on the 2023 and 2024 Commission Reports on Kosovo [2025/2019(INI)] – Committee on Foreign Affairs. Rapporteur: Riho Terras (A10-0075/2025)

    The debate had taken place on 6 May 2025 (minutes of 6.5.2025, item 17).

    (Majority of the votes cast)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0094)

    Detailed voting results

    20

    (The sitting was suspended at 13:39.)


    IN THE CHAIR: Javi LÓPEZ
    Vice-President

    9. Resumption of the sitting

    The sitting resumed at 13:44.


    10. Approval of the minutes of the previous sitting

    The minutes of the previous sitting were approved.


    11. Winning the global tech race: boosting innovation and closing funding gaps (topical debate)

    The following spoke: Eva Maydell to open the debate proposed by the PPE Group.

    The following spoke: Adam Szłapka (President-in-Office of the Council) and Costas Kadis (Member of the Commission).

    The following spoke: Pablo Arias Echeverría, on behalf of the PPE Group, Alex Agius Saliba, on behalf of the S&D Group, Julie Rechagneux, on behalf of the PfE Group, Elena Donazzan, on behalf of the ECR Group, Christophe Grudler, on behalf of the Renew Group, Kim Van Sparrentak, on behalf of the Verts/ALE Group, Leila Chaibi, on behalf of The Left Group, Marcin Sypniewski, on behalf of the ESN Group, Tomislav Sokol, Christel Schaldemose, Kosma Złotowski, Svenja Hahn, David Cormand, Milan Mazurek, Massimiliano Salini, Giorgio Gori, Philippe Olivier, Charlie Weimers, Morten Løkkegaard, Eszter Lakos, Laura Ballarín Cereza, Diego Solier, Fernando Navarrete Rojas, Matthias Ecke, Mario Mantovani and Elena Sancho Murillo.

    The following spoke: Costas Kadis and Adam Szłapka.

    The debate closed.


    12. Competition policy – annual report 2024 (debate)

    Report on competition policy – annual report 2024 [2024/2079(INI)] – Committee on Economic and Monetary Affairs. Rapporteur: Lara Wolters (A10-0071/2025)

    Lara Wolters introduced the report.

    The following spoke: Teresa Ribera (Executive Vice-President of the Commission).

    The following spoke: Andreas Schwab, on behalf of the PPE Group, and Thomas Bajada, on behalf of the S&D Group.

    IN THE CHAIR: Antonella SBERNA
    Vice-President

    The following spoke: Pierre Pimpie, on behalf of the PfE Group, Francesco Ventola, on behalf of the ECR Group, Stéphanie Yon-Courtin, on behalf of the Renew Group, Kira Marie Peter-Hansen, on behalf of the Verts/ALE Group, Martin Schirdewan, on behalf of The Left Group, Rada Laykova, on behalf of the ESN Group, Markus Ferber, René Repasi, Enikő Győri, Marlena Maląg, Marie Toussaint, Marcin Sypniewski, Branislav Ondruš, who also answered a blue-card question from João Oliveira, Georgios Aftias, Nikos Papandreou, Dirk Gotink, Adnan Dibrani, Marco Falcone and Jonás Fernández.

    The following spoke under the catch-the-eye procedure: Ralf Seekatz, Sebastian Tynkkynen, Petras Gražulis, João Oliveira and Alexander Jungbluth.

    The following spoke: Teresa Ribera and Lara Wolters.

    The debate closed.

    Vote: 8 May 2025.


    13. Resilience and the need to improve the interconnection of energy grid infrastructure in the EU: the first lessons from the blackout in the Iberian Peninsula (debate)

    Council and Commission statements: Resilience and the need to improve the interconnection of energy grid infrastructure in the EU: the first lessons from the blackout in the Iberian Peninsula (2025/2686(RSP))

    Adam Szłapka (President-in-Office of the Council) and Dan Jørgensen (Member of the Commission) made the statements.

    The following spoke: Dolors Montserrat, on behalf of the PPE Group, Nicolás González Casares, on behalf of the S&D Group, Jorge Buxadé Villalba, on behalf of the PfE Group, Diego Solier, on behalf of the ECR Group, Anna Stürgkh, on behalf of the Renew Group, Diana Riba i Giner, on behalf of the Verts/ALE Group, Estrella Galán, on behalf of The Left Group, Petr Bystron, on behalf of the ESN Group, Paulo Cunha, who also answered a blue-card question from Petras Gražulis, Francisco Assis, António Tânger Corrêa, who also answered a blue-card question from Bruno Gonçalves, Patryk Jaki, Oihane Agirregoitia Martínez, Jaume Asens Llodrà, Irene Montero, Marc Jongen, Lefteris Nikolaou-Alavanos, François-Xavier Bellamy, who also answered a blue-card question from Nicolás González Casares, Sofie Eriksson, Paolo Borchia, Nora Junco García, Christophe Grudler, Pernando Barrena Arza, Pilar del Castillo Vera, who also declined to take a blue-card question from Nicolás González Casares, and Elena Sancho Murillo.

    IN THE CHAIR: Christel SCHALDEMOSE
    Vice-President

    The following spoke: András Gyürk, Nicolas Bay, Michał Kobosko, João Oliveira, Ana Miguel Pedro, Bruno Gonçalves, Pascale Piera, Daniel Obajtek, Seán Kelly, Bruno Tobback, Georg Mayer, Aleksandar Nikolic and Juan Carlos Girauta Vidal.

    The following spoke under the catch-the-eye procedure: Davor Ivo Stier, Susana Solís Pérez, Sebastian Tynkkynen, Maria Zacharia and Lukas Sieper.

    The following spoke: Dan Jørgensen and Adam Szłapka.

    The debate closed.


    14. High levels of retail food prices and their consequences for European consumers (debate)

    Council and Commission statements: High levels of retail food prices and their consequences for European consumers (2025/2687(RSP))

    Adam Szłapka (President-in-Office of the Council) and Costas Kadis (Member of the Commission) made the statements.

    The following spoke: Tomislav Sokol, on behalf of the PPE Group, Camilla Laureti, on behalf of the S&D Group, Gilles Pennelle, on behalf of the PfE Group, Stefano Cavedagna, on behalf of the ECR Group, Asger Christensen, on behalf of the Renew Group, David Cormand, on behalf of the Verts/ALE Group, Hanna Gedin, on behalf of The Left Group, Milan Mazurek, on behalf of the ESN Group, Carmen Crespo Díaz, Adnan Dibrani, Tomasz Buczek, Veronika Vrecionová, Christine Singer, Ana Miranda Paz, who also answered a blue-card question from João Oliveira, Konstantinos Arvanitis, who also answered a blue-card question from Rody Tolassy, Kateřina Konečná, Péter Magyar, Biljana Borzan, Marieke Ehlers, Sergio Berlato, Ciaran Mullooly, Marc Botenga, Nikolaos Anadiotis, Krzysztof Hetman, Pierfrancesco Maran, Barbara Bonte, Jessika Van Leeuwen, Laura Ballarín Cereza, Margarita de la Pisa Carrión and France Jamet.

    IN THE CHAIR: Esteban GONZÁLEZ PONS
    Vice-President

    The following spoke under the catch-the-eye procedure: Cristina Maestre, Mireia Borrás Pabón, Csaba Dömötör, Sebastian Tynkkynen, Rasmus Andresen, Elena Kountoura, João Oliveira, Lukas Sieper and Maria Zacharia.

    The following spoke: Costas Kadis and Adam Szłapka.

    The debate closed.


    15. Malta’s Golden Passport scheme circumventing EU sanctions against Russia (debate)

    Council and Commission statements: Malta’s Golden Passport scheme circumventing EU sanctions against Russia (2025/2688(RSP))

    Adam Szłapka (President-in-Office of the Council) and Michael McGrath (Member of the Commission) made the statements.

    The following spoke: David Casa, on behalf of the PPE Group, Alex Agius Saliba, on behalf of the S&D Group, Jadwiga Wiśniewska, on behalf of the ECR Group, Raquel García Hermida-Van Der Walle, on behalf of the Renew Group, Saskia Bricmont, on behalf of the Verts/ALE Group, Giuseppe Antoci, on behalf of The Left Group, Luděk Niedermayer, Birgit Sippel, Georgiana Teodorescu, who also declined to take a blue-card question from Raquel García Hermida-Van Der Walle, Irena Joveva, Daniel Freund, Peter Agius, Thomas Bajada, who also answered a blue-card question from Raquel García Hermida-Van Der Walle and did not accept a blue-card question from Daniel Freund, Alice Teodorescu Måwe, Daniel Attard, who also answered a blue-card question from Daniel Freund, and Evelyn Regner.

    The following spoke under the catch-the-eye procedure: Juan Fernando López Aguilar and Sebastian Tynkkynen.

    The following spoke: Alex Agius Saliba (the President cut off the speaker as his remarks did not constitute a point of order).

    The following spoke under the catch-the-eye procedure: Maria Zacharia.

    The following spoke: Michael McGrath and Adam Szłapka.

    The debate closed.


    16. The role of gas storage for securing gas supplies ahead of the winter season (debate)

    Report on the proposal for a regulation of the European Parliament and of the Council amending Regulation (EU) 2017/1938 as regards the role of gas storage for securing gas supplies ahead of the winter season [COM(2025)0099 – C10-0041/2025 – 2025/0051(COD)] – Committee on Industry, Research and Energy. Rapporteur: Borys Budka (A10-0079/2025)

    Borys Budka introduced the report.

    The following spoke: Dan Jørgensen (Member of the Commission).

    The following spoke: Andrea Wechsler, on behalf of the PPE Group, Jens Geier, on behalf of the S&D Group, András Gyürk, on behalf of the PfE Group, Ondřej Krutílek, on behalf of the ECR Group, Yvan Verougstraete, on behalf of the Renew Group, Marie Toussaint, on behalf of the Verts/ALE Group, Dario Tamburrano, on behalf of The Left Group, Alexander Sell, on behalf of the ESN Group, Jüri Ratas, Nicolás González Casares, Julie Rechagneux, Michael Bloss, Thomas Geisel and Mirosława Nykiel.

    IN THE CHAIR: Ewa KOPACZ
    Vice-President

    The following spoke: Michalis Hadjipantela and Virgil-Daniel Popescu.

    The following spoke under the catch-the-eye procedure: Liudas Mažylis, Sebastian Tynkkynen, Marta Wcisło and Billy Kelleher.

    The following spoke: Dan Jørgensen and Borys Budka.

    The debate closed.

    Vote: 8 May 2025.


    17. Banking Union – annual report 2024 (debate)

    Report on Banking Union – annual report 2024 [2024/2055(INI)] – Committee on Economic and Monetary Affairs. Rapporteur: Ralf Seekatz (A10-0044/2025)

    Ralf Seekatz introduced the report.

    The following spoke: Michael McGrath (Member of the Commission).

    The following spoke: Marco Falcone, on behalf of the PPE Group, Jonás Fernández, on behalf of the S&D Group, Marlena Maląg, on behalf of the ECR Group, Billy Kelleher, on behalf of the Renew Group, Jussi Saramo, on behalf of The Left Group, Costas Mavrides and Giovanni Crosetto.

    The following spoke under the catch-the-eye procedure: Marta Wcisło, Sebastian Tynkkynen and Lukas Sieper.

    The following spoke: Michael McGrath and Ralf Seekatz.

    The debate closed.

    Vote: 8 May 2025.


    18. The fine against TikTok and the need to strengthen the protection of citizens’ rights on social media platforms (debate)

    Commission statement: The fine against TikTok and the need to strengthen the protection of citizens’ rights on social media platforms (2025/2704(RSP))

    Michael McGrath (Member of the Commission) made the statement.

    The following spoke: François-Xavier Bellamy, on behalf of the PPE Group, Alex Agius Saliba, on behalf of the S&D Group, Virginie Joron, on behalf of the PfE Group, Gheorghe Piperea, on behalf of the ECR Group, Veronika Cifrová Ostrihoňová, on behalf of the Renew Group, Alexandra Geese, on behalf of the Verts/ALE Group, Konstantinos Arvanitis, on behalf of The Left Group, Mary Khan, Pablo Arias Echeverría, Elisabeth Dieringer, Sandro Gozi, Fidias Panayiotou, Sunčana Glavak, Cynthia Ní Mhurchú and Moritz Körner.

    The following spoke under the catch-the-eye procedure: Juan Fernando López Aguilar, Billy Kelleher and Lukas Sieper.

    The following spoke: Michael McGrath.

    The debate closed.


    19. Debate on cases of breaches of human rights, democracy and the rule of law (debate)

    (For the titles and authors of the motions for resolutions, see minutes of 7.5.2025, item I.)


    19.1. Arrest and risk of execution of Tundu Lissu, Chair of Chadema, the main opposition party in Tanzania

    Motions for resolutions B10-0260/2025, B10-0261/2025, B10-0262/2025, B10-0263/2025, B10-0264/2025 and B10-0265/2025 (2025/2690(RSP))

    Reinhold Lopatka, Marit Maij, Jan-Christoph Oetjen, Catarina Vieira and Tomasz Froelich introduced their groups’ motions for resolutions.

    The following spoke under the catch-the-eye procedure: Lukas Sieper.

    The following spoke: Michael McGrath (Member of the Commission).

    The debate closed.

    Vote: 8 May 2025.


    19.2. Return of Ukrainian children forcibly transferred and deported by Russia

    Motions for resolutions B10-0247/2025, B10-0249/2025, B10-0250/2025, B10-0252/2025, B10-0255/2025 and B10-0258/2025 (2025/2691(RSP))

    Jessika Van Leeuwen, Thijs Reuten, Petras Auštrevičius, Villy Søvndal and Małgorzata Gosiewska introduced their groups’ motions for resolutions.

    The following spoke: Michał Szczerba, on behalf of the PPE Group, and Pina Picierno, on behalf of the S&D Group.

    IN THE CHAIR: Antonella SBERNA
    Vice-President

    The following spoke: Karin Karlsbro, on behalf of the Renew Group, Ingeborg Ter Laak, Sandra Gómez López, Charles Goerens, Lukas Mandl, Pierfrancesco Maran, Isabel Wiseler-Lima, Davor Ivo Stier and Alice Teodorescu Måwe.

    The following spoke under the catch-the-eye procedure: Liudas Mažylis, Nikos Papandreou, Lukas Sieper and Marta Wcisło.

    The following spoke: Michael McGrath (Member of the Commission).

    The debate closed.

    Vote: 8 May 2025.


    19.3. Violations of religious freedom in Tibet

    Motions for resolutions B10-0248/2025, B10-0251/2025, B10-0253/2025, B10-0254/2025, B10-0256/2025 and B10-0259/2025 (2025/2692(RSP))

    Danuše Nerudová, Hannes Heide, Mariusz Kamiński, Engin Eroglu and Ville Niinistö introduced their groups’ motions for resolutions.

    The following spoke: Michael McNamara, on behalf of the Renew Group.

    The following spoke under the catch-the-eye procedure: Vytenis Povilas Andriukaitis and Lukas Sieper.

    The following spoke: Michael McNamara, on the previous speaker’s comments, and Lukas Sieper on Michael McNamara’s contribution.

    The following spoke: Michael McGrath (Member of the Commission).

    The debate closed.

    Vote: 8 May 2025.


    20. Democratic legitimacy and the Commission’s continued authorisation of genetically modified organisms despite Parliament’s objections (debate)

    Commission statement: Democratic legitimacy and the Commission’s continued authorisation of genetically modified organisms despite Parliament’s objections (2025/2645(RSP))

    Olivér Várhelyi (Member of the Commission) made the statement.

    The following spoke: Esther Herranz García, on behalf of the PPE Group, Biljana Borzan, on behalf of the S&D Group, Paolo Inselvini, on behalf of the ECR Group, Martin Häusling, on behalf of the Verts/ALE Group, Nikolas Farantouris, on behalf of The Left Group, Daniel Buda, Maria Noichl, Georgiana Teodorescu and Günther Sidl.

    The following spoke under the catch-the-eye procedure: Kristian Vigenin, Diana Iovanovici Şoşoacă, Vytenis Povilas Andriukaitis and Lukas Sieper.

    The following spoke: Olivér Várhelyi.

    The debate closed.


    21. The illegal visit of President Erdoğan to the occupied areas of Cyprus (debate)

    Council and Commission statements: The illegal visit of President Erdoğan to the occupied areas of Cyprus (2025/2705(RSP))

    Michael McGrath (Member of the Commission) made the statement on behalf of the Commission.

    The following spoke: Loucas Fourlas, on behalf of the PPE Group, Costas Mavrides, on behalf of the S&D Group, Afroditi Latinopoulou, on behalf of the PfE Group, Geadis Geadi, on behalf of the ECR Group (the President reminded the speaker of the rules on conduct), Kai Tegethoff, on behalf of the Verts/ALE Group, and Irene Montero, on behalf of The Left Group.

    The following spoke: Michael McGrath.

    The debate closed.


    22. Explanations of vote


    22.1. Discharge 2023: EU general budget – European External Action Service (A10-0069/2025 – Joachim Stanisław Brudziński) (oral explanations of vote)

    Lynn Boylan


    22.2. Written explanations of vote

    Explanations of vote submitted in writing under Rule 201 appear on the Members’ pages on Parliament’s website.


    23. Agenda of the next sitting

    The next sitting would be held the following day, 8 May 2025, starting at 09:00. The agenda was available on Parliament’s website.


    24. Approval of the minutes of the sitting

    In accordance with Rule 208(3), the minutes of the sitting would be put to the House for approval at the beginning of the afternoon of the next sitting.


    25. Closure of the sitting

    The sitting closed at 22:21.


    LIST OF DOCUMENTS SERVING AS A BASIS FOR THE DEBATES AND DECISIONS OF PARLIAMENT


    I. Motions for resolutions tabled

    Arrest and risk of execution of Tundu Lissu, Chair of Chadema, the main opposition party in Tanzania

    The following Members or political groups had requested that a debate be held, in accordance with Rule 150, on the following motions for resolutions:

    on the arrest and risk of execution of Tundu Lissu, Chair of Chadema, the main opposition party in Tanzania (2025/2690(RSP)) (B10-0260/2025)
    Catarina Vieira, Nicolae Ştefănuță, Mounir Satouri, Maria Ohisalo, Mélissa Camara, Ville Niinistö
    on behalf of the Verts/ALE Group

    on the arrest and risk of execution of Tundu Lissu, Chair of Chadema, the main opposition party in Tanzania (2025/2690(RSP)) (B10-0261/2025)
    Yannis Maniatis, Francisco Assis, Marit Maij
    on behalf of the S&D Group

    on the arrest and risk of execution of Tundu Lissu, Chair of Chadema, the main opposition party in Tanzania (2025/2690(RSP)) (B10-0262/2025)
    Tomasz Froelich
    on behalf of the ESN Group

    on the arrest and risk of execution of Tundu Lissu, Chair of Chadema, the main opposition party in Tanzania (2025/2690(RSP)) (B10-0263/2025)
    Jan-Christoph Oetjen, Oihane Agirregoitia Martínez, Petras Auštrevičius, Malik Azmani, Dan Barna, Benoit Cassart, Olivier Chastel, Engin Eroglu, Svenja Hahn, Ilhan Kyuchyuk, Karin Karlsbro, Moritz Körner, Urmas Paet, Marie-Agnes Strack-Zimmermann, Hilde Vautmans, Michal Wiezik, Lucia Yar
    on behalf of the Renew Group

    on the arrest and risk of execution of Tundu Lissu, Chair of Chadema, the main opposition party in Tanzania (2025/2690(RSP)) (B10-0264/2025)
    Sebastião Bugalho, Reinhold Lopatka, Michael Gahler, David McAllister, Antonio López-Istúriz White, Ana Miguel Pedro, Davor Ivo Stier, Tomas Tobé, Liudas Mažylis, Ingeborg Ter Laak, Isabel Wiseler-Lima, Mirosława Nykiel, Wouter Beke, Luděk Niedermayer, Vangelis Meimarakis, Milan Zver, Tomáš Zdechovský, Danuše Nerudová, Miriam Lexmann, Jan Farský, Loránt Vincze, Jessica Polfjärd, Andrey Kovatchev, Inese Vaidere
    on behalf of the PPE Group

    on the arrest and risk of execution of Tundu Lissu, Chair of Chadema, the main opposition party in Tanzania (2025/2690(RSP)) (B10-0265/2025)
    Adam Bielan, Sebastian Tynkkynen, Waldemar Tomaszewski, Ondřej Krutílek, Veronika Vrecionová, Alexandr Vondra, Joachim Stanisław Brudziński, Ivaylo Valchev, Jadwiga Wiśniewska, Assita Kanko, Alberico Gambino, Carlo Fidanza
    on behalf of the ECR Group

    Return of Ukrainian children forcibly transferred and deported by Russia

    The following Members or political groups had requested that a debate be held, in accordance with Rule 150, on the following motions for resolutions:

    on the return of Ukrainian children forcibly transferred and deported by Russia (2025/2691(RSP)) (B10-0247/2025)
    Merja Kyllönen
    on behalf of The Left Group

    on the return of Ukrainian children forcibly transferred and deported by Russia (2025/2691(RSP)) (B10-0249/2025)
    Villy Søvndal, Sergey Lagodinsky, Nicolae Ştefănuță, Mounir Satouri, Maria Ohisalo, Catarina Vieira, Ville Niinistö
    on behalf of the Verts/ALE Group

    on the return of Ukrainian children forcibly transferred and deported by Russia (2025/2691(RSP)) (B10-0250/2025)
    Yannis Maniatis, Francisco Assis, Thijs Reuten, Evin Incir, Pina Picierno
    on behalf of the S&D Group

    on the return of Ukrainian children forcibly transferred and deported by Russia (2025/2691(RSP)) (B10-0252/2025)
    Petras Auštrevičius, Oihane Agirregoitia Martínez, Abir Al-Sahlani, Malik Azmani, Dan Barna, Helmut Brandstätter, Benoit Cassart, Olivier Chastel, Veronika Cifrová Ostrihoňová, Engin Eroglu, Svenja Hahn, Karin Karlsbro, Ľubica Karvašová, Moritz Körner, Ilhan Kyuchyuk, Nathalie Loiseau, Jan-Christoph Oetjen, Urmas Paet, Marie-Agnes Strack-Zimmermann, Eugen Tomac, Hilde Vautmans, Lucia Yar, Michał Kobosko
    on behalf of the Renew Group

    on the return of Ukrainian children forcibly transferred and deported by Russia (2025/2691(RSP)) (B10-0255/2025)
    Sebastião Bugalho, Jessika Van Leeuwen, Michael Gahler, David McAllister, Sandra Kalniete, Andrzej Halicki, Antonio López-Istúriz White, Ana Miguel Pedro, Dariusz Joński, Davor Ivo Stier, Tomas Tobé, Reinhold Lopatka, Liudas Mažylis, Ingeborg Ter Laak, Isabel Wiseler-Lima, Mirosława Nykiel, Wouter Beke, Luděk Niedermayer, Vangelis Meimarakis, Milan Zver, Tomáš Zdechovský, Danuše Nerudová, Miriam Lexmann, Ondřej Kolář, Jan Farský, Loránt Vincze, Jessica Polfjärd, Andrey Kovatchev, Ewa Kopacz, Matej Tonin, Inese Vaidere
    on behalf of the PPE Group

    on the return of Ukrainian children forcibly transferred and deported by Russia (2025/2691(RSP)) (B10-0258/2025)
    Adam Bielan, Mariusz Kamiński, Małgorzata Gosiewska, Sebastian Tynkkynen, Michał Dworczyk, Veronika Vrecionová, Ondřej Krutílek, Jaak Madison, Alexandr Vondra, Arkadiusz Mularczyk, Bogdan Rzońca, Roberts Zīle, Ivaylo Valchev, Joachim Stanisław Brudziński, Assita Kanko, Aurelijus Veryga, Jadwiga Wiśniewska, Rihards Kols, Maciej Wąsik, Marlena Maląg, Charlie Weimers, Cristian Terheş
    on behalf of the ECR Group

    Violations of religious freedom in Tibet

    The following Members or political groups had requested that a debate be held, in accordance with Rule 150, on the following motions for resolutions:

    on the violations of religious freedom in Tibet (2025/2692(RSP)) (B10-0248/2025)
    Ville Niinistö, Catarina Vieira, Maria Ohisalo, Erik Marquardt, Nicolae Ştefănuță, Mounir Satouri, Leoluca Orlando
    on behalf of the Verts/ALE Group

    on the violations of religious freedom in Tibet (2025/2692(RSP)) (B10-0251/2025)
    Yannis Maniatis, Francisco Assis, Hannes Heide
    on behalf of the S&D Group

    on the violations of religious freedom in Tibet (2025/2692(RSP)) (B10-0253/2025)
    Hermann Tertsch, Jorge Martín Frías, Jaroslav Bžoch, Susanna Ceccardi
    on behalf of the PfE Group

    on the violations of religious freedom in Tibet (2025/2692(RSP)) (B10-0254/2025)
    Engin Eroglu, Oihane Agirregoitia Martínez, Petras Auštrevičius, Malik Azmani, Dan Barna, Helmut Brandstätter, Benoit Cassart, Olivier Chastel, Bernard Guetta, Svenja Hahn, Ľubica Karvašová, Moritz Körner, Ilhan Kyuchyuk, Nathalie Loiseau, Karin Karlsbro, Jan-Christoph Oetjen, Marie-Agnes Strack-Zimmermann, Lucia Yar, Dainius Žalimas
    on behalf of the Renew Group

    on the violations of religious freedom in Tibet (2025/2692(RSP)) (B10-0256/2025)
    Sebastião Bugalho, Danuše Nerudová, Michael Gahler, Antonio López-Istúriz White, Ana Miguel Pedro, Davor Ivo Stier, Tomas Tobé, Reinhold Lopatka, Liudas Mažylis, Ingeborg Ter Laak, Isabel Wiseler-Lima, Mirosława Nykiel, Wouter Beke, Luděk Niedermayer, Vangelis Meimarakis, Milan Zver, Tomáš Zdechovský, Miriam Lexmann, Ondřej Kolář, Jan Farský, Loránt Vincze, Jessica Polfjärd, Andrey Kovatchev, Inese Vaidere
    on behalf of the PPE Group

    on the violations of religious freedom in Tibet (2025/2692(RSP)) (B10-0259/2025)
    Adam Bielan, Mariusz Kamiński, Waldemar Tomaszewski, Alberico Gambino, Sebastian Tynkkynen, Carlo Fidanza, Małgorzata Gosiewska, Ondřej Krutílek, Veronika Vrecionová, Assita Kanko, Michał Dworczyk, Arkadiusz Mularczyk, Bogdan Rzońca, Alexandr Vondra, Joachim Stanisław Brudziński, Jadwiga Wiśniewska, Maciej Wąsik, Marlena Maląg
    on behalf of the ECR Group


    II. Delegated acts (Rule 114(2))

    Draft delegated acts forwarded to Parliament

    – Commission Delegated Regulation supplementing Regulation (EU) 2023/2631 of the European Parliament and of the Council by establishing the content, methodologies, and presentation of the information to be voluntarily disclosed by issuers of bonds marketed as environmentally sustainable or of sustainability-linked bonds in the templates for periodic post-issuance disclosures (C(2025)00005 – 2025/2674(DEA))

    Deadline for raising objections: 3 months from the date of receipt of 16 April 2025

    referred to committee responsible: ECON

    – Commission Delegated Regulation supplementing Regulation (EU) 2023/2631of the European Parliament and of the Council by specifying rules of procedure for the exercise of the power to impose fines or periodic penalty payments by the European Securities and Markets Authority on external reviewers (C(2025)00006 – 2025/2676(DEA))

    Deadline for raising objections: 3 months from the date of receipt of 16 April 2025

    referred to committee responsible: ECON

    – Commission Delegated Regulation supplementing Regulation (EU) 2023/2631 of the European Parliament and of the Council by specifying the type of fees to be charged by ESMA to external reviewers of European Green Bonds, the matters in respect of which fees are due, the amount of the fees, and the manner in which those fees are to be paid (C(2025)00007 – 2025/2677(DEA))

    Deadline for raising objections: 3 months from the date of receipt of 16 April 2025

    referred to committee responsible: ECON

    – Commission Delegated Regulation supplementing Directive 2013/36/EU of the European Parliament and of the Council with regard to regulatory technical standards specifying the general conditions for the functioning of supervisory colleges, and repealing Commission Delegated Regulation (EU) 2016/98 (C(2025)00701 – 2025/2678(DEA))

    Deadline for raising objections: 3 months from the date of receipt of 23 April 2025

    referred to committee responsible: ECON

    – Commission Delegated Regulation amending Regulation (EU) 2023/1804 of the European Parliament and of the Council as regards additional data types on alternative fuels infrastructure (C(2025)01912 – 2025/2661(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 2 April 2025

    referred to committee responsible: TRAN

    – Commission Delegated Regulation supplementing Regulation (EU) 2023/1804 of the European Parliament and of the Council as regards common technical requirements for a common application programme interface (C(2025)01913 – 2025/2659(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 2 April 2025

    referred to committee responsible: TRAN

    – Commission Delegated Regulation amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council as regards the harmonised classification and labelling of certain substances (C(2025)01916 – 2025/2660(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 2 April 2025

    referred to committee responsible: ENVI
    opinion: IMCO

    – Commission Delegated Regulation amending Regulation (EU) 2023/1804 of the European Parliament and of the Council as regards standards for wireless recharging, electric road system, vehicle-to-grid communication and hydrogen supply for road transport vehicles (C(2025)01918 – 2025/2662(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 2 April 2025

    referred to committee responsible: TRAN

    – Commission Delegated Regulation amending Delegated Regulation (EU) 2015/68 and Delegated Regulation (EU) 2015/208 with regard to vehicle braking requirements and to vehicle functional safety requirements for agricultural and forestry vehicles (C(2025)01944 – 2025/2663(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 3 April 2025

    referred to committee responsible: IMCO

    – Commission Delegated Regulation amending Delegated Regulation (EU) 2023/205 as regards the European Maritime Single Window environment data set (C(2025)02021 – 2025/2667(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 7 April 2025

    referred to committee responsible: TRAN

    – Commission Delegated Regulation supplementing Regulation (EU) No 305/2011 of the European Parliament and of the Council by establishing threshold levels and classes of performance for permanent anchor devices and safety hooks (C(2025)02119 – 2025/2670(DEA))

    Deadline for raising objections: 3 months from the date of receipt of 9 April 2025

    referred to committee responsible: IMCO

    – Commission Delegated Directive amending Directive 2005/36/EC of the European Parliament and of the Council as regards the minimum training requirements for the profession of veterinary surgeon (C(2025)02128 – 2025/2671(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 10 April 2025

    referred to committee responsible: IMCO

    – Commission Delegated Regulation amending Regulation (EU) 2019/1021 of the European Parliament and of the Council as regards perfluorooctane sulfonic acid and its derivatives (C(2025)02189 – 2025/2672(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 14 April 2025

    referred to committee responsible: ENVI

    – Commission delegated decision on the unilateral inclusion of sectors by Finland in the emissions trading system within the Union for buildings, road transport and additional sectors pursuant to Article 30j of Directive 2003/87/EC of the European Parliament and of the Council (C(2025)02232 – 2025/2673(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 15 April 2025

    referred to committee responsible: ENVI
    opinion: ITRE

    – Commission Delegated Regulation amending Delegated Regulation (EU) 2023/2197 as regards the date of application (C(2025)02258 – 2025/2675(DEA))

    Deadline for raising objections: 3 months from the date of receipt of 16 April 2025

    referred to committee responsible: SANT

    – Commission Delegated Regulation supplementing Regulation (EU) No 575/2013 of the European Parliament and of the Council with regard to regulatory technical standards specifying the conditions and indicators that the EBA is to use to determine whether extraordinary circumstances in the sense of Article 325az(5) and Article 325bf(6) of that Regulation have occurred (C(2025)02287 – 2025/2679(DEA))

    Deadline for raising objections: 3 months from the date of receipt of 23 April 2025

    referred to committee responsible: ECON

    – Commission Delegated Regulation supplementing Regulation (EU) 2023/1114 of the European Parliament and of the Council with regard to regulatory technical standards specifying the arrangements, systems and procedures to prevent, detect and report market abuse, the templates to be used for reporting suspected market abuse, and the coordination procedures between the competent authorities for the detection and sanctioning of market abuse in cross-border market abuse situations (C(2025)02480 – 2025/2684(DEA))

    Deadline for raising objections: 3 months from the date of receipt of 29 April 2025

    referred to committee responsible: ECON

    – Commission Delegated Regulation amending Annex I to Regulation (EU) 2019/1021 of the European Parliament and of the Council as regards perfluorooctanoic acid (PFOA), its salts and PFOA-related compounds (C(2025)02566 – 2025/2701(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 5 May 2025

    referred to committee responsible: ENVI

    – Commission Delegated Regulation (EU)…/ … amending Annex I to Regulation (EU) 2019/1021 of the European Parliament and of the Council as regards UV-328 (C(2025)02567 – 2025/2703(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 5 May 2025

    referred to committee responsible: ENVI

    – Commission Delegated Regulation amending Delegated Regulation (EU) 2024/2910 on the implementation of the Union’s international obligations, as referred to in Article 15(2) of Regulation (EU) No 1380/2013 of the European Parliament and of the Council, under the General Fisheries Commission for the Mediterranean (C(2025)02570 – 2025/2702(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 5 May 2025

    referred to committee responsible: PECH


    III. Implementing measures (Rule 115)

    Draft implementing measures falling under the regulatory procedure with scrutiny forwarded to Parliament

    – Commission Regulation correcting certain language versions of Regulation (EU) No 142/2011 implementing Regulation (EC) No 1069/2009 of the European Parliament and of the Council laying down health rules as regards animal by-products and derived products not intended for human consumption and implementing Council Directive 97/78/EC as regards certain samples and items exempt from veterinary checks at the border under that Directive (D010438/05 – 2025/2693(RPS) – deadline: 22 July 2025)
    referred to committee responsible: ENVI
    opinion: AGRI

    – Commission Regulation amending Annex II to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for acetamiprid in or on certain products (D102375/03 – 2025/2664(RPS) – deadline: 4 June 2025)
    referred to committee responsible: ENVI

    – Commission Regulation amending Annex III to Regulation (EC) No 1333/2008 of the European Parliament and of the Council as regards the use of polyvinylpolypyrrolidone (E 1202) as a carrier in colour tablets for the decorative colouring of poultry eggshells (D106245/02 – 2025/2680(RPS) – deadline: 29 June 2025)
    referred to committee responsible: ENVI

    – Commission Regulation amending Regulation (EU) 2023/915 as regards maximum levels of inorganic arsenic in fish and other seafood (D106246/02 – 2025/2681(RPS) – deadline: 29 July 2025)
    referred to committee responsible: ENVI


    IV. Documents received

    The following documents had been received from other institutions:

    – Proposal for transfer of appropriations DEC 05/2025 – Section III – Commission (N10-0013/2025 – C10-0065/2025 – 2025/2078(GBD))
    referred to committee responsible: BUDG

    – Proposal for transfer of appropriations INF 1/2025 – Section VI – Economic and Social Committee (N10-0014/2025 – C10-0078/2025 – 2025/2091(GBD))
    referred to committee responsible: BUDG

    – Proposal for transfer of appropriations No. 2/2025 – Section IX – European Data Protection Supervisor (N10-0015/2025 – C10-0079/2025 – 2025/2092(GBD))
    referred to committee responsible: BUDG


    V. Transfers of appropriations and budgetary decisions

    In accordance with Article 31(1) of the Financial Regulation, the Committee on Budgets had decided to approve the European Commission’s transfers of appropriations DEC 03/2025 and DEC 04/2025 – Section III – Commission.

    In accordance with Article 31(6) of the Financial Regulation, the Council of the European Union had decided to approve the European Commission’s transfers of appropriations DEC 03/2025 and DEC 04/2025 – Section III – Commission.


    ATTENDANCE REGISTER

    Present:

    Aaltola Mika, Abadía Jover Maravillas, Adamowicz Magdalena, Aftias Georgios, Agirregoitia Martínez Oihane, Agius Peter, Agius Saliba Alex, Alexandraki Galato, Allione Grégory, Al-Sahlani Abir, Anadiotis Nikolaos, Anderson Christine, Andersson Li, Andresen Rasmus, Andrews Barry, Andriukaitis Vytenis Povilas, Androuët Mathilde, Angel Marc, Annemans Gerolf, Annunziata Lucia, Antoci Giuseppe, Arias Echeverría Pablo, Arimont Pascal, Arłukowicz Bartosz, Arnaoutoglou Sakis, Arndt Anja, Arvanitis Konstantinos, Asens Llodrà Jaume, Assis Francisco, Attard Daniel, Aubry Manon, Auštrevičius Petras, Axinia Adrian-George, Azmani Malik, Bajada Thomas, Baljeu Jeannette, Ballarín Cereza Laura, Bardella Jordan, Barna Dan, Barrena Arza Pernando, Bartulica Stephen Nikola, Bartůšek Nikola, Bay Nicolas, Bay Christophe, Beke Wouter, Beleris Fredis, Bellamy François-Xavier, Benea Dragoş, Benifei Brando, Benjumea Benjumea Isabel, Beňová Monika, Berendsen Tom, Berger Stefan, Berlato Sergio, Bernhuber Alexander, Biedroń Robert, Bielan Adam, Bischoff Gabriele, Blaha Ľuboš, Blinkevičiūtė Vilija, Blom Rachel, Bloss Michael, Bocheński Tobiasz, Boeselager Damian, Bogdan Ioan-Rareş, Bonaccini Stefano, Bonte Barbara, Borchia Paolo, Borrás Pabón Mireia, Borvendég Zsuzsanna, Borzan Biljana, Bosanac Gordan, Boßdorf Irmhild, Bosse Stine, Botenga Marc, Boyer Gilles, Boylan Lynn, Brandstätter Helmut, Brasier-Clain Marie-Luce, Bricmont Saskia, Brnjac Nikolina, Brudziński Joachim Stanisław, Bryłka Anna, Buchheit Markus, Buczek Tomasz, Buda Daniel, Buda Waldemar, Budka Borys, Bugalho Sebastião, Buła Andrzej, Bullmann Udo, Burkhardt Delara, Buxadé Villalba Jorge, Bystron Petr, Bžoch Jaroslav, Camara Mélissa, Canfin Pascal, Carberry Nina, Cârciu Gheorghe, Carême Damien, Casa David, Caspary Daniel, Cassart Benoit, Castillo Laurent, del Castillo Vera Pilar, Cavazzini Anna, Cavedagna Stefano, Cepeda José, Ceulemans Estelle, Chahim Mohammed, Chaibi Leila, Chastel Olivier, Chinnici Caterina, Christensen Asger, Ciccioli Carlo, Cifrová Ostrihoňová Veronika, Ciriani Alessandro, Cisint Anna Maria, Clausen Per, Clergeau Christophe, Cormand David, Corrado Annalisa, Costanzo Vivien, Cotrim De Figueiredo João, Cowen Barry, Cremer Tobias, Crespo Díaz Carmen, Cristea Andi, Crosetto Giovanni, Cunha Paulo, Dahl Henrik, Danielsson Johan, Dauchy Marie, Dávid Dóra, David Ivan, Decaro Antonio, de la Hoz Quintano Raúl, Della Valle Danilo, Deloge Valérie, De Masi Fabio, De Meo Salvatore, Demirel Özlem, Deutsch Tamás, Devaux Valérie, Dibrani Adnan, Diepeveen Ton, Dieringer Elisabeth, Dîncu Vasile, Di Rupo Elio, Disdier Mélanie, Dobrev Klára, Doherty Regina, Doleschal Christian, Dömötör Csaba, Do Nascimento Cabral Paulo, Donazzan Elena, Dorfmann Herbert, Dostalova Klara, Dostál Ondřej, Droese Siegbert Frank, Dworczyk Michał, Ecke Matthias, Ehler Christian, Ehlers Marieke, Eriksson Sofie, Erixon Dick, Eroglu Engin, Estaràs Ferragut Rosa, Everding Sebastian, Falcă Gheorghe, Falcone Marco, Farantouris Nikolas, Farreng Laurence, Farský Jan, Ferber Markus, Ferenc Viktória, Fernández Jonás, Fidanza Carlo, Fiocchi Pietro, Firea Gabriela, Firmenich Ruth, Fita Claire, Fourlas Loucas, Fourreau Emma, Fragkos Emmanouil, Freund Daniel, Frigout Anne-Sophie, Fritzon Heléne, Froelich Tomasz, Fuglsang Niels, Funchion Kathleen, Furet Angéline, Furore Mario, Gahler Michael, Gál Kinga, Galán Estrella, Gálvez Lina, Gambino Alberico, García Hermida-Van Der Walle Raquel, Garraud Jean-Paul, Gasiuk-Pihowicz Kamila, Geadi Geadis, Gedin Hanna, Geese Alexandra, Geier Jens, Geisel Thomas, Gemma Chiara, Georgiou Giorgos, Gerbrandy Gerben-Jan, Germain Jean-Marc, Gerzsenyi Gabriella, Geuking Niels, Gieseke Jens, Giménez Larraz Borja, Girauta Vidal Juan Carlos, Glavak Sunčana, Glück Andreas, Glucksmann Raphaël, Goerens Charles, Gomart Christophe, Gomes Isilda, Gómez López Sandra, Gonçalves Bruno, Gonçalves Sérgio, González Casares Nicolás, González Pons Esteban, Gori Giorgio, Gosiewska Małgorzata, Gotink Dirk, Gozi Sandro, Grapini Maria, Gražulis Petras, Grims Branko, Griset Catherine, Gronkiewicz-Waltz Hanna, Groothuis Bart, Grossmann Elisabeth, Grudler Christophe, Gualmini Elisabetta, Guarda Cristina, Győri Enikő, Gyürk András, Hadjipantela Michalis, Hahn Svenja, Haider Roman, Halicki Andrzej, Hansen Niels Flemming, Hauser Gerald, Häusling Martin, Hava Mircea-Gheorghe, Heide Hannes, Heinäluoma Eero, Henriksson Anna-Maja, Herbst Niclas, Herranz García Esther, Hetman Krzysztof, Hohlmeier Monika, Hojsík Martin, Holmgren Pär, Hölvényi György, Homs Ginel Alicia, Humberto Sérgio, Imart Céline, Incir Evin, Inselvini Paolo, Iovanovici Şoşoacă Diana, Jamet France, Jarubas Adam, Jerković Romana, Jongen Marc, Joński Dariusz, Joron Virginie, Jouvet Pierre, Joveva Irena, Juknevičienė Rasa, Junco García Nora, Jungbluth Alexander, Kabilov Taner, Kalfon François, Kaliňák Erik, Kaljurand Marina, Kalniete Sandra, Kamiński Mariusz, Karlsbro Karin, Kartheiser Fernand, Karvašová Ľubica, Katainen Elsi, Kefalogiannis Emmanouil, Kelleher Billy, Keller Fabienne, Kelly Seán, Kennes Rudi, Khan Mary, Kircher Sophia, Knafo Sarah, Knotek Ondřej, Kobosko Michał, Köhler Stefan, Kohut Łukasz, Kokalari Arba, Kolář Ondřej, Kols Rihards, Konečná Kateřina, Kopacz Ewa, Körner Moritz, Kountoura Elena, Kovařík Ondřej, Kovatchev Andrey, Krištopans Vilis, Kruis Sebastian, Krutílek Ondřej, Kubín Tomáš, Kuhnke Alice, Kulja András Tivadar, Kulmuni Katri, Kyllönen Merja, Kyuchyuk Ilhan, Lakos Eszter, Lalucq Aurore, Lange Bernd, Langensiepen Katrin, Laššáková Judita, László András, Latinopoulou Afroditi, Laurent Murielle, Laureti Camilla, Laykova Rada, Lazarov Ilia, Le Callennec Isabelle, Leggeri Fabrice, Lenaers Jeroen, Leonardelli Julien, Lewandowski Janusz, Lexmann Miriam, Liese Peter, Loiseau Nathalie, Løkkegaard Morten, Lopatka Reinhold, López Javi, López Aguilar Juan Fernando, López-Istúriz White Antonio, Lövin Isabella, Lucano Mimmo, Luena César, Łukacijewska Elżbieta Katarzyna, Lupo Giuseppe, McAllister David, Madison Jaak, Maestre Cristina, Magoni Lara, Magyar Péter, Maij Marit, Maląg Marlena, Manda Claudiu, Mandl Lukas, Maniatis Yannis, Mantovani Mario, Maran Pierfrancesco, Marczułajtis-Walczak Jagna, Maréchal Marion, Mariani Thierry, Marino Ignazio Roberto, Marquardt Erik, Martín Frías Jorge, Martusciello Fulvio, Marzà Ibáñez Vicent, Mato Gabriel, Mavrides Costas, Maydell Eva, Mayer Georg, Mazurek Milan, Mažylis Liudas, McNamara Michael, Mebarek Nora, Meimarakis Vangelis, Meleti Eleonora, Mendes Ana Catarina, Mendia Idoia, Mertens Verena, Mesure Marina, Metsola Roberta, Metz Tilly, Mikser Sven, Milazzo Giuseppe, Millán Mon Francisco José, Minchev Nikola, Miranda Paz Ana, Molnár Csaba, Montero Irene, Montserrat Dolors, Morace Carolina, Morano Nadine, Moratti Letizia, Moreira de Sá Tiago, Moreno Sánchez Javier, Moretti Alessandra, Motreanu Dan-Ştefan, Mularczyk Arkadiusz, Müller Piotr, Mullooly Ciaran, Mureşan Siegfried, Muşoiu Ştefan, Nagyová Jana, Navarrete Rojas Fernando, Negrescu Victor, Nemec Matjaž, Nerudová Danuše, Nesci Denis, Neuhoff Hans, Neumann Hannah, Nevado del Campo Elena, Nica Dan, Niebler Angelika, Niedermayer Luděk, Niinistö Ville, Nikolaou-Alavanos Lefteris, Nikolic Aleksandar, Ní Mhurchú Cynthia, Noichl Maria, Nordqvist Rasmus, Novakov Andrey, Nykiel Mirosława, Obajtek Daniel, Ódor Ľudovít, Oetjen Jan-Christoph, Ohisalo Maria, Olivier Philippe, Omarjee Younous, Ondruš Branislav, Ó Ríordáin Aodhán, Orlando Leoluca, Ozdoba Jacek, Paet Urmas, Pajín Leire, Palmisano Valentina, Panayiotou Fidias, Papadakis Kostas, Papandreou Nikos, Pappas Nikos, Pascual de la Parte Nicolás, Patriciello Aldo, Paulus Jutta, Pedro Ana Miguel, Pedulla’ Gaetano, Pellerin-Carlin Thomas, Peltier Guillaume, Penkova Tsvetelina, Pennelle Gilles, Pereira Lídia, Peter-Hansen Kira Marie, Petrov Hristo, Picaro Michele, Picierno Pina, Picula Tonino, Piera Pascale, Pietikäinen Sirpa, Pimpie Pierre, Piperea Gheorghe, de la Pisa Carrión Margarita, Pokorná Jermanová Jaroslava, Polato Daniele, Polfjärd Jessica, Popescu Virgil-Daniel, Pozņaks Reinis, Prebilič Vladimir, Princi Giusi, Protas Jacek, Pürner Friedrich, Rackete Carola, Radev Emil, Radtke Dennis, Rafowicz Emma, Ratas Jüri, Razza Ruggero, Rechagneux Julie, Regner Evelyn, Repasi René, Repp Sabrina, Ressler Karlo, Reuten Thijs, Riba i Giner Diana, Ricci Matteo, Ridel Chloé, Riehl Nela, Ripa Manuela, Rodrigues André, Ros Sempere Marcos, Roth Neveďalová Katarína, Rougé André, Ruissen Bert-Jan, Ruotolo Sandro, Rzońca Bogdan, Saeidi Arash, Salini Massimiliano, Salis Ilaria, Salla Aura, Sánchez Amor Nacho, Sanchez Julien, Sancho Murillo Elena, Saramo Jussi, Sardone Silvia, Sargiacomo Eric, Satouri Mounir, Saudargas Paulius, Sbai Majdouline, Sberna Antonella, Schaldemose Christel, Schaller-Baross Ernő, Schenk Oliver, Scheuring-Wielgus Joanna, Schieder Andreas, Schilling Lena, Schneider Christine, Schnurrbusch Volker, Schwab Andreas, Scuderi Benedetta, Seekatz Ralf, Sell Alexander, Serrano Sierra Rosa, Sidl Günther, Sienkiewicz Bartłomiej, Sieper Lukas, Simon Sven, Singer Christine, Sinkevičius Virginijus, Sippel Birgit, Sjöstedt Jonas, Śmiszek Krzysztof, Smith Anthony, Smit Sander, Sokol Tomislav, Solier Diego, Solís Pérez Susana, Sommen Liesbet, Sonneborn Martin, Sorel Malika, Sousa Silva Hélder, Søvndal Villy, Squarta Marco, Staķis Mārtiņš, Stancanelli Raffaele, Ştefănuță Nicolae, Steger Petra, Stier Davor Ivo, Storm Kristoffer, Stöteler Sebastiaan, Stoyanov Stanislav, Strack-Zimmermann Marie-Agnes, Strada Cecilia, Streit Joachim, Strik Tineke, Strolenberg Anna, Sturdza Şerban Dimitrie, Stürgkh Anna, Sypniewski Marcin, Szczerba Michał, Szekeres Pál, Szydło Beata, Tamburrano Dario, Tânger Corrêa António, Tarczyński Dominik, Tarquinio Marco, Tarr Zoltán, Târziu Claudiu-Richard, Tavares Carla, Tegethoff Kai, Teodorescu Georgiana, Teodorescu Måwe Alice, Terheş Cristian, Ter Laak Ingeborg, Terras Riho, Tertsch Hermann, Thionnet Pierre-Romain, Timgren Beatrice, Tinagli Irene, Tobback Bruno, Tobé Tomas, Tolassy Rody, Tomac Eugen, Tomašič Zala, Tomaszewski Waldemar, Tomc Romana, Tonin Matej, Toom Jana, Torselli Francesco, Tosi Flavio, Toussaint Marie, Tovaglieri Isabella, Tridico Pasquale, Trochu Laurence, Tsiodras Dimitris, Tudose Mihai, Turek Filip, Tynkkynen Sebastian, Ušakovs Nils, Vaidere Inese, Valchev Ivaylo, Vălean Adina, Valet Matthieu, Van Brempt Kathleen, Van Brug Anouk, van den Berg Brigitte, Vandendriessche Tom, Van Dijck Kris, Van Lanschot Reinier, Van Leeuwen Jessika, Vannacci Roberto, Van Sparrentak Kim, Varaut Alexandre, Vasconcelos Ana, Vasile-Voiculescu Vlad, Vautmans Hilde, Vedrenne Marie-Pierre, Ventola Francesco, Verougstraete Yvan, Veryga Aurelijus, Vicsek Annamária, Vieira Catarina, Vigenin Kristian, Vilimsky Harald, Vincze Loránt, Vind Marianne, Vistisen Anders, Vivaldini Mariateresa, Volgin Petar, von der Schulenburg Michael, Vondra Alexandr, Voss Axel, Vozemberg-Vrionidi Elissavet, Vrecionová Veronika, Vázquez Lázara Adrián, Waitz Thomas, Walsh Maria, Walsmann Marion, Warborn Jörgen, Warnke Jan-Peter, Wąsik Maciej, Wawrykiewicz Michał, Wcisło Marta, Wechsler Andrea, Weimers Charlie, Werbrouck Séverine, Wiesner Emma, Wiezik Michal, Winkler Iuliu, Winzig Angelika, Wiseler-Lima Isabel, Wiśniewska Jadwiga, Wölken Tiemo, Wolters Lara, Yar Lucia, Yon-Courtin Stéphanie, Yoncheva Elena, Zacharia Maria, Zalewska Anna, Žalimas Dainius, Zan Alessandro, Zarzalejos Javier, Zdechovský Tomáš, Zdrojewski Bogdan Andrzej, Zijlstra Auke, Zīle Roberts, Zingaretti Nicola, Złotowski Kosma, Zver Milan

    Excused:

    Verheyen Sabine

    MIL OSI Europe News –

    May 8, 2025
  • MIL-OSI Europe: France: EIB and Groupe BPCE sign an agreement to provide €200 million in support for French agricultural businesses

    Source: European Investment Bank

    • Through an intermediated loan to the BPCE banking group, this operation will help to finance investments made by small businesses and mid-caps in the farming and bioeconomy sectors in France.
    • It will provide special support to young farmers, helping to address one of the most urgent challenges facing the French farming sector.
    • This is the first operation signed by the EIB in France as part of the €3 billion package set up in 2024 to support agricultural businesses.

    The European Investment Bank (EIB) and the BPCE banking group have signed an agreement to mobilise €200 million in loans for small and medium-sized enterprises (SMEs) and mid-caps in the French farming and bioeconomy sectors. This is the first operation that the EIB has signed in France as part of the €3 billion package it approved in 2024 to support businesses in the farming sector.

    The particular focus of this operation is to meet the specific needs of young farmers, thus facilitating the creation of new holdings and the takeover of existing ones. It will help to sustain and create jobs in rural communities by encouraging people to stay in those areas. The operation will help residents to purchase and modernise farms and to invest in sustainable technologies.

    “We are delighted to sign this agreement with Groupe BPCE. It is the first in France as part of the EIB’s €3 billion package to support agricultural businesses, with an emphasis on young farmers. The aim of this operation is to provide affordable and tailored financing to support the agricultural sector on its path to a more sustainable and resilient future,” said EIB Vice-President Gelsomina Vigliotti, who is responsible for operations in the agricultural sector.

    “Thanks to our long-standing partnership with the EIB, we have a credit envelope of €200 million dedicated to the farming and winegrowing sectors. The Banques Populaires and the Caisses d’Epargne will thus be stepping up their support for young farmers, winegrowers and new entrants, encouraging the renewal of generations, which is essential to the vitality of our regions. At the same time, we are committed to supporting projects aimed at accelerating the transition to sustainable agriculture”, added Cédric Glorieux, Director of Products and Solutions, Banque Populaire and Caisse d’Epargne.

    Present at the signing of the agreement in Brussels, as part of the conference on the vision for Agriculture and Food organised by the European Commission the european commissioner for agriculture and food Christophe Hansen welcomed the agreement : “”When launching the €3 billion package last December, the European Commission and the EIB set a clear aim: to support the EU’s agricultural priorities by facilitating generational renewal in a sector that encounters various hurdles in access to finance, and driving the ecological transition in rural areas. Today’s signature is a testament to the essential role these funds play in the agriculture and bioeconomy sectors. We remain committed to meeting the needs of our farmers.”

    Almost all of this finance will be allocated to projects in regions that fall within the scope of European cohesion and transition programmes. In addition, 30% of the funds will be dedicated to projects helping to promote climate action, efficient water use and biodiversity protection. These projects will involve energy-efficient irrigation systems, solar panel installation, low-carbon machinery, soil regeneration, and sustainable resource management. Thanks to the EIB’s operation, SMEs and mid-caps will be able to access loans with more favourable financing conditions and repayment deadlines that are adapted to the business cycle of their investments.

    Background information

    EIB

    The European Investment Bank is the long-term lending institution of the European Union, owned by its Member States. Built around eight core priorities, we finance investments that contribute to EU policy objectives, by bolstering climate action and the environment, digitalisation and technological innovation, security and defence, cohesion, agriculture and bioeconomy, social infrastructure, the capital markets union, and a stronger Europe in a more peaceful and prosperous world. The EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing for over 900 high-impact projects in 2024, boosting Europe’s competitiveness and security. The EIB Group signed more than 100 operations in France in 2024 for a total amount of €12.6 billion, mobilising €62 billion of investment in the real economy. All projects financed by the EIB Group are in line with the Paris Climate Agreement, as pledged in our Climate Bank Roadmap. Almost 60% of the EIB Group’s annual financing supports projects directly contributing to climate change mitigation, adaptation, and a healthier environment. Fostering market integration and mobilising investment, the Group supported a record of over €100 billion in new investment for Europe’s energy security in 2024 and unlocked €110 billion in growth capital for startups, scale-ups and European pioneers. Approximately half of the EIB’s financing within the European Union is directed towards cohesion regions, where per capita income is lower than the EU average.

    High-quality, up-to-date photos of our headquarters for media use are available here.

    Groupe BPCE

    Groupe BPCE is the second-largest banking group in France. It employs 100 000 staff serving 35 million customers worldwide – individuals, professionals, companies, investors and local government. It operates in the retail banking and insurance fields in France via its two major networks, Banque Populaire and Caisse d’Epargne, along with Banque Palatine and Oney. It also pursues its activities worldwide with the asset and wealth management services provided by Natixis Investment Managers and the wholesale banking expertise of Natixis Corporate & Investment Banking. The group’s financial strength is recognised by four rating agencies with the following preferred senior long-term ratings: Moody’s (A1, stable outlook), Standard & Poor’s (A+, stable outlook), Fitch (A+, stable outlook) and R&I (A+, stable outlook).

    MIL OSI Europe News –

    May 8, 2025
  • MIL-OSI Europe: Portugal: EIB provides €400 million loan to Santander to boost financing for SMEs and mid-caps and the agricultural sector

    Source: European Investment Bank

    • €75 million will go exclusively to the agricultural sector, while €325 million will support small businesses and mid-caps.

    The European Investment Bank (EIB) and Santander have signed a €400 million financing operation to boost investment in small and medium-sized enterprises (SMEs) and mid-caps, as well as to support the agricultural sector in Portugal. The operation aims to improve access to finance for companies operating in strategic sectors, with a view to accelerating development in the agricultural sector and to supporting cohesion regions.

    The operation includes €75 million to be allocated specifically to the agricultural sector under the Pan-European Agricultural Programme. An EIB initiative, this programme aims to strengthen farming and the bioeconomy in Europe, which is one of the EIB’s eight core priorities.

    At least 10% of this amount will support young and newly established farmers. The financing will also be available for the purchase of agricultural land. This is the first operation that the EIB has signed under the €3 billion package launched in 2024 to support businesses in the agricultural sector, with a particular focus on companies led by young entrepreneurs.

    The remaining €325 million will be used to finance SMEs and mid-caps in Portugal. It is expected that around 60% of this figure will be allocated to cohesion regions, promoting economic development in areas where credit is less accessible, and encouraging businesses to modernise.

    “This financing agreement reinforces the EIB’s commitment to sustainable economic growth, ensuring that SMEs and the agricultural sector have access to favourable financing conditions,” said EIB Director-General and Head of Operations Jean-Christophe Laloux. “By supporting young farmers and innovative projects, we are helping to make the Portuguese economy more resilient and competitive.”

    Santander Portugal Executive Board Member Amílcar Lourenço added: “It is with great commitment to our companies that we have concluded yet another agreement with the EIB. Every day we work to provide the best solutions for our clients, and we are aware that sustainable investment decisions are crucial for business growth and for Portugal’s development.”

    This agreement reinforces the EIB’s commitment to supporting the agricultural sector and economic development, promoting financial inclusion and sustainable growth in Portugal.

    To carry out the operation, Santander is issuing debt securities in the form of premium European covered bonds subscribed exclusively by the EIB. In this way, the EIB will provide financing directly to Santander, which in turn will use these resources to support SMEs and mid-caps – including young farmers – thus ensuring better financing conditions.

    Background information

    The European Investment Bank (ElB) is the long-term lending institution of the European Union, owned by its Member States. Built around eight core priorities, we finance investments that contribute to EU policy objectives by bolstering climate action and the environment, digitalisation and technological innovation, security and defence, cohesion, agriculture and bioeconomy, social infrastructure, high-impact investments outside the European Union and the capital markets union.

    The EIB Group, which includes the European Investment Fund (EIF), signed almost €89 billion in new financing for over 900 high-impact projects in 2024, boosting Europe’s competitiveness and security.

    All projects financed by the EIB Group are in line with the Paris Climate Agreement, as pledged in our Climate Bank Roadmap. Almost 60% of the EIB Group’s annual financing supports projects directly contributing to climate change mitigation, adaptation, and a healthier environment.

    Fostering market integration and mobilising investment, the Group supported a record of over €100 billion in new investment for Europe’s energy security in 2024 and mobilised €110 billion in growth capital for startups, scale-ups and European pioneers. Around half of the EIB’s financing within the European Union is directed towards cohesion regions, where per capita income is lower than the EU average.

    High-quality, up-to-date photos of our headquarters for media use are available here.

    About Santander Portugal

    Santander Portugal is a leading bank in the Portuguese financial system, whose mission is to contribute to the development of people and companies. Serving around 3 million customers, Santander’s vision is to be the best open financial services platform, all while acting responsibly and earning the trust of partners, clients, shareholders and society. 

    Santander is the largest private bank in Portugal in terms of credit granted, with a privileged position in segments such as mortgage and corporate credit, and also in profitability and efficiency, with a return on equity of 32.2% in March 2025. The strength of its balance sheet is reflected in high capital ratios (CET1 of 14.2% in March 2025, above the SREP requirement of 8.4%) and high credit portfolio quality (non-performing exposure ratio of 1.5%).

    The bank has been implementing a comprehensive digitalisation strategy, geared towards simplifying processes and innovation, thus providing its clients with a more attentive and personalised service to ensure they have the best possible experience. 

    MIL OSI Europe News –

    May 8, 2025
  • MIL-OSI Europe: A breath of fresh air powered by science

    Source: European Investment Bank

    “As scientists, we have a strong commitment to creating practical solutions that can contribute to a better future for all people,” says Aleksandar Rodić, head of the Centre for Robotics at the institute and one of the purifier’s designers. “This is why we’ve developed an ad-hoc technical solution aimed at mitigating pollution in large urban areas.”

    Pollution in Belgrade is exacerbated by a nearby coal-fired power plant, which provides close to half the country’s electricity. The city also has many industrial plants and dense road traffic. Air pollution is a leading cause of mortality, diseases and respiratory illnesses in the country. According to estimates, around 7,000 residents in Serbia are diagnosed with lung cancer annually, mainly because of smoking and the air pollution.

    Addressing the causes of a city’s air pollution requires substantial long-term investments in cleaner power generation and road traffic. The new air purifier, however, offers immediate improvements at a much lower cost, Rodić says. “Such solutions are also scalable, allowing for replication throughout the region and beyond,” he says.

    The purifier was supported by the EU for Green Agenda in Serbia initiative. It received technical and financial assistance from the European Union, with additional funding from Sweden, Switzerland and Serbia. The initiative is implemented by United Nations Development Programme and the Serbian Ministry of Environmental Protection, in cooperation with Sweden and the European Investment Bank. The EIB is providing technical assistance to banks and businesses for many green innovations like this one.

    Under the Green Agenda initiative, the air purifier project received €44 000 from the European Union to build a pilot filtration system at the Ušće Shopping Center in Belgrade. The system includes two air purifiers and the wind and kinetic energy devices that generate green electricity to run the filtration systems.

    MIL OSI Europe News –

    May 8, 2025
  • MIL-OSI Europe: Written question – Dangerous rise in water levels in Greece’s coastal areas – E-001799/2025

    Source: European Parliament

    Question for written answer  E-001799/2025
    to the Commission
    Rule 144
    Emmanouil Fragkos (ECR)

    The risk from rising sea levels is visible and increasing all the time. The problem affects coastal areas either through frequent flooding or by a gradual increase in soil salinity, affecting crops and eroding infrastructure, a dangerous reality in the case of coastal roads. The rise in the level depends on the level of global warming, a matter on which, as things stand, no international/interstate agreement can be reached in order to identify joint solutions.

    For Greece, with a predicted temperature increase of 3°C by 2100, the sea level is expected to rise by 0.5 to 0.7 metres, with the possibility of a greater rise due to vertical land displacements. Significant Greek scientific studies warn that as early as 2050, at least ten regions of the country will face serious problems. The impacts include the loss of arable land, degradation of water quality and the need to relocate infrastructure and – possibly – populations. It is considered necessary that studies are carried out and measures put in place before these consequences occur.

    In view of the above:

    • 1.Does the Commission have or does it intend to pursue a detailed mapping of the impacts, in order to support policy choices by the affected Member States and affected citizens?
    • 2.Does the Commission have a framework for the preparation of forecast studies and adaptation/coping measures for those affected and local authorities in coastal areas?
    • 3.Does the Commission intend to propose new financial frameworks to local authorities for investments to facilitate their adaptation?

    Submitted: 2.5.2025

    Last updated: 8 May 2025

    MIL OSI Europe News –

    May 8, 2025
  • MIL-OSI Security: Met Police continues clampdown on tool theft across London

    Source: United Kingdom London Metropolitan Police

    Met officers have seized around half a million pounds worth of suspected stolen tools following a proactive policing operation at a car boot sale in east London.

    Local officers made six arrests and recovered around 1,500 tools worth £150,000 at the Warren Farm Bonzer Boot Sale in Romford. A further 159 tools were seized during another search at a property in Hackney.

    The intelligence-led activity was carried out in response to concerns from tradespeople about tool theft and is part of the Met’s continued focus on tackling the crimes that matter most to Londoners.

    Inspector Mark Connolly, from the Met’s Havering Safer Neighbourhood Team who led the operation, said:

    “We know tool theft has a significant impact on tradespeople and we’re working hard across the Met to tackle it through targeted operations like this and prevention, such as holding tool marking events and issuing advice on keeping vehicles secure.

    “While victims have their livelihoods disrupted, organised crime groups are making huge sums of money from selling on suspected stolen tools and we won’t stand for it.

    “This is the second operation of this kind we’ve carried out over the past month and we will continue to take action against those who make the lives of Londoners a misery through this type of offending.”

    Among the items recovered were three surveillance systems used to monitor earth and infrastructure movements each worth more than £30,000, a device used to measure ground depth worth around £20,000, and a motorised heist worth £17,000.

    Met officers were also joined by partners including Havering Council’s trading standards team at the operation on Thursday, 1 May.

    Councillor Ray Morgon, Leader of Havering Council, added:

    “This is once again excellent work from our trading standards team working in partnership with police and other partners.

    “Illegal and harmful products have been taken off the streets in our borough as a result of this operation. I know there has been a lot of work to get this result, so I thank everyone involved.

    “It’s our aim to help keep our residents safe and we want to continue to crackdown on a crime that is often hiding in plain sight in venues such as car boot sales and our town centres. That is why we will continue to take the strongest action we can against those trying to sell these harmful and illegal products and work with the police to bring them to justice.”

    Four men and two women, aged between 25 and 60 and from Hackney, Newham and Kent, were arrested on suspicion of handling stolen goods. They have since been bailed while officers carry out further enquiries.

    Tradesperson and social media influencer Shoaib Awan, widely known as The Gas Expert, said:

    “As a tradesperson who has invested years in education, training and building a business, repeated incidents of tool theft are not only demoralising, but financially crippling, and is forcing many to walk away from their respective trades.

    “I fully support the great work the Met Police is doing to crack down on this type of illegal activity and I’ll continue to work with them alongside our partners to bring down the organised crime groups and people who have a complete disregard for the law and their victims.”

    The activity is part of the Met’s continued crackdown on tool theft which last month resulted in around £50,000 worth of suspected stolen tools being recovered from a car boot sale in Rainham.

    Officers will work over the coming weeks to identify the tools and trace their original owners.

    Any tradespeople or those in possession of power tools are advised to mark their property, take photographs, and record serial numbers so that, in the event of theft, officers have more chance of returning property.

    If you suspect anyone of selling stolen or counterfeit goods, you can report this to us online or anonymously to the independent charity Crimestoppers by calling 0800 555 111.

    MIL Security OSI –

    May 8, 2025
  • MIL-OSI: Brookfield Wealth Solutions Announces First Quarter Results and Declares Quarterly Distribution

    Source: GlobeNewswire (MIL-OSI)

    BROOKFIELD, NEWS, May 08, 2025 (GLOBE NEWSWIRE) — Brookfield Wealth Solutions (NYSE, TSX: BNT) today announced financial results for the three months ended March 31, 2025.

    Sachin Shah, CEO of Brookfield Wealth Solutions, stated, “Our business is off to a strong start in 2025. We have entered the U.K. market and begun offering new products that expand our asset base while maintaining our fundamental objective of generating high-quality earnings and durable risk-adjusted returns within our business.”

    Unaudited
    As of and for the periods ended March 31
    (US$ millions, except per share amounts)
    Three Months Ended
      2025       2024
    Total assets $ 141,612     $ 63,113
    Distributable operating earnings1   437       279
    Net income (loss)   (282 )     337
    Net income per each class A share $ 0.09     $ 0.08

    1. See Non-GAAP and Performance Measures on page 6 and a reconciliation from net income on page 5.

    First Quarter Highlights

    • Launched our U.K. pension risk transfer business under Blumont Annuity UK in late March, following a comprehensive authorization process and expect to be active in the market in 2025
    • Deployed $3 billion into Brookfield originated strategies across our investment portfolio at returns greater than 8%
    • Completed our first funding agreement-backed note (“FABN”) issuance at American National for $500 million
    • Originated $4 billion of annuity sales during the quarter across our retail, PRT and FABN channels
    • Our Property and Casualty float remained stable at approximately $8 billion, providing us with investment flexibility and risk diversification

    Operating Update
    We recognized $437 million of distributable operating earnings (“DOE”) for the three months ended March 31, 2025, compared to $279 million in the prior year period. The increase in earnings for the current period reflects contributions from AEL, which we acquired in May 2024, as well as higher net investment income resulting from progress made in repositioning assets into higher yielding investment strategies.

    We recorded a net loss of $282 million for the three months ended March 31, 2025, compared to net income of $337 million in the prior year period. The net loss in the current period is primarily the result of unrealized movements on reserves due to interest rate and equity market movements, which more than offset our strong operating performance. Net income in the prior year period resulted from our DOE and favorable mark-to-market on derivatives.

    Today, we are in a strong liquidity position, with approximately $25 billion of cash and short-term liquid investments across our investment portfolios, and another $22 billion of long-term liquid investments. These liquid assets position us well to mitigate current market volatility and support the ongoing rotation of our portfolio into higher yielding investment strategies.

    Regular Distribution Declaration
    The Board declared a quarterly return of capital of $0.09 per class A share and class B share payable on June 30, 2025 to shareholders of record as at the close of business on June 13, 2025. This distribution is identical in amount per share and has the same payment date as the quarterly distribution announced today by Brookfield Corporation on the Brookfield class A shares.

    Brookfield Corporation Operating Results
    An investment in class A shares of our company is intended to be, as nearly as practicable, functionally and economically, equivalent to an investment in the Brookfield class A shares. A summary of Brookfield Corporation’s first quarter operating results is provided below:

    Unaudited
    For the periods ended March 31
    (US$ millions, except per share amounts)
    Three Months Ended   Last Twelve Months Ended
      2025     2024     2025     2024
    Net income of consolidated business1 $ 215   $ 519   $ 1,549   $ 5,200
    Net income attributable to Brookfield shareholders2   73     102     612     1,112
    Distributable earnings before realizations3   1,301     1,001     5,171     4,279
    – Per Brookfield class A share3   0.82     0.63     3.26     2.70
    Distributable earnings3   1,549     1,216     6,607     4,865
    – Per Brookfield class A share3   0.98     0.77     4.17     3.07

    1. Consolidated basis – includes amounts attributable to non-controlling interests.
    2. Excludes amounts attributable to non-controlling interests.
    3. See Reconciliation of Net Income to Distributable Earnings on page 5 and Non-IFRS and Performance Measures section on page 8 of Brookfield Corporation’s press release dated May 8, 2025.

    Brookfield Corporation net income above is presented under IFRS. Given the economic equivalence, we expect that the market price of the class A shares of our company will be impacted significantly by the market price of the Brookfield class A shares and the business performance of Brookfield as a whole. In addition to carefully considering the disclosure made in this news release in its entirety, shareholders are strongly encouraged to carefully review Brookfield Corporation’s letter to shareholders, supplemental information and its other continuous disclosure filings. Investors, analysts and other interested parties can access Brookfield Corporation’s disclosure on its website under the Reports & Filings section at bn.brookfield.com.

    CONSOLIDATED BALANCE SHEETS

               
    Unaudited   March 31     December 31
    (US$ millions)     2025       2024
    Assets          
               
    Insurance invested assets          
    Cash, cash equivalents and short-term investments $ 16,686     $ 16,643  
    Investments   90,184       88,566  
    Reinsurance funds withheld   1,492       1,517  
    Accrued investment income   841   109,203     860   107,586
    Deferred policy acquisition costs     10,848       10,696
    Reinsurance recoverables and deposit assets     12,957       13,195
          133,008       131,477
               
    Other assets     8,604       8,476
    Total assets     141,612       139,953
               
    Liabilities and equity          
               
    Policy and contract claims     7,588       7,659
    Future policy benefits     14,582       14,088
    Policyholders’ account balances     84,606       83,079
    Deposit liabilities     1,483       1,502
    Market risk benefits     4,066       3,655
    Unearned premium reserve     1,674       1,843
    Funds withheld for reinsurance liabilities     3,266       3,392
          117,265       115,218
               
    Corporate borrowings     1,004       1,022
    Subsidiary borrowings     3,332       3,329
    Other liabilities     7,001       7,308
               
    Non-controlling interest   771       850  
    Class A and class B   1,469       1,470  
    Class C   10,770   13,010     10,756   13,076
    Total liabilities and equity   $ 141,612     $ 139,953


    CONSOLIDATED STATEMENTS OF OPERATIONS

    Unaudited
    For the periods ended March 31
    US$ millions
    Three Months Ended
      2025       2024  
    Net premiums and other policy revenue $ 1,301     $ 1,643  
    Net investment income, including funds withheld   1,429       670  
    Net investment gains (losses), including funds withheld   (112 )     172  
    Total revenues   2,618       2,485  
           
    Benefits and claims paid on insurance contracts   (1,107 )     (1,414 )
    Interest sensitive contract benefits   (524 )     (185 )
    Amortization of deferred policy acquisition costs   (339 )     (225 )
    Change in fair value of insurance-related derivatives and embedded derivatives   (200 )     44  
    Change in fair value of market risk benefits   (361 )     (31 )
    Other reinsurance expenses   (1 )     (7 )
    Operating expenses   (382 )     (233 )
    Interest expense   (73 )     (72 )
    Total benefits and expenses   (2,987 )     (2,123 )
    Net income (loss) before income taxes   (369 )     362  
    Income tax recovery (expense)   87       (25 )
    Net income (loss) $ (282 )   $ 337  
           
    Attributable to:      
    Class A and class B shareholders1 $ 4     $ 3  
    Class C shareholder   (330 )     332  
    Non-controlling interest   44       2  
      $ (282 )   $ 337  

    1. Class A shares receive distributions at the same amount per share as the cash dividends paid on each Brookfield class A share.


    SUMMARIZED FINANCIAL RESULTS

    RECONCILIATION OF NET INCOME TO DISTRIBUTABLE OPERATING EARNINGS

    Unaudited
    For the periods ended March 31
    US$ millions
    Three Months Ended
      2025       2024  
    Net income (loss) $ (282 )   $ 337  
    Unrealized net investment losses (gains), including funds withheld   112       (172 )
    Mark-to-market losses (gains) on insurance contracts and other net assets   685       65  
        515       230  
    Deferred income tax expense (recovery)   (183 )     15  
    Transaction costs   41       12  
    Depreciation   64       22  
    Distributable operating earnings1 $ 437     $ 279  

    1. Non-GAAP measure – see Non-GAAP and Performance Measures on page 6.

    Additional Information

    The statements contained herein are based primarily on information that has been extracted from our financial statements for the quarter ended March 31, 2025, which have been prepared using generally accepted accounting principles in the United States of America (“US GAAP” or “GAAP”).

    Brookfield Wealth Solutions’ Board of Directors have reviewed and approved this document, including the summarized unaudited consolidated financial statements prior to its release.

    Information on our distributions can be found on our website under Stock & Distributions/Distribution History.

    Brookfield Wealth Solutions Ltd. (NYSE, TSX: BNT) is focused on securing the financial futures of individuals and institutions through a range of retirement services, wealth protection products and tailored capital solutions. Each class A exchangeable limited voting share of Brookfield Wealth Solutions is exchangeable on a one-for-one basis with a class A limited voting share of Brookfield Corporation (NYSE, TSX: BN). For more information, please visit our website at bnt.brookfield.com or contact:

    Non-GAAP and Performance Measures

    This news release and accompanying financial statements are based on US GAAP, unless otherwise noted.

    We make reference to Distributable operating earnings. We define distributable operating earnings as net income after applicable taxes excluding the impact of depreciation and amortization, deferred income taxes related to basis and other changes, and breakage and transaction costs, as well as certain investment and insurance reserve gains and losses, including gains and losses related to asset and liability matching strategies, non-operating adjustments related to changes in cash flow assumptions for future policy benefits, and change in market risk benefits, and is inclusive of returns on equity invested in certain variable interest entities and our share of adjusted earnings from our investments in certain associates. Distributable operating earnings is a measure of operating performance. We use distributable operating earnings to assess our operating results.

    We provide additional information on key terms and non-GAAP measures in our filings available at bnt.brookfield.com.

    Notice to Readers

    Brookfield Wealth Solutions Ltd. (“Brookfield Wealth Solutions” or “our” or “we”) is not making any offer or invitation of any kind by communication of this news release and under no circumstance is it to be construed as a prospectus or an advertisement.

    This news release contains “forward-looking information” within the meaning of Canadian provincial securities laws, “forward-looking statements” within the meaning of Canadian provincial securities laws, “forward-looking statements” within the meaning of the U.S. Securities Act of 1933, the U.S. Securities Exchange Act of 1934, and “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and in any applicable Canadian securities regulations (collectively, “forward-looking statements”). Forward-looking statements include statements that are predictive in nature, depend upon or refer to future results, events or conditions, and include, but are not limited to, statements which reflect management’s current estimates, assumptions and expectations regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, strategies, capital management and outlook of Brookfield Wealth Solutions, Brookfield Corporation and their respective subsidiaries, as well as the outlook for North American and international economies for the current fiscal year and subsequent periods. Particularly, statements regarding international expansion plans and future capital markets initiatives, including statements relating to the redeployment of capital into higher yielding investments constitute forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terminology such as “expects,” “anticipates,” “plans,” “believes,” “estimates,” “seeks,” “intends,” “targets,” “projects,” “foresees,” “forecasts” or negative versions thereof and other similar expressions, or future or conditional verbs such as “may,” “will,” “should,” “would” and “could.” In particular, the forward-looking statements contained in this news release include statements referring to the growth of our business, international expansion, investment opportunities and expected future deployment of capital and financial earnings. Although we believe that our anticipated future results, performance or achievements expressed or implied by the forward-looking statements and information are based upon reasonable estimates, assumptions and expectations, the reader should not place undue reliance on forward-looking statements and information because they involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, which may cause the actual results, performance or achievements of Brookfield Wealth Solutions or Brookfield Corporation to differ materially from anticipated future results, performance or achievement expressed or implied by such forward-looking statements and information.

    Factors that could cause actual results to differ materially from those contemplated or implied by forward-looking statements include, but are not limited to: (i) investment returns that are lower than target; (ii) the impact or unanticipated impact of general economic, political and market factors in the countries in which we do business; (iii) the behavior of financial markets, including fluctuations in interest and foreign exchange rates and heightened inflationary pressures; (iv) global equity and capital markets and the availability of equity and debt financing and refinancing within these markets; (v) strategic actions including acquisitions and dispositions; the ability to complete and effectively integrate acquisitions into existing operations and the ability to attain expected benefits; (vi) changes in accounting policies and methods used to report financial condition (including uncertainties associated with critical accounting assumptions and estimates); (vii) the ability to appropriately manage human capital; (viii) the effect of applying future accounting changes; (ix) business competition; (x) operational and reputational risks; (xi) technological change; (xii) changes in government regulation and legislation within the countries in which we operate; (xiii) governmental investigations and sanctions; (xiv) litigation; (xv) changes in tax laws; (xvi) ability to collect amounts owed; (xvii) catastrophic events, including but not limited to, earthquakes, hurricanes, epidemics and pandemics; (xviii) the possible impact of international conflicts and other developments including terrorist acts and cyberterrorism; (xix) the introduction, withdrawal, success and timing of business initiatives and strategies; (xx) the failure of effective disclosure controls and procedures and internal controls over financial reporting and other risks; (xxi) health, safety and environmental risks; (xxii) the maintenance of adequate insurance coverage; (xxiii) the existence of information barriers between certain businesses within our asset management operations; (xxiv) risks specific to our business segments; and (xxv) factors detailed from time to time in our documents filed with the securities regulators in Canada and the United States.

    We caution that the foregoing list of important factors that may affect future results is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the foregoing risks, as well as other uncertainties, factors and assumptions carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such forward-looking information. Except as required by law, Brookfield Wealth Solutions undertakes no obligation to publicly update or revise any forward-looking statements or information, whether written or oral, that may be as a result of new information, future events or otherwise.

    Past performance is not indicative nor a guarantee of future results. There can be no assurance that comparable results will be achieved in the future, that future investments will be similar to the historic investments discussed herein, that targeted returns, growth objectives, diversification or asset allocations will be met or that an investment strategy or investment objectives will be achieved (because of economic conditions, the availability of investment opportunities or otherwise).

    Certain of the information contained herein is based on or derived from information provided by independent third-party sources. While Brookfield Wealth Solutions believes that such information is accurate as of the date it was produced and that the sources from which such information has been obtained are reliable, Brookfield Wealth Solutions does not make any assurance, representation or warranty, express or implied, with respect to the accuracy, reasonableness or completeness of any of the information or the assumptions on which such information is based, contained herein, including but not limited to, information obtained from third parties, and undue reliance should not be put on them.

    The MIL Network –

    May 8, 2025
  • MIL-OSI: YieldMax™ Introduces Option Income Strategy ETF on Robinhood Markets, Inc. (HOOD)

    Source: GlobeNewswire (MIL-OSI)

    CHICAGO and MILWAUKEE and NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) — YieldMax™ announced the launch today of the following ETF:

    YieldMax™ HOOD Option Income Strategy ETF (NYSE Arca: HOOY)

    HOOY seeks to generate current income by pursuing options-based strategies on Robinhood Markets, Inc. (HOOD). HOOY is managed by Tidal Financial Group. HOOY does not invest directly in HOOD.

    HOOY is the newest member of the YieldMax™ ETF family and like all YieldMax™ ETFs, aims to deliver current income to investors. With respect to distributions, HOOY will be a Group C ETF, and its first distribution is expected to be announced on May 28, 2025. Please see the table below for distribution information for all outstanding YieldMax™ ETFs.

    ETF
    Ticker
    1
    ETF Name Distribution
    Frequency
    Distribution
    per Share
    Distribution
    Rate
    2,4
    30-Day
    SEC Yield3
    ROC5
    CHPY YieldMax™ Semiconductor Portfolio Option Income ETF Weekly $0.3767 – – 97.94%
    GPTY YieldMax™ AI & Tech Portfolio Option Income ETF Weekly $0.2738 35.61% 0.00% 100.00%
    LFGY YieldMax™ Crypto Industry & Tech Portfolio Option Income ETF Weekly $0.7511 105.48% 0.00% 100.00%
    QDTY YieldMax™ Nasdaq 100 0DTE Covered Call Strategy ETF Weekly $0.2841 36.92% 0.00% 100.00%
    RDTY YieldMax™ R2000 0DTE Covered Call Strategy ETF Weekly $0.4634 55.54% 0.00% 100.00%
    SDTY YieldMax™ S&P 500 0DTE Covered Call Strategy ETF Weekly $0.2714 33.51% 0.00% 100.00%
    ULTY YieldMax™ Ultra Option Income Strategy ETF Weekly $0.1181 103.33% 0.00% 100.00%
    YMAG YieldMax™ Magnificent 7 Fund of Option Income ETFs Weekly $0.1059 36.97% 70.00% 94.72%
    YMAX YieldMax™ Universe Fund of Option Income ETFs Weekly $0.1679 66.24% 95.10% 89.73%
    BIGY YieldMax™ Target 12™ Big 50 Option Income ETF Monthly $0.4609 12.17% 0.18% 66.89%
    RNTY* YieldMax™ Target 12™ Real Estate Option Income ETF Monthly – – – –
    SOXY YieldMax™ Target 12™ Semiconductor Option Income ETF Monthly $0.4384 11.99% 0.12% 100.00%
    ABNY YieldMax™ ABNB Option Income Strategy ETF Every 4 weeks $0.6020 67.26% 3.22% 94.97%
    AIYY YieldMax™ AI Option Income Strategy ETF Every 4 weeks $0.3245 87.29% 3.75% 96.09%
    AMDY YieldMax™ AMD Option Income Strategy ETF Every 4 weeks $0.3365 62.11% 3.31% 94.47%
    AMZY YieldMax™ AMZN Option Income Strategy ETF Every 4 weeks $0.7963 65.77% 3.68% 94.99%
    APLY YieldMax™ AAPL Option Income Strategy ETF Every 4 weeks $0.6512 63.24% 3.13% 94.81%
    BABO YieldMax™ BABA Option Income Strategy ETF Every 4 weeks $0.6587 49.99% 4.01% 91.80%
    CONY YieldMax™ COIN Option Income Strategy ETF Every 4 weeks $0.6510 115.53% 3.39% 96.77%
    CRSH YieldMax™ Short TSLA Option Income Strategy ETF Every 4 weeks $0.5616 116.94% 1.81% 0.00%
    CVNY YieldMax™ CVNA Option Income Strategy ETF Every 4 weeks $2.6816 88.82% 2.37% 68.30%
    DIPS YieldMax™ Short NVDA Option Income Strategy ETF Every 4 weeks $0.6186 76.30% 2.19% 0.00%
    DISO YieldMax™ DIS Option Income Strategy ETF Every 4 weeks $0.5291 49.63% 3.72% 94.23%
    FBY YieldMax™ META Option Income Strategy ETF Every 4 weeks $0.5216 43.30% 3.86% 91.40%
    FEAT YieldMax™ Dorsey Wright Featured 5 Income ETF Every 4 weeks $1.6435 59.38% 55.86% 0.00%
    FIAT YieldMax™ Short COIN Option Income Strategy ETF Every 4 weeks $0.5618 105.46% 1.14% 0.00%
    FIVY YieldMax™ Dorsey Wright Hybrid 5 Income ETF Every 4 weeks $1.0283 35.56% 38.10% 0.00%
    GDXY YieldMax™ Gold Miners Option Income Strategy ETF Every 4 weeks $0.7284 60.35% 2.66% 0.00%
    GOOY YieldMax™ GOOGL Option Income Strategy ETF Every 4 weeks $0.3729 41.63% 3.52% 90.74%
    JPMO YieldMax™ JPM Option Income Strategy ETF Every 4 weeks $0.5612 46.19% 3.39% 92.60%
    MARO YieldMax™ MARA Option Income Strategy ETF Every 4 weeks $1.8468 110.67% 3.33% 97.16%
    MRNY YieldMax™ MRNA Option Income Strategy ETF Every 4 weeks $0.1261 71.18% 4.27% 0.00%
    MSFO YieldMax™ MSFT Option Income Strategy ETF Every 4 weeks $0.5255 40.57% 3.26% 92.04%
    MSTY YieldMax™ MSTR Option Income Strategy ETF Every 4 weeks $2.3734 123.15% 1.00% 98.39%
    NFLY YieldMax™ NFLX Option Income Strategy ETF Every 4 weeks $0.9230 65.94% 2.79% 95.72%
    NVDY YieldMax™ NVDA Option Income Strategy ETF Every 4 weeks $0.6734 57.41% 3.56% 85.30%
    OARK YieldMax™ Innovation Option Income Strategy ETF Every 4 weeks $0.2923 51.00% 3.10% 93.61%
    PLTY YieldMax™ PLTR Option Income Strategy ETF Every 4 weeks $4.6556 95.97% 2.36% 98.08%
    PYPY YieldMax™ PYPL Option Income Strategy ETF Every 4 weeks $0.5519 56.42% 3.54% 94.52%
    SMCY YieldMax™ SMCI Option Income Strategy ETF Every 4 weeks $1.4128 100.24% 3.85% 97.08%
    SNOY YieldMax™ SNOW Option Income Strategy ETF Every 4 weeks $0.6864 56.07% 2.87% 94.51%
    TSLY YieldMax™ TSLA Option Income Strategy ETF Every 4 weeks $0.6598 103.22% 3.27% 96.85%
    TSMY YieldMax™ TSM Option Income Strategy ETF Every 4 weeks $0.5635 49.99% 3.43% 16.38%
    WNTR YieldMax™ Short MSTR Option Income Strategy ETF Every 4 weeks $2.7190 85.90% 3.26% 95.65%
    XOMO YieldMax™ XOM Option Income Strategy ETF Every 4 weeks $0.3500 35.44% 3.42% 90.74%
    XYZY YieldMax™ XYZ Option Income Strategy ETF Every 4 weeks $0.4140 59.93% 3.80% 95.54%
    YBIT YieldMax™ Bitcoin Option Income Strategy ETF Every 4 weeks $0.4110 49.16% 1.20% 30.49%
    YQQQ YieldMax™ Short N100 Option Income Strategy ETF Every 4 weeks $0.4357 34.61% 2.97% 91.77%


    Standardized Performance
    and Fund details can be obtained by clicking the ETF Ticker in the table above or by visiting us at www.yieldmaxetfs.com

    Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted above. Performance current to the most recent month-end can be obtained by calling (833) 378-0717.

    Note: DIPS, FIAT, CRSH, YQQQ and WNTR are hereinafter referred to as the “Short ETFs.”

    Distributions are not guaranteed.   The Distribution Rate and 30-Day SEC Yield are not indicative of future distributions, if any, on the ETFs. In particular, future distributions on any ETF may differ significantly from its Distribution Rate or 30-Day SEC Yield. You are not guaranteed a distribution under the ETFs. Distributions for the ETFs (if any) are variable and may vary significantly from period to period and may be zero. Accordingly, the Distribution Rate and 30-Day SEC Yield will change over time, and such change may be significant.

    Investors in the Funds will not have rights to receive dividends or other distributions with respect to the underlying reference asset(s).

    *The inception date for RNTY is April 16, 2025.

    1All YieldMax™ ETFs shown in the table above (except YMAX, YMAG, FEAT, FIVY and ULTY) have a gross expense ratio of 0.99%. YMAX and FEAT have a Management Fee of 0.29% and Acquired Fund Fees and Expenses of 0.99% for a gross expense ratio of 1.28%. YMAG has a management fee of 0.29% and Acquired Fund Fees and Expenses of 0.83% for a gross expense ratio of 1.12%. FIVY has a Management Fee of 0.29% and Acquired Fund Fees and Expenses of 0.59% for a gross expense ratio of 0.88%. “Acquired Fund Fees and Expenses” are indirect fees and expenses that the Fund incurs from investing in the shares of other investment companies, namely other YieldMax™ ETFs. ULTY has a gross expense ratio of 1.40%, and a net expense ratio after the fee waiver of 1.30%. The Advisor has agreed to a fee waiver of 0.10% through at least February 28, 2026. 

    2The Distribution Rate shown is as of close on May 7, 2025. The Distribution Rate is the annual distribution rate an investor would receive if the most recent distribution, which includes option income, remained the same going forward. The Distribution Rate is calculated by annualizing an ETF’s Distribution per Share and dividing such annualized amount by the ETF’s most recent NAV. The Distribution Rate represents a single distribution from the ETF and does not represent its total return. Distributions may also include a combination of ordinary dividends, capital gain, and return of investor capital, which may decrease an ETF’s NAV and trading price over time. As a result, an investor may suffer significant losses to their investment. These Distribution Rates may be caused by unusually favorable market conditions and may not be sustainable. Such conditions may not continue to exist and there should be no expectation that this performance may be repeated in the future.

    3The 30-Day SEC Yield represents net investment income, which excludes option income, earned by such ETF over the 30-Day period ended April 30, 2025, expressed as an annual percentage rate based on such ETF’s share price at the end of the 30-Day period.

    4Each ETF’s strategy (except those of the Short ETFs) will cap potential gains if its reference asset’s shares increase in value, yet subjects an investor to all potential losses if the reference asset’s shares decrease in value. Such potential losses may not be offset by income received by the ETF. Each Short ETF’s strategy will cap potential gains if its reference asset decreases in value, yet subjects an investor to all potential losses if the reference asset increases in value. Such potential losses may not be offset by income received by the ETF.

    5ROC refers to Return of Capital. The ROC percentage is the portion of the distribution that represents an investor’s original investment.

    Each Fund has a limited operating history and while each Fund’s objective is to provide current income, there is no guarantee the Fund will make a distribution. Distributions are likely to vary greatly in amount.

    Important Information

    This material must be preceded or accompanied by the prospectus. For all prospectuses, click here.

    Tidal Financial Group is the adviser for all YieldMax™ ETFs.

    THE FUND, TRUST, AND ADVISER ARE NOT AFFILIATED WITH ANY UNDERLYING REFERENCE ASSET.

    Risk Disclosures

    Investing involves risk. Principal loss is possible.

    Referenced Index Risk. The Fund invests in options contracts that are based on the value of the Index (or the Index ETFs). This subjects the Fund to certain of the same risks as if it owned shares of companies that comprised the Index or an ETF that tracks the Index, even though it does not.

    Indirect Investment Risk. The Index is not affiliated with the Trust, the Fund, the Adviser, or their respective affiliates and is not involved with this offering in any way. Investors in the Fund will not have the right to receive dividends or other distributions or any other rights with respect to the companies that comprise the Index but will be subject to declines in the performance of the Index.

    Russell 2000 Index Risks. The Index, which consists of small-cap U.S. companies, is particularly susceptible to economic changes, as these firms often have less financial resilience than larger companies. Market volatility can disproportionately affect these smaller businesses, leading to significant price swings. Additionally, these companies are often more exposed to specific industry risks and have less diverse revenue streams. They can also be more vulnerable to changes in domestic regulatory or policy environments.

    Call Writing Strategy Risk. The path dependency (i.e., the continued use) of the Fund’s call writing strategy will impact the extent that the Fund participates in the positive price returns of the underlying reference asset and, in turn, the Fund’s returns, both during the term of the sold call options and over longer periods.

    Counterparty Risk. The Fund is subject to counterparty risk by virtue of its investments in options contracts. Transactions in some types of derivatives, including options, are required to be centrally cleared (“cleared derivatives”). In a transaction involving cleared derivatives, the Fund’s counterparty is a clearing house rather than a bank or broker. Since the Fund is not a member of clearing houses and only members of a clearing house (“clearing members”) can participate directly in the clearing house, the Fund will hold cleared derivatives through accounts at clearing members.

    Derivatives Risk. Derivatives are financial instruments that derive value from the underlying reference asset or assets, such as stocks, bonds, or funds (including ETFs), interest rates or indexes. The Fund’s investments in derivatives may pose risks in addition to, and greater than, those associated with directly investing in securities or other ordinary investments, including risk related to the market, imperfect correlation with underlying investments or the Fund’s other Index (or ETFs that track the Index’s performance)holdings, higher price volatility, lack of availability, counterparty risk, liquidity, valuation and legal restrictions.

    Options Contracts. The use of options contracts involves investment strategies and risks different from those associated with ordinary Index (or ETFs that track the Index’s performance) securities transactions. The prices of options are volatile and are influenced by, among other things, actual and anticipated changes in the value of the underlying instrument, including the anticipated volatility, which are affected by fiscal and monetary policies and by national and international political, changes in the actual or implied volatility or the reference asset, the time remaining until the expiration of the option contract and economic events.

    Distribution Risk. As part of the Fund’s investment objective, the Fund seeks to provide current income. There is no assurance that the Fund will make a distribution in any given period. If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next. Additionally, monthly distributions, if any, may consist of returns of capital, which would decrease the Fund’s NAV and trading price over time.

    High Index (or Index ETF) Turnover Risk. The Fund may actively and frequently trade all or a significant portion of the Fund’s holdings. A high Index (or Index ETF) turnover rate increases transaction costs, which may increase the Fund’s expenses.

    Liquidity Risk. Some securities held by the Fund, including options contracts, may be difficult to sell or be illiquid, particularly during times of market turmoil.

    Non-Diversification Risk. Because the Fund is “non-diversified,” it may invest a greater percentage of its assets in the securities of a single issuer or a smaller number of issuers than if it was a diversified fund.

    New Fund Risk. The Fund is a recently organized management investment company with no operating history. As a result, prospective investors do not have a track record or history on which to base their investment decisions.

    Price Participation Risk. The Fund employs an investment strategy that includes the sale of call option contracts, which limits the degree to which the Fund will participate in increases in value experienced by the underlying reference asset over the Call Period.

    Inflation Risk. Inflation risk is the risk that the value of assets or income from investments will be less in the future as inflation decreases the value of money. As inflation increases, the present value of the Fund’s assets and distributions, if any, may decline.

    Single Issuer Risk. Issuer-specific attributes may cause an investment in the Fund to be more volatile than a traditional pooled investment which diversifies risk or the market generally. The value of the Fund, which focuses on an individual security (ARKK, TSLA, AAPL, NVDA, AMZN, META, GOOGL, NFLX, COIN, MSFT, DIS, XOM, JPM, AMD, PYPL, SQ, MRNA, AI, MSTR, Bitcoin ETP, GDX®, SNOW, ABNB, BABA, TSM, SMCI, PLTR, MARA, CVNA, HOOD), may be more volatile than a traditional pooled investment or the market as a whole and may perform differently from the value of a traditional pooled investment or the market as a whole.

    Risk Disclosures (applicable only to GPTY)

    Artificial Intelligence Risk. Issuers engaged in artificial intelligence typically have high research and capital expenditures and, as a result, their profitability can vary widely, if they are profitable at all. The space in which they are engaged is highly competitive and issuers’ products and services may become obsolete very quickly. These companies are heavily dependent on intellectual property rights and may be adversely affected by loss or impairment of those rights. The issuers are also subject to legal, regulatory and political changes that may have a large impact on their profitability. A failure in an issuer’s product or even questions about the safety of the product could be devastating to the issuer, especially if it is the marquee product of the issuer. It can be difficult to accurately capture what qualifies as an artificial intelligence company.

    Technology Sector Risk. The Fund will invest substantially in companies in the information technology sector, and therefore the performance of the Fund could be negatively impacted by events affecting this sector. Market or economic factors impacting technology companies and companies that rely heavily on technological advances could have a significant effect on the value of the Fund’s investments. The value of stocks of information technology companies and companies that rely heavily on technology is particularly vulnerable to rapid changes in technology product cycles, rapid product obsolescence, government regulation and competition, both domestically and internationally, including competition from foreign competitors with lower production costs. Stocks of information technology companies and companies that rely heavily on technology, especially those of smaller, less-seasoned companies, tend to be more volatile than the overall market. Information technology companies are heavily dependent on patent and intellectual property rights, the loss or impairment of which may adversely affect profitability.

    Risk Disclosure (applicable only to MARO)

    Digital Assets Risk: The Fund does not invest directly in Bitcoin or any other digital assets. The Fund does not invest directly in derivatives that track the performance of Bitcoin or any other digital assets. The Fund does not invest in or seek direct exposure to the current “spot” or cash price of Bitcoin. Investors seeking direct exposure to the price of Bitcoin should consider an investment other than the Fund. Digital assets like Bitcoin, designed as mediums of exchange, are still an emerging asset class. They operate independently of any central authority or government backing and are subject to regulatory changes and extreme price volatility.

    Risk Disclosures (applicable only to BABO and TSMY)

    Currency Risk: Indirect exposure to foreign currencies subjects the Fund to the risk that currencies will decline in value relative to the U.S. dollar. Currency rates in foreign countries may fluctuate significantly over short periods of time for a number of reasons, including changes in interest rates and the imposition of currency controls or other political developments in the U.S. or abroad.

    Depositary Receipts Risk: The securities underlying BABO and TSMY are American Depositary Receipts (“ADRs”). Investment in ADRs may be less liquid than the underlying shares in their primary trading market.

    Foreign Market and Trading Risk: The trading markets for many foreign securities are not as active as U.S. markets and may have less governmental regulation and oversight.

    Foreign Securities Risk: Investments in securities of non-U.S. issuers involve certain risks that may not be present with investments in securities of U.S. issuers, such as risk of loss due to foreign currency fluctuations or to political or economic instability, as well as varying regulatory requirements applicable to investments in non-U.S. issuers. There may be less information publicly available about a non-U.S. issuer than a U.S. issuer. Non-U.S. issuers may also be subject to different regulatory, accounting, auditing, financial reporting and investor protection standards than U.S. issuers.

    Risk Disclosures (applicable only to GDXY)

    Risk of Investing in Foreign Securities. The Fund is exposed indirectly to the securities of foreign issuers selected by GDX®’s investment adviser, which subjects the Fund to the risks associated with such companies. Investments in the securities of foreign issuers involve risks beyond those associated with investments in U.S. securities.

    Risk of Investing in Gold and Silver Mining Companies. The Fund is exposed indirectly to gold and silver mining companies selected by GDX®’s investment adviser, which subjects the Fund to the risks associated with such companies.

    The Fund invests in options contracts based on the value of the VanEck Gold Miners ETF (GDX®), which subjects the Fund to some of the same risks as if it owned GDX®, as well as the risks associated with Canadian, Australian and Emerging Market Issuers, and Small-and Medium-Capitalization companies.

    Risk Disclosures (applicable only to YBIT)

    YBIT does not invest directly in Bitcoin or any other digital assets. YBIT does not invest directly in derivatives that track the performance of Bitcoin or any other digital assets. YBIT does not invest in or seek direct exposure to the current “spot” or cash price of Bitcoin. Investors seeking direct exposure to the price of Bitcoin should consider an investment other than YBIT.

    Bitcoin Investment Risk: The Fund’s indirect investment in Bitcoin, through holdings in one or more Underlying ETPs, exposes it to the unique risks of this emerging innovation. Bitcoin’s price is highly volatile, and its market is influenced by the changing Bitcoin network, fluctuating acceptance levels, and unpredictable usage trends.

    Digital Assets Risk: Digital assets like Bitcoin, designed as mediums of exchange, are still an emerging asset class. They operate independently of any central authority or government backing and are subject to regulatory changes and extreme price volatility. Potentially No 1940 Act Protections. As of the date of this Prospectus, there is only a single eligible Underlying ETP, and it is an investment company subject to the 1940 Act.

    Bitcoin ETP Risk: The Fund invests in options contracts that are based on the value of the Bitcoin ETP. This subjects the Fund to certain of the same risks as if it owned shares of the Bitcoin ETP, even though it does not. Bitcoin ETPs are subject, but not limited, to significant risk and heightened volatility. An investor in a Bitcoin ETP may lose their entire investment. Bitcoin ETPs are not suitable for all investors. In addition, not all Bitcoin ETPs are registered under the Investment Company Act of 1940. Those Bitcoin ETPs that are not registered under such statute are therefore not subject to the same regulations as exchange traded products that are so registered.

    Risk Disclosures (applicable only to the Short ETFs)

    Investing involves risk. Principal loss is possible.

    Price Appreciation Risk. As part of the Fund’s synthetic covered put strategy, the Fund purchases and sells call and put option contracts that are based on the value of the underlying reference asset. This strategy subjects the Fund to certain of the same risks as if it shorted the underlying reference asset, even though it does not. By virtue of the Fund’s indirect inverse exposure to changes in the value of the underlying reference asset, the Fund is subject to the risk that the value of the underlying reference asset increases. If the value of the underlying reference asset increases, the Fund will likely lose value and, as a result, the Fund may suffer significant losses.

    Put Writing Strategy Risk. The path dependency (i.e., the continued use) of the Fund’s put writing (selling) strategy will impact the extent that the Fund participates in decreases in the value of the underlying reference asset and, in turn, the Fund’s returns, both during the term of the sold put options and over longer periods.

    Purchased OTM Call Options Risk. The Fund’s strategy is subject to potential losses if the underlying reference asset increases in value, which may not be offset by the purchase of out-of-the-money (OTM) call options. The Fund purchases OTM calls to seek to manage (cap) the Fund’s potential losses from the Fund’s short exposure to the underlying reference asset if it appreciates significantly in value. However, the OTM call options will cap the Fund’s losses only to the extent that the value of the underlying reference asset increases to a level that is at or above the strike level of the purchased OTM call options. Any increase in the value of the underlying reference asset to a level that is below the strike level of the purchased OTM call options will result in a corresponding loss for the Fund. For example, if the OTM call options have a strike level that is approximately 100% above the then-current value of the underlying reference asset at the time of the call option purchase, and the value of the underlying reference asset increases by at least 100% during the term of the purchased OTM call options, the Fund will lose all its value. Since the Fund bears the costs of purchasing the OTM calls, such costs will decrease the Fund’s value and/or any income otherwise generated by the Fund’s investment strategy.

    Counterparty Risk. The Fund is subject to counterparty risk by virtue of its investments in options contracts. Transactions in some types of derivatives, including options, are required to be centrally cleared (“cleared derivatives”). In a transaction involving cleared derivatives, the Fund’s counterparty is a clearing house rather than a bank or broker. Since the Fund is not a member of clearing houses and only members of a clearing house (“clearing members”) can participate directly in the clearing house, the Fund will hold cleared derivatives through accounts at clearing members.

    Derivatives Risk. Derivatives are financial instruments that derive value from the underlying reference asset or assets, such as stocks, bonds, or funds (including ETFs), interest rates or indexes. The Fund’s investments in derivatives may pose risks in addition to, and greater than, those associated with directly investing in securities or other ordinary investments, including risk related to the market, imperfect correlation with underlying investments or the Fund’s other portfolio holdings, higher price volatility, lack of availability, counterparty risk, liquidity, valuation and legal restrictions.

    Options Contracts. The use of options contracts involves investment strategies and risks different from those associated with ordinary portfolio securities transactions. The prices of options are volatile and are influenced by, among other things, actual and anticipated changes in the value of the underlying reference asset, including the anticipated volatility, which are affected by fiscal and monetary policies and by national and international political, changes in the actual or implied volatility or the reference asset, the time remaining until the expiration of the option contract and economic events.

    Distribution Risk. As part of the Fund’s investment objective, the Fund seeks to provide current income. There is no assurance that the Fund will make a distribution in any given period. If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next.

    High Portfolio Turnover Risk. The Fund may actively and frequently trade all or a significant portion of the Fund’s holdings.

    Liquidity Risk. Some securities held by the Fund, including options contracts, may be difficult to sell or be illiquid, particularly during times of market turmoil.

    Non-Diversification Risk. Because the Fund is “non-diversified,” it may invest a greater percentage of its assets in the securities of a single issuer or a smaller number of issuers than if it was a diversified fund.

    New Fund Risk. The Fund is a recently organized management investment company with no operating history. As a result, prospective investors do not have a track record or history on which to base their investment decisions.

    Price Participation Risk. The Fund employs an investment strategy that includes the sale of put option contracts, which limits the degree to which the Fund will participate in decreases in value experienced by the underlying reference asset over the Put Period.

    Single Issuer Risk. Issuer-specific attributes may cause an investment in the Fund to be more volatile than a traditional pooled investment which diversifies risk or the market generally. The value of the Fund, for any Fund that focuses on an individual security (e.g., TSLA, COIN, NVDA, MSTR), may be more volatile than a traditional pooled investment or the market as a whole and may perform differently from the value of a traditional pooled investment or the market as a whole.

    Inflation Risk. Inflation risk is the risk that the value of assets or income from investments will be less in the future as inflation decreases the value of money. As inflation increases, the present value of the Fund’s assets and distributions, if any, may decline.

    Risk Disclosures (applicable only to CHPY)

    Semiconductor Industry Risk. Semiconductor companies may face intense competition, both domestically and internationally, and such competition may have an adverse effect on their profit margins. Semiconductor companies may have limited product lines, markets, financial resources or personnel. Semiconductor companies’ supply chain and operations are dependent on the availability of materials that meet exacting standards and the use of third parties to provide components and services.

    The products of semiconductor companies may face obsolescence due to rapid technological developments and frequent new product introduction, unpredictable changes in growth rates and competition for the services of qualified personnel. Capital equipment expenditures could be substantial, and equipment generally suffers from rapid obsolescence. Companies in the semiconductor industry are heavily dependent on patent and intellectual property rights. The loss or impairment of these rights would adversely affect the profitability of these companies.

    Risk Disclosures (applicable only to YQQQ)

    Index Overview. The Nasdaq 100 Index is a benchmark index that includes 100 of the largest non-financial companies listed on the Nasdaq Stock Market, based on market capitalization.

    Index Level Appreciation Risk. As part of the Fund’s synthetic covered put strategy, the Fund purchases and sells call and put option contracts that are based on the Index level. This strategy subjects the Fund to certain of the same risks as if it shorted the Index, even though it does not. By virtue of the Fund’s indirect inverse exposure to changes in the Index level, the Fund is subject to the risk that the Index level increases. If the Index level increases, the Fund will likely lose value and, as a result, the Fund may suffer significant losses. The Fund may also be subject to the following risks: innovation and technological advancement; strong market presence of Index constituent companies; adaptability to global market trends; and resilience and recovery potential.

    Index Level Participation Risk. The Fund employs an investment strategy that includes the sale of put option contracts, which limits the degree to which the Fund will benefit from decreases in the Index level experienced over the Put Period. This means that if the Index level experiences a decrease in value below the strike level of the sold put options during a Put Period, the Fund will likely not experience that increase to the same extent and any Fund gains may significantly differ from the level of the Index losses over the Put Period. Additionally, because the Fund is limited in the degree to which it will participate in decreases in value experienced by the Index level over each Put Period, but has significant negative exposure to any increases in value experienced by the Index level over the Put Period, the NAV of the Fund may decrease over any given period. The Fund’s NAV is dependent on the value of each options portfolio, which is based principally upon the inverse of the performance of the Index level. The Fund’s ability to benefit from the Index level decreases will depend on prevailing market conditions, especially market volatility, at the time the Fund enters into the sold put option contracts and will vary from Put Period to Put Period. The value of the options contracts is affected by changes in the value and dividend rates of component companies that comprise the Index, changes in interest rates, changes in the actual or perceived volatility of the Index and the remaining time to the options’ expiration, as well as trading conditions in the options market. As the Index level changes and time moves towards the expiration of each Put Period, the value of the options contracts, and therefore the Fund’s NAV, will change. However, it is not expected for the Fund’s NAV to directly inversely correlate on a day-to-day basis with the returns of the Index level. The amount of time remaining until the options contract’s expiration date affects the impact that the value of the options contracts has on the Fund’s NAV, which may not be in full effect until the expiration date of the Fund’s options contracts. Therefore, while changes in the Index level will result in changes to the Fund’s NAV, the Fund generally anticipates that the rate of change in the Fund’s NAV will be different than the inverse of the changes experienced by the Index level.

    YieldMax™ ETFs are distributed by Foreside Fund Services, LLC. Foreside is not affiliated with Tidal Financial Group, or YieldMax™ ETFs.

    © 2025 YieldMax™ ETFs

    The MIL Network –

    May 8, 2025
  • MIL-OSI: Willis Lease Finance Corporation Moves its Consultancy and Advisory Arm to Willis Mitsui & Co. Engine Support Limited

    Source: GlobeNewswire (MIL-OSI)

    COCONUT CREEK, Fla., May 08, 2025 (GLOBE NEWSWIRE) — Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC” or the “Company”), the leading lessor of commercial aircraft engines and global provider of aviation services, today announced it has entered into an agreement to sell Bridgend Asset Management Limited, the consultancy and advisory arm of WLFC, to Willis Mitsui & Co. Engine Support Limited (“WMES”), its longstanding joint venture with Mitsui & Co., Ltd (“Mitsui”). This strategic move reflects WLFC’s commitment to strengthening collaboration with its partners and enhancing this joint venture’s capabilities in aviation services. Together, WLFC and Mitsui will focus on significantly expanding WMES’s services offerings and aviation asset portfolio. The completion of the transaction is subject to customary regulatory approvals and closing conditions.

    Established in 2011 and headquartered in Dublin, WMES currently owns and manages assets totaling approximately $360 million. The integration of WLFC’s technical consultancy and record management services will further expand the joint venture’s service offerings, leveraging the combined expertise, global reach and operational efficiencies of both partners. As a 50% owner of WMES, WLFC plans to continue utilizing WMES for its services and to leverage synergistic benefits.

    “We think this transaction is a real win for our shareholders,” said Austin C. Willis, Chief Executive Officer of WLFC. “Not only does the expansion of WMES allow for a premium return on equity when considering earnings plus fees, but the transaction itself unlocks fresh capital that can be reinvested to accelerate WLFC’s portfolio growth.

    “We see tremendous opportunity in the commercial aviation space, and this transaction provides us the substance to drive growth for our global platform,” said Yuichi Nagata, General Manager of Aerospace Business Division of Mitsui & Co. “This transaction will continue to strengthen Mitsui’s and WLFC’s long-term relationship.”

    Willis Lease Finance Corporation

    Willis Lease Finance Corporation (“WLFC”) leases large and regional spare commercial aircraft engines, auxiliary power units and aircraft to airlines, aircraft engine manufacturers and maintenance, repair, and overhaul providers worldwide. These leasing activities are integrated with engine and aircraft trading, engine lease pools and asset management services through Willis Asset Management Limited, as well as various end-of-life solutions for engines and aviation materials provided through Willis Aeronautical Services, Inc. Through Willis Engine Repair Center®, Jet Centre by Willis, and Willis Aviation Services Limited, the Company’s service offerings include Part 145 engine maintenance, aircraft line and base maintenance, aircraft disassembly, parking and storage, airport FBO and ground and cargo handling services. Willis Sustainable Fuels intends to develop, build and operate projects to help decarbonize aviation.

    Except for historical information, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties. Do not unduly rely on forward-looking statements, which give only expectations about the future and are not guarantees. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which the forward-looking statement is based, except as required by law. Our actual results may differ materially from the results discussed in forward-looking statements. Factors that might cause such a difference include, but are not limited to: the effects on the airline industry and the global economy of events such as war, terrorist activity and the COVID-19 pandemic; changes in oil prices, rising inflation and other disruptions to world markets; trends in the airline industry and our ability to capitalize on those trends, including growth rates of markets and other economic factors; risks associated with owning and leasing jet engines and aircraft; our ability to successfully negotiate equipment purchases, sales and leases, to collect outstanding amounts due and to control costs and expenses; changes in interest rates and availability of capital, both to us and our customers; our ability to continue to meet changing customer demands; regulatory changes affecting airline operations, aircraft maintenance, accounting standards and taxes; the market value of engines and other assets in our portfolio; and risks detailed in the Company’s Annual Report on Form 10-K and other continuing and current reports filed with the Securities and Exchange Commission. It is advisable, however, to consult any further disclosures the Company makes on related subjects in such filings. These statements constitute the Company’s cautionary statements under the Private Securities Litigation Reform Act of 1995.

     CONTACT: Lynn Mailliard Kohler
      Director, Global Corporate Communications
      (415) 328-4798

    The MIL Network –

    May 8, 2025
←Previous Page
1 … 630 631 632 633 634 … 1,544
Next Page→
NewzIntel.com

NewzIntel.com

MIL Open Source Intelligence

  • Blog
  • About
  • FAQs
  • Authors
  • Events
  • Shop
  • Patterns
  • Themes

Twenty Twenty-Five

Designed with WordPress